var title_f27_32_28160="Aneurysm and pseudoaneurysm of the left ventricular apex";
var content_f27_32_28160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aneurysm and pseudoaneurysm of the left ventricular apex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four-chamber view in panel A shows an aneurysm (AN) of the left ventricular (LV) apex; the LV does not narrow at the opening to the aneurysm. Panel B shows a pseudoaneurysm (PAN) identified by its connection to the LV across a narrow neck (n).",
"    <div class=\"footnotes\">",
"     LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28160=[""].join("\n");
var outline_f27_32_28160=null;
var title_f27_32_28161="Patient information: Animal bites (The Basics)";
var content_f27_32_28161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/51/15155\">",
"         Patient information: Insect bites and stings (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/15/22770\">",
"         Patient information: Animal bites (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/55/30578\">",
"         Patient information: Rabies (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Animal bites (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/animal-bites-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H41742249\">",
"      <span class=\"h1\">",
"       What should I do if I get bitten by an animal or a person?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Make sure you wash the wound with lots of soap and water&mdash;even if it stings to do so. This can help prevent infection. If you are bleeding, press on the wound with a clean towel or bandage to slow or stop the bleeding.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H41742256\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See a doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        You were bitten by a wild animal, such as a raccoon, skunk, fox, coyote, or bat. These animals can carry rabies. It is very important that you see a doctor or nurse right away.",
"       </li>",
"       <li>",
"        You were bitten by a cat or a person and it broke the skin. (Cat bites often lead to infection. Experts usually recommend antibiotics for anyone bitten by a cat.)",
"       </li>",
"       <li>",
"        You were bitten by a dog or a person on the hand, foot or head. Also see a doctor or nurse for a dog or human bite anywhere on your body if the wound is deep or large.",
"       </li>",
"       <li>",
"        You were bitten by any animal and you have diabetes, liver disease, cancer, HIV or AIDS, or you take medicine that could impair your ability to fight infection.",
"       </li>",
"       <li>",
"        You are bleeding, and it won&rsquo;t stop even after applying pressure for 15 minutes.",
"       </li>",
"       <li>",
"        You think you might have a broken bone or another serious injury.",
"       </li>",
"       <li>",
"        You were bitten on a joint and you can&rsquo;t bend the joint as easily as before.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you do not fit into any of the groups listed above, you do not need to see a doctor or nurse. But you should see a doctor or nurse if you develop signs of infection, which include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain that gets worse",
"       </li>",
"       <li>",
"        Redness or warmth",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Oozing pus from the wound",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H41742263\">",
"      <span class=\"h1\">",
"       How are animal bites treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you get treated for a bite, your doctor or nurse will first clean and disinfect your wound. Depending on how big the wound is and where it is, he or she might also put in stitches. Plus, you might get antibiotics to prevent infection, but that is not always needed.",
"     </p>",
"     <p>",
"      Some people who are bitten need a &ldquo;booster shot&rdquo; of the tetanus vaccine. This is a vaccine most people have had at least once. It helps prevent infections that can be caused by bites. The tetanus booster is especially important for people who got their last booster more than 5 years ago.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H41742270\">",
"      <span class=\"h1\">",
"       Should I worry about rabies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you were bitten by an animal that could be infected with rabies, you should get a series of shots to prevent rabies. You could be at risk for rabies if you were bitten by a:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Dog, cat, or ferret that you know or suspect has rabies",
"       </li>",
"       <li>",
"        Wild animal, such as a raccoon, fox, skunk, coyote, or bat. (Bat bites are especially likely to carry rabies. But bat bites are also hard to see.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you were bitten by a farm animal or large rodent, call your doctor or nurse for advice. The risk of these types of bites is decided on a case-by-case basis.",
"     </p>",
"     <p>",
"      Do not worry about rabies if you were bitten by a lizard, fish, or other animal that does not have fur. Animals without fur (besides humans) cannot carry rabies.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H41742277\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"       Patient information: Insect bites and stings (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=see_link\">",
"       Patient information: Animal bites (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/55/30578?source=see_link\">",
"       Patient information: Rabies (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/32/28161?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15340 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28161=[""].join("\n");
var outline_f27_32_28161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41742249\">",
"      What should I do if I get bitten by an animal or a person?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41742256\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41742263\">",
"      How are animal bites treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41742270\">",
"      Should I worry about rabies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41742277\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=related_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=related_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/55/30578?source=related_link\">",
"      Patient information: Rabies (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_32_28162="Female self-catheterization PI";
var content_f27_32_28162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F85929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F85929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Putting in a catheter (Women)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 650px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Most women find it easier to put one foot up on the toilet when putting in a catheter. But you might find a different position more comfortable. Put the other end of the catheter over the toilet or another container.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28162=[""].join("\n");
var outline_f27_32_28162=null;
var title_f27_32_28163="Patient information: Cervical cancer (The Basics)";
var content_f27_32_28163=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15414\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/57/32658\">",
"          Radical hysterectomy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/18/12579\">",
"         Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/40/33411\">",
"         Patient information: Vaginal cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/53/8019\">",
"         Patient information: Cervical cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/4/15429\">",
"         Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/48/6914\">",
"         Patient information: Colposcopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/46/30436\">",
"         Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/45/38610\">",
"         Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/44/17092\">",
"         Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/57/14227\">",
"         Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cervical cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cervical-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H454110518\">",
"      <span class=\"h1\">",
"       What is cervical cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cervical cancer happens when normal cells in the cervix change into abnormal cells, and grow out of control (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ). Most women whose cervical cancer is found and treated early do very well.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454110525\">",
"      <span class=\"h1\">",
"       What are the symptoms of cervical cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cervical cancer may not cause any symptoms at first. When it does cause symptoms, it can cause vaginal bleeding that occurs:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        In between menstrual cycles (other than your during period)",
"       </li>",
"       <li>",
"        After sex",
"       </li>",
"       <li>",
"        After menopause",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms can also be caused by conditions that are not cancer. But if you have vaginal bleeding at these times, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454110532\">",
"      <span class=\"h1\">",
"       Is there a test for cervical cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. A Pap test (also called a &ldquo;Pap smear&rdquo;) is used to screen women for cervical cancer. For this test, your doctor or nurse props open the walls of your vagina using a device that looks like a duck beak (called a speculum). He or she will then use a small brush to collect cells from the cervix. A doctor will look at the cells under a microscope to see if they are abnormal.",
"     </p>",
"     <p>",
"      If the cells are abnormal, the doctor follows up with a test called a biopsy. During a biopsy, the doctor removes a tiny piece of abnormal-looking tissue from the cervix. To see the cervix better during a biopsy, the doctor uses a magnifying lens called a &ldquo;colposcope.&rdquo;",
"     </p>",
"     <p>",
"      Doctors sometimes find cells in the cervix that are not cancer, but are abnormal and have a high chance of turning into cancer. Your doctor can treat these &ldquo;pre-cancer&rdquo; cells in different ways. He or she might remove them to prevent them from turning into cancer. Or he or she might watch them closely over time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454110539\">",
"      <span class=\"h1\">",
"       What is cervical cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out how far a cancer has spread.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the stage of your cancer, your age, and other health problems. Your treatment will also depend on whether you might want to get pregnant in the future.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454110546\">",
"      <span class=\"h1\">",
"       How is cervical cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cervical cancer can be treated in different ways. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &ndash; Cervical cancer is usually treated with surgery to remove the cancer. Different types of surgery can involve:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Removing the cervix, uterus, and upper part of the vagina &ndash; This is called a &ldquo;radical hysterectomy&rdquo; (",
"        <a class=\"graphic graphic_figure graphicRef78941 \" href=\"UTD.htm?31/57/32658\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Removing all or part of the cervix &ndash; The uterus is left in place. This type of surgery is done only in special situations.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &ndash; Radiation kills cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. Women usually receive chemotherapy at the same time as radiation therapy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454110553\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant one day?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to have a baby one day, talk with your doctor before having treatment. Some women can still get pregnant after being treated for cervical cancer. But, a woman cannot get pregnant after some types of treatment, such as a hysterectomy, radiation therapy, or some types of chemotherapy.",
"     </p>",
"     <p>",
"      Women are often able to get pregnant after other types of treatment. But they usually need to wait 6 to 12 months before they start trying to get pregnant, because their body needs time to heal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454110560\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the cancer comes back. Follow up tests can include exams, Pap tests, and X-rays.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454110567\">",
"      <span class=\"h1\">",
"       What happens if the cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cancer comes back or spreads, you might have more surgery, radiation, or chemotherapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454110574\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for cervical cancer involves making many choices, such as which type of surgery to have.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454110581\">",
"      <span class=\"h1\">",
"       Can cervical cancer be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In many cases, yes. Almost all cervical cancer is caused by a virus called HPV (human papillomavirus) that is spread through skin-to-skin contact and sex. Vaccines (shots) that prevent people from getting infected with HPV are now available. Ask your doctor if and when you should get an HPV vaccine. This vaccine is available for men and women, and works best if a person receives it before he or she starts having sex.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454110588\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/18/12579?source=see_link\">",
"       Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/40/33411?source=see_link\">",
"       Patient information: Vaginal cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"       Patient information: Cervical cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"       Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/48/6914?source=see_link\">",
"       Patient information: Colposcopy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"       Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=see_link\">",
"       Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"       Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=see_link\">",
"       Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/32/28163?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15414 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28163=[""].join("\n");
var outline_f27_32_28163=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454110518\">",
"      What is cervical cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454110525\">",
"      What are the symptoms of cervical cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454110532\">",
"      Is there a test for cervical cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454110539\">",
"      What is cervical cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454110546\">",
"      How is cervical cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454110553\">",
"      What if I want to get pregnant one day?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454110560\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454110567\">",
"      What happens if the cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454110574\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454110581\">",
"      Can cervical cancer be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454110588\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15414\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/57/32658\">",
"       Radical hysterectomy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=related_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=related_link\">",
"      Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/48/6914?source=related_link\">",
"      Patient information: Colposcopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=related_link\">",
"      Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=related_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/18/12579?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=related_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/40/33411?source=related_link\">",
"      Patient information: Vaginal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_32_28164="Nephrology pattern 16 answer";
var content_f27_32_28164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 16 answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 253px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD9AY8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3fxk8K6mPtDAAWwKjvnc3Oa5G3so5IGuWyzv83Xkc16JrC2tzqK2kwUzGHcM9hk/4GuGntjaanPZ2e6dSfuAfdNVTlq0d1Kb5bIxPFL3tja2MrEjdkkg/pVcH7TGsznjqPrW9r2m3c9kZLqEGJRxzwv0rk/EME9v4flisWCzEhSw7A+lddG00lfU7XUiqV+qLH9p6fNKbSaUASEBgM9ak05GguzByz2pLIM/fj+tcLpFvObhEcNJcqcb/AMMHNepTaFv02C4S623MaZ3L1PFXVUab5W9ycNiHJOM9mRS3YnTfb4CYGSOx6fnWXf6PHMXdfvHLM3qaZYtI7TSOh+QjzVXow/vCp/EWpW9jpaT2oyjYGSeCT1zSinGSjE2mnhndGBPBPaIGIIXp1qGORXKxoSzNjjPWqljrFxd6rDbSOHW5ZgwznGATW3pGlGPUVL4+9wPWuiXufEdeHx0atNuW6NvSbU28S7+5B5PQVX8TSP8A2XJJvB4I/CtZ4mRX3Egg7ea5jxfMHWC0jG6WRun/ANaueHvzTMaLdSqmdd8K7FWsoZ+6At+Oa9NAymRxxXMeAtNNloyKww+ApHTpXUY4xXkYupz1WzzMbU9pWk0fMfi3wU+n/EF1Kb4ZJjcqfUZzz/KuwsYWklcvkhmJYY71oePLwzeJbjyPmEIWH6nv/OsiS9/s/cQwMr/MSOgxXtqpOrCLe9j0cDh3Cn7u71NSSO0tyEdto9AM5/xrn9S1cw3MywRKkAARMjJAz1z61Rmv2uGd2JO1S7Mx4ArLt4p9TkEipIlkvM0/90DqRWkadtZHpKlCgueq9jRfUZbiRQhfceFA6muSnnmu7x1+fe0nlRqOd5HXiut0CVYdVaTT4W+zRZzJKuSR681u+EtEh0m7bVU0l54zIzxysd2w5JJA+tW6ipp6HnYnGzrq2F0Xcg8P/DK81KxSa8fy2I5AzkV0ulfC2xZ8Xkjsi8AZ711uj+LdPlBjmYwOCQd1b63EDxiRJVbcOoPBryKuLxF2noc1XG4te7JtHinjv4Q3YH2jw3LvIGPKc89exridP+H3jk3nkC18ts5MjuMAevFfVA2soO7OeevWn4w2ex4pQzOrGPK0mckcVXi7qb+8+fpfBHjG02skqTADnBz09q46+17XdOumt7qwuCytyBFkHn1Ar6xCAZHY+1V5bC2mA8yCJz6lQaqGZfzxudLzSu10+4+WF8e3CmON4GRAfuspxXR3NhquvaZCTYyPD99GUkYr3K/8PaPJAxnsbZge5QD9am0f7G9giWqxBE+XavQVrLMIpc0IgsfOUX7SCaPm238FiwlMtxpc7SLyCTu/nXSf21a2sC7pZoZyMogG0D1OK94a1hkB3IhHY461434++Hsh1ie/gDyJMRtTHCDjitaOMjiJctTQUcbTgtKa+Rz8niLTWud1zLudxjBqS7FtqulS2VpeiGSTkMR2FTaV8L7nUNRtXu4nhRGDSMe4HbFeh6z8ONOvnZ4SYJsY3rxzWlTEUabS5jaOOp1k4VVyo8Z0Lwr/AGdfG6uZTJk/L15PTNdvp13HG/DkhSee1ZGqWmpeG9Qe1uw1xbI3yuOeKZY3kLufLPB52Hgg1rNuor7nfDDQVO1PY7J5JEC+U2CxzuJ+bHTFSQzStPiYswUBs9ce1YYvT5MasMoOmPvKcfyqLTJ7m7vCqcpnnH8ia5nTdmedUi6b1R2duiuwdzu38+nvTtWuxBaFgCCpynoM4rNOqR6XY3t7KpkFsMhB69q4aPxtretXMiBIUtkyRujx78/lWcKEpu62Rx1qqi7Mg1LW9cuNRYxXUf7tsrgkDGetet2sUOt+Ere/YATNDklT1bv+oritD0fTtW0+21CZGtizYljz1Nb93q0Xh+xFvaAyW8C5Vexz/wDXp4hqTUaas0YxU4u7ehl27SRxzWzdSeTjrWXezXc8ohtmYRrhTjv7V0UBt7zThLxGWBLA9zWXbIoumjTgLySe47VcHq7nq4dxleVhljpEtw/+n3bBOMohwCPc1auLSysoZfs6KB/ET6UkshiLzTMUjAI6c/h61zuoahJcJ5VkrzSEfMzfdUVUU5M6YQc5X6FO+vXklEFrnzHPX0q3a6ONyLds8jPyeaNK042qtPIQ00g3ZI/lWzGojWKQ8t97d3Oe1aTnbSJpWxFny09irNpUKM32TesftUAa504C4STManDAnFYHiPXLlNRntrUhFiXIAPJPU1paTJc6n4fUXG0TDOeMZp8klG8tjz449t8u5sXMsOr2i3lqAt7F1A/iFXtLksWshdajKyR52lVPOa5awjk0m5hkJJjc4Yegq94gt3jXfb828p3lewPr7VnKCfup6HRVpudNcu/T/I9d8V3sen6sZ1DPd/ZQI0Azn5m61meGL+CBLn7aMXRcu7Y6itHxawGsL5n+rECbsdcFmGKo38dh9qgtYEYSMPm7fLXnS5WrM8uCXIr9Rvii8+2WWLOQNEy8qOSTniuMS5+xpNFMA4lOclfSvRP7GhFohthhwOPc1w3i3T3juGjtwkj78sy9v8mtcNKL9xHRhXBvk7lRIreOUm3jVc87lpB4misJpYAjMQuSf4cYxWXY3L2tx5c44Pc9qrXOjq9w1ws6shI+bd1zXZ7ON/fNMRSnTsoI3NOvUtZmvI4vOsZgQ6jlkPtWb460A3+kK+lMzQTYkCqehHOa1dNt1S08pEHlDPzE9fX+tT6LItrdnTJSPLkbzYSfTOStSpuEuddDVP2kWpq7tr5/8McB4N07OuR3NxF5MVsGHzNyzYx/jXoZijjuvMgYtETuXjpXm3xk8RWPgvWLHFvJO14sjFYpNpTbtwSO+ST+VX/COvXWpaFb3umMLqOUYO1SFDj7wAbkYOaqclWd0yaOHpfBSlr2Z2+r6lHBGZpyFOM4rO8EaLN4g1oahcgi1iOEz3xWVZ6Reapehr58LnJWvaPDlta6do0UcZCRoMMTwBisa81QhaO7Na8o4SnaGsn+BrwxrDEiLwF4x7VQ8Qasml6fJNkM5B2J6mud174h6RaCW306Rb2+X5dkfIU+5rzzV9b1LU2R7gb2C8AdBmuPD4Oc3zT0Rw4TByrtSexXkuW3zTSsWnZmYnPVick1z13fs4cy8Ajkg1e1G6ijQRKwH7rqD1b/AD3rk7uTapUEZPcnPOa9yEVufUUKaihZbiWd3ijdiCMkD0Fe9+D/AApa3Wi/6TEY4ZI1GwcDjvXM/Dz4cJf6Wt5qzFVlIdFTgsMfyr1+wgisbeO2gU+VGoVee1edjcUn7lN6o+fzLGOrUcIvRf0zjfGWkWmleHo0s4VTdIASByav6cj2/h2ydSDG685H3c0fEI+fosiIMOpBBxnBryqH4nzTSWWh6cqrY2cmby9wG80jP7qPPA5+8/bGBzkjGnGdWmrau5zxfLQjfudvrWkxXIaWEBJgpOF4zXB6veakk8dpb3skATlADglvSvRfDmp2+rWzTo6rJnG309M1xfjKSGw19LvbHMkThnQ9D24rrw8mpOEldo6kpVouinr0NrwV4t1H+xVfU+ZEYoWY447fyrTi8aX94Wezs28ns23PevEda8Xzy3cjrsis2c7IcnLDtX0B8P7zT7/S7NogissSqYvQ4qcVQjRXPKO5zw9lGDbXM1uVW8b31sB9qsmK9Sdp6VsaZ4ysr+3kkjVvMTG5SRxXSNa28qYaJGX3Ga8V+JlrFo3im2j0g7BcxZljQ8ZzxXJRjRxEuTlsyqEKOKnyKPKze8QeK59QkFrYkrFg+YR/jWRY315p83mQMy4HI7GpfD0ENxbBFcLMp+ZG6jmtvUNOtLOwlmlJT5c5Zv6V1/u6f7tI7v3dJezSOt8L6pFqemwvuG/kN9azvF/i2HRpYbe3ha9vZM/uk6KB3JrzrwxcX1/cHT7adrWIIZ893Bbt/Ouot9Hg06SViXuLhwfnY54rmeGhCbcvuOOeFpwqPmfyHWPj+R3zd2yrzgoldFYXEurbZ/N8uPP3Qf515c8SR3TvMMJks2D2rW8O69M+oRR20chR22qO2BWtTCxUW6asViqVKlZQ3Z6Ze6VaXUDI8SsT1JFcPqPgGxu5iqP5TsMq61peIPGC6LZKsyMJGXO4DIUYrE8GeM7e/aY6jcRwjcNkjNjjHT9axpQrwi5x2OSlVqUW7SsctrPhvWNCLeYPtFr1BHWqFpqUtvJut22TDjZJxXukr2l/YGO3dLgMp2lTuya8q+IWirbWwlWNt7Zcsg+6fT9K68Pifa+7NanfSzGMlavEINVhnjlt7+MKJ02vjo309KqNocsG9NNvEeyfGQVy3SuMtNQ1G23+dbTTQISN/lnpW/Bcvd28txYS+TOFLKn3c8cDFdMqThsTUwtDEr2lN7HfWZsbTQorODLSR/KG67jnkms7U9Kiv4VUybCPkII6gdK8pbxZ4itLlVNvLMwYDyzCeTn1FerM2pva209xb+UbiIMVC52HH/6q550Z0ne+5xQhCp7kWPhijsdM8qV9wDAlz16VU0/KK13I20AcFhziq1xcQrtN3I0pT5cAcKfT+dQXd4L8La2wEcKnklvmc/nTjF/eejSoezj5MgnnudbnKqClqpIJ7tzWhLDHp4EMQXK8gj0xSQp9mSNYflYcHnr9ap37b4mVQDg5z6U99FsW5OpJRjpEY985fBOVUbU9qdHfqHTIyoAHPaqJjJXzFBKdKs/YW8lX6FwSPyrRqKN5UoW1IL7w7a6hdNeJcvEzD58HIPb8q1bS1itrVIYT+7UcEdx61jiV9pCsQp4IrRsrhiqqfu7SOtKXNa1zklgo0/eiXZrZZrdxNgqR8pArKtJZxbyQSHfGh4U9ua2Fl2RNtkYHAAYdMHrWRpxMv2nK7QGxyfepjs7muH2aex6V8TrlLO/imJ/eeSuwD1DN19qr+E9U0+/Cz3M8IlVCNshwQQc1D8XVsY9Utri+dgPICAL/ALzGuBWFAEvbNC9uCCNy8H1H+fWuZUlOmuhyUKEalCN3ZnqE3iCSQzQafbtKiHO8HjbVFrONLM3AlVi2Xk3dSD2q5ompQX+myPbwKjsuGQDk46CqNhCsk0anGxSd4PfvisI2hfS1jmScG1a1jPvdFuNT0/dFFHCwJIJ+8R2FYz+Fb4WyHzUZzzsBr0a6vjAJfMiVJDwD2Fcjda39mcyx5DgEAdsnr1ralVqS0R2YetWfuxOT0u9a2uCkykANtPXir3iFfNsRcRZ86HEile2Kz5Jnu74kAAMwI4rfYK9nIkmcFSDgV1y0kmdtZ8lSMjxzxh4ZvPiD8TFicuuk6XaxLdTLxywMmxfViGH0HPoD6LBrmn+HoItO02w/0SHEaovGz/63vWx4cuIYNFEzoAuXDbVA3tnALevQc+wrJvNIj1VbjZJ9neX5iw5yT6VNOEVJ8559XDzg5Sp73Kup+K5rQGbT0zIM7iVHy1nQ6t4g8R3C215JMLRl3ExDaAfSuoGkafpOkS3V75fGCzuB2qzpl7auqNblSr4KhV6DFa80Erxj8y1CVRqUn8jL0zw3Zabbf6OxWR8lm/ib8aXVJES0KQ/K2eHPp3rYuHCyENhUU5JNcb4g1Az3a21sPM3fKgUdaULzd2elhad2nbRHP6or/bdqZdicbQM4+ldn4I+G9zrNxDdaiyw2i/MI8/Mx/pWpoPgu50yBNQvIY5tSnOILdmwqf7RPtXoXgzTv7Ftnm1LUY57uX5n2sAiewFZYnFcsH7N6nLmOYqcfY0vmzorBTbQpBgBI12oB/dHA/p+dSuyE7k4IxxWPqfirS7AO904UJkFzwMYyeT9P0r5I1j4keLPHPxVvW8Hpqdxptwos10+0coZbVWySzf8ALMt8x38FQ2M15Hs5Xu9DwJOz1PoPxHe3Xj/U7nRNAmMGhQMYdR1GI4MzDrBCf0dx06DnJHF+MvA/9jz2/wDZ8aQRxIFRUACFR0FekaQ0FitpBFbLp1tFGsSWqAARAD7vHHHtU3i2Bb/Tm8tC7r8y9fy/z6V24acqE0lsd1Kmk1CezPLvBdumlT3Es83l+YowgOcmq2sQXWu6o1rBGXGMuB0UdOarS6Vqf2iWRFEYVsAk4J9MCu/8ES22i6RetqG77VON5k7kgdP8PrXo1Jct6i1Z6kacMLD92uZnldz4KvbK9Nyot5441wDMwITOf1rpPh/4fv7tEEMrlIsIWViM8+3apLUS+JdVa3jLCBpOnQY56/57V7f4d0i10a3EFpGBHjr71li8W6cLPc5qqhgk5RXvSOW/4RvxIsL/AGXWZIcDhSd2TXHXGk6lpuofb9VP2q6jI+d8ngc8V7k0nUAZFcx4ult3sjDJgzY3AdwPX6VwYfEycrNbnPhsVJz5WlqeaWl5E8v2lARMzZYKMc5ra0q2bXtXVL92FnEC0mTxgc1xgLR6oyRgqjnPsOea9G1C3tdL8BXlxOZI7iZMBh1LHoo/Ou6t7tkt3oehi5ezj7u72OK17xTDf+ObOLQrcILY+V5qAfMnTB9q9CnhcW0s1s2YQn7x36bvQVx3w48OHSEl1LU1je6uU+QEYKZ6n6113jC+t7Pwo6Q/LjGMnnPesazi5xhDppc4IKfuU3ucDqFjf6jb3LaehlMLgMq/xLyT0rS+HWj3aaor3JkjjByEkGCpJ6D9Kl8CeJbGyvo41EhhnAjaTbxv61394RLdf6PEyf7TcU61aUb02tH1Mq8lUrOSex594v0rUvFGs31ppipiH5WZjge1eUa3pc+k67Np+pxywOYwqEnAzwc/jXtei+KLLw/ea19pjOya48xdvXkBQPz/AJ1yfi7WNO8ceIbG2SBoHgD72/i9h79DXRhqlSD5XH3UtxVaTqSVO1tLo3v2fJpDoeoxzs7rDOAjMeCuO34123iO4igtJGuI8oXxmsPRrux8NeF5ILOHG07FOOZGPQmue1K61LVSsZfKs/CgdK45U/a1pVNkPD4WUneWyNj/AISzRWaSG4sTGhUgMcY/Guf1LQ7bV5Y7rw3vljJJkKZAU+h9KrfE3wrPp3h61vEYkqdsgHGCeag+AGsyjxPrGn3B/dXEaTooGFDd8fhW6jGFJ1qTvYKtVUZp0Nn+hlXOv3Ghag8WoW7qsb7N7LzXWaTqP9qj7ULxmUKQVJ7DoK9C1/w1ZazBKksSLI3O/GfzrwiazvPBfiz7NMsotZnwpzkYopVKeJj7ukkXSxXtZctRK76m7qqB9QVYyfLbLAHuRWObGaCaSSMO3uO3X/GtvULgXHiGzt7eLZFHAzAlgdxJ610UECQ2ot4iDJIMu55A7/yrR1HBI6cXFtRTMKWfEKMVIdlXgnuKgt0muJmCrhRyR6U7UNkuoxwWybXGMgc8muwsbP7Dabp4fmxliKmU1CKfVm0XGlDm6s464AjXysEkccVAbiRUMfzKpXoK2XiBvG3QsEd/l/8Ar1S1logI2B2yKMFcdapSTdmbqopNRaIdPt4nUtKwO75QB2z3pL63TTJRunQhlyPmGR+FV2kMDb4yRgFh3wfpXGsl7d3McpJkhdWEmSQwck4H8q1jDme+hy4vESoSXVM9DhkU2hcuBlc4xmoNMUlDLImYWOCR1qPY4trS3CFZ3GXJPQd6XVLy00exi865EKysdqs2ASO4FZ26LqaRklHm2udN8bJN/iiygcDy1tFkbP8AvuKg0e3EujwqqLtyTtA/nXQfFlbeLUIbi6iLxtAEbA7Auf5muD8O3hR2t42Yw4BQN29qxjeVJW6GVL95hI8v2SS7mu7DUkS0ldEjbKqpOD+XWt7T9TCROGIOQST7nk1XVYpXuW6SAFVyB1+vpXMnzfNKLncSRx/Sr5VU3FhqCnzOTOzi1n7ZYOzl32MRlucn/JrO8TwLDptmUAJkbcXznt0pumWkkdt5aZd3+d19BVjVP9N06JASSpHzEcYA/wAioilGemwRcYVbR2MLShDbObu8cpCDtBHPPrirGtagt3DGlhIFMhwMHoPWq/iWxlt9Jha1Zn3JukG3Own6dawNGS4fU1YIUwjnYy46ADj8a6VCMlz3J+sOpirNaHfQ2UEGgraqd5U/MRwc1nRMIZcRnoQhGeFGa5zwZcaxqOvwqFkjjEhWUMpG8DrwfSuu8QCJPFcy2O1IiyrjqMis3Fwk4P1Hg8R7ZtfM5/4n2l/eaUljpsL3Hzjc4PH1NbOlWk1ppNiL6OMSxxIkxXpuAq3HKBJK85ZUAzx3IPXiuc8TeJQoeG1AyTx7U1zSSguhtQw0pVXJCeL9ZjkuZRENifdAHX64qTwekWnWcV28Ilv5Tlc/wqe/tWFpmj3mrTgCN55f4lVSQvuxrvLDQLmxhaS6WQNjGSOMelVPlhHkudtaVOEPZJiXt/f3s4EkqAgcAelTT6Df7FkhaR1ALHZk7axtamMDgw8tnG3/AB9K9S8Baj9s8O2zyRkH5lLY+9g1z1pujFSitDhxE3QpqUFoeO+MNEufFGhy6WL9oSpy+wcyKQcpnsTgc88ZHeuh+DlrbeFYDa2thHZxzYVgBgs3Ys3ViOeTVjxXMtl4w1GOxUl2hRiAM7T60xdI0+C3ja+vrr+0JyWOGwE74xTmozhqtzlnho1JKq9Ez0jUIbeWWN3RWkHRvamX0sUenOVCqQCAD9K4jwvqtzb6xFp127MHbZG7rncCeMVa+MktxofhNruxlkLBwsg/2Tnn25rjVFqpGm3uYyo+ymoSehiSa7YRXl3LcFQir8qqM5PtXH614gkv4JRZ7VXgc8E81e+Hp0vV5Psmqqsk0yBkYN+Peux1bwbBDpVydOhDAI3OAc16HNCjPlluelQxGHTTjf5nP/C28hj1DyZQgaR/lZj0OK9muLlLW1eaeSNFA7nAr5vi0fUo4xeWByqjeQvbNdNoeg6v4hh+0avfyQWYO2PzXOHPTpWeJw8Zy53KyHjcLTqS9o52R0l94/8AsLSKhLs5ypPO0VjPrjXubiRxJI3JOePpXM+LdPt9K11rCCZpBHDkvnqcdqveGtNvri5ht7WNd/XP3h65xWsaNOEeeJtDD0acPaR6nT6b4ecNHqWpxCO2fAVM4PXOcV0GiQf8Jbqj3F+2NOsm/wBGtezNyN7fl0rG17+14pora/lJVWCgquB0rS0tZtNjjlhOzeu5Tkc5PSuapeUb31exw1Yucee+r2NvXre10kpcNLsiZthTqefSvLfiZqEt0YrewYmAgrjuT6n8q7LVorrWLhYw0k0uR8voP85qCbwVeHJkCiTqgPQcEY/U0YdxotSqPUy0pUm3L3rHDeD7GWaeOS2KbQ4TykznAA717fq91Fp1gJpdqSIuOe/HNZ3hHw7Bo9p5kmwyBV+6MBcDk15z8YvE9xdSWVpZHFrJIU8z1OO57Upf7XWUY7I8+jC2stluc34s1UaheXFzGFSOQlX2Nx1H61gaM8Wm6utzHclpC2WBbJAI71mXdpcnSrqxdSbgsJE5zvGTnb64rP0i1cHc2U8tgSTnJxnivXjTUY26Hp0cUq1SCp0z6JF3a6v4Wt3hKpNBKGAzyx9K5+z8WppOtxJdxExKRuGM4FQw2JfwZb30UxtzAgJB/j715xfa4l/q67Vlnll4LrwqjHA569K4qVCM+ZbrU1jKlCU4VdI9P+AfQGraxpfiXRpo0nRoSobYRzu9MeteSSCXwzr1lf6bHtSOUF8enQitP4facdR1KFQ5MZXftA5IFemeI7Dw7o+jzajqxMdrENnGWaRjwqovVmJ4CjqcVg5wwj9m9UzCqqWH929zpdI1CLU7FJ4T94cjuDWd4t8PWuu6eyTwo8yKfLYjkHtXn/wusL5vF9xc+IkniuYIibKwL/LaI46vjgyleCeg6DuT6ut3Ebn7M0iLclS4hLDeUBwW29cZIGfWvNmnRqXgefUj7Od47bo+fLR2s7mxlmJWWCVrebI7AHGf0pqeK7+5jR7K2gazZmCgOQ52jnj8q1viNYf2b4ouIcEw3aiZRj+IE1zFroGopLbixEQt2DFZT1Kt6gdxXuw5JxU5HoY+U5whUhs/6/zO18CS21/4jtLyQfuJhkKx6NjGPwNd1eyJJqU6ZGwHaO2T3rzvw5ax6XJbWs7sGiPJAxk8knH416a7wSOkj/KinLMRwBXBidJpomtze7KXY4/VFxOZZCIwrcD+8P8AOaxNc2STByQvGFweo967HWlsLjHkq7yHqw6deAK4rU7KQXjiNWAHXPatKEr6s6sLrZszyWYKM4HTPtVvT0iRCrxRl1bPTBpsNvzifdx0FX7hls45JG4WME5I/wA+lbyl0RriGpJRIXuIm1nDOFymGY8ceorz7x/evdaykmmgSC3BhVDg7vU816r4D8K/22kmq6sP9HmP7tOny5x+VVvib4N0uyuLW/tohEkjGN0UYGQvBpUq9OFVQ6nFiuWr/s8Xr+B0PxgkY61FCM7WtFPsPneuF8ORFLpt4XaBtAz1rs/jLMV8Q28Ybbus1I4/23ry2zttQbVYIRA4807jIc4HPXP+etFGN6W5cayo4SKt8R32oOIkAiUK2T78UyOweKeVpCBI21l/H/8AX+taMmnxQxRSSPvBHRjzmrLR5vo/LIG5R1PTHQVgp2WhEZ2Vl1MTU9XtNJlgBLrdTIdsSdTjqfTFP0vUbfUIpHtyVXO0xlckH6Vz/jWzWLVra/njlni2Bf3QyImyc546HNWPAkc7TXl2E2pK2EQgjK4FbunFU+bqccas3VcWdPNmVdpzKgGSVHOBXJ3kvleKbMowcMrIV6bQe9ber3gs4GkdtrL0wcZ9sVkeHYHu9Qk1O4jzGgwgfilTVk2z1sJBpOo9joDqcotIrazBjZSUaTGNw9u4rJKsL7MhLFSNxHOKuzSxxmXYT5gA49M1m6lq0GlWMkrjdI5wB/te1VGNtkdFKFlaC3G+Jb2Vo0tLdh58g2gjHyiuTtdOLmdsSSGIB2cEDIPp61Svze6g9xOVmUYBTaD84POP516Bofw11640xZ/tcBjmjwsT9VUjpn8a3bjRiuZ2POxeYzpN0aHTd+Z33wbWzPhFPsyr529vNY8kn3/Cul8Q26HR7pgdjBCR061574f8Ca74d01ra2vWkUtvOxyoB74HeoddTxFa2bm+luWiPynJ3cV5LoxqVnOE09TKFFVqiqRmtdbHA69qpS5kOCWY4HtXa+CPHtrpujxWl3EwAXKHGM1w15pVvqU4JkeOQ7lwB1HepRojrC3lyO6wp8oVc4x7enNerUp06kVGR6s0qjcKy93S3c6fSb/+0fEs98867pZNxDDoo7e1egXvh+y1KQ3Mdykk0nzoikfXivCopZoADbyYaQ7eD1NdDbWer6TdpcvNIgZeWDHoewrGtQbacZWDEYVtpwlax2ni+BIGsLi3dGmtZApUdQOorrtdhi8ReEntLi3eQ3cONoxwfXNea6T9l1rWLe2+1gRkgykuM8V6frWpQaLpyGJw23aqjqQOmf8APeuKunFwitZI8zFJLkhu0eN+AvDtjpniqG2vbqZZo8qY5eASPuivfJVhTT5QxVYNh56ACvn7xNJLfeOGu0YKu1XiKDAODya6PVvGzxaemnpKGfOxlLcnnOM1tiKFSvKMi62B0g4aX6FaxnSxh1lVQyRhyiHPAyMj9TWjo13Z3OjJa37PCyuuGB5x1/Wq/wAPpbbX4NU0vytl3IPNWU84A4/rWZq8Nzod69pOAHUM0bj+MDtWtlKTh1OxqMpulLRmB4h8v/hI78XbSOW4tm/h29vfpXq3wkt7C20gykoLssc7j8wFee61Kmr6ZaG1hI1KCXA287wRwMe39a1dI8N6ncWkl1pt4Z5wcTxElWV8DqPSnXSnT5W7Dxfv0FBux6b4ttvttgfIUMyDeGA7jNczoF/FqunPablE1uwYZGCB3q4vjKbTLP7Lq+lTi52bU8lCwc46V57p+qx6bLK52zXkknmvGjEbOclfqBXLQoz5XFrbY86C9lTcammuh6ZpGo21gZVETNIf+WpPLe1TS+KrWN0M6FFU/MTzjg81wFnr8OqXAismfDAlg/BVqdqs0OWt1VfMxjp9MVTwsW/eWpvHCU6lpPqepWtzFqls0kLH7O4wNp5NeYXXh+yOvHStYQyW05IjQH7zZ4H4132hW32DS7aKRhtZdzBOuSKyfHsUltb6fq9tCZJtOnWYr6rnkE/SsKMuSbhHrsclOShKVNbPQxLH4Trp98lzp8oj8vIhSZjIIweoH+Nch4x8GX2jSSTToklsTzJGMBSema9oufFWkpo0Opm6QwzAGMD7zZ7Y9a8m1b4otr2p3+jRWCi3Hzu0h5VR/wDXxXRhquJqSu1dLcWDxE6FVRj16Efgs/27ptx4fvJCsbJ+7bH3Tjjn0rEtfhPrLasyeZDDZrOqmVTnPbIFVtK1CXTrqS7s8rztx7Z6Z+lbXiT4hvpHhi/vpTtWJNsahuXkP3F9f/rA+ldU3UpXlDZnoY/C3k6mllqaVzPpHga/muk1SCR9OdYLy3Rt0qmRcouzqSe2Oua6LSrW61e8j8VeJEEciZfT9O3Bo7BSPvuRw0zDqf4R8o7k/MXgHwZ4o8QeIB4kvJfsgaU3DT3KbnnY9Qqdec4ycYzxXfX3xFL6be2OjXS3k4kaBYFzn5eCxP8AcA53flzxXF7N1rSm9fzOJL20PaVna3fqjsfDfxEnl8e+IEsrL7fqt6EgsLZTtyy9Wkb+GMDkt+AySBXq/hHw3/Y5ub7Ubg6hr97hry+ZcbsdI4x/BGvOF/E5JJr5/wDhFYy6Z430++tvMuricFbyYgAAEfdHoAccf1r6g5PDZUkdutYY+nyTVtLo4JtzfOzy342RpDdaHeEnIkaNvTaayPDd1/ockW5VaNyq9ORnp7V1/wAZLGObwfJJ96eFlZD1PvXlmn6v5OlXMsbBJXUfMOvQ5x+FdmF9+gl2PZpSTwN/5Tpb6CQ3PnA5bILO3T8K7BZopIcGQPuwRjpgjpivC4b6SS6i+zz3Hnsw4LbvMOeSRngYB/OvQ1vJZEs7a2GHC5Y57561rWw7SV2RQqfWoduUv6lKbQk7xvIxjNZsctxclfLUB2PGeetYZ1W0udSWB7ppCW2byMKzeg7/AI12Vuw0+ze4WFW2KcZbhWAHb8aUo+zVramrxFOMPcd2R/2Y8LKbpchvlH+FYHiibz54tPiXgsGkwx4FZ1/45vvv3DNNFHKqlVAOBnHB/D9arX+prZw6nqrqXC4WMHkkk4q4Upp3kZ4WvGo5VJP4T6D0ZIo9Gs0tsCIRAL9MeteZ/FbXo7qSG2tZVdbYkuwH8R4x+VcKvjLW7S3trKa42W0xVfs8cm2RVYbs49MVu6RpzaxK0sSMLePiMMPvnufwrnp4X2M/aVDLCRppyxF7pHTfHDH/AAkunkFS62y/Kf8Afas7TZfP0yPLkbRjntVv40RvL44iCnAXTIzx2/eyf/WrK8M4eDYx3lW6DuK0S/dR8jel7+Ci+xeLZIhkV3lyOM5GKvyI5zIMFAnvxUHlBLrzWyxPzYH8jVbW/Een+HJlNyjuLtTGlvEuWycDvx1qLOTtFGFWShE4y78V6hCxlLw+R5nFvtDYB9T19a7uwuUuNPhmwNpTIAONvrXCz+Gxe6vd/Y3ktJXVXkglG7aDzlSp5FdhGItL0byd2fLBXJHet6yg7chy4T2km1LUwTBPrlzIqgmOJskqMgD/ACa6/wCxGCDT7aJCqSYJ7Y5rA8GCaa8uIojsjlGW9xmt/wCJ2pL4T0aykH7zULg4iXsgUf8A16icm5qmvkevi8RGg1F6JGJqMfl6vcMw3kKMge1ZXgvw63jXxjO92SNOtW3SAHIPPCj61Wj1mebQLm+uWQ3DDyt6AgH6A8j0r0z4Iacll4dMsqlZrht+T3HYUsROVKk2t9i6lb2WFdWG70R2N5pGl2WlSFbWFIoIiR8o4wPWuP0DWfFEWmRT29hBqdiDtUbtsuM9M9DXTeP7oW/h2SPPzTuIxU/g6GO28NWi8AbS5P1NebGTjR5pq931PFhaNFzkr3Zn6B460zU4blbrdYXFu22WG4OCKkuvGPh+bfH/AGhDIo4ZRkj6VwPieyg1f4gW9vC2y31B9shC4Pyrk/yr0BPCegWcMdumnxIwGAy/eb3J71pOlRg1J311t2Np0aNPlcr662XQ4nUbHw3e6h9rW4uYhuJIhXGPX/8AVVeDUodLvWa2s7oWkybBJcp9/J5ODXb2vg/ToNSScb3jDbgrnjNXPHNpDceHZ3c7RAN4P0rVYiDkoatM2eJpuUYK7XmeAeILP7Jqk25AscpMiHoMGrFz4g1K80z+zVmW5U4AwdpxkZG76VR8b3v23T7KCK6UTIfJMp5wD0z7CqHwuttR1nxLBCNscsedzqu4cEjdx7V61rQ55dDpxOJXP9Xmt1v23O6+HvhxobqO8ltngt1YMzOfun0B616xqjw39mwe2Y9NpYf0rMTwFp7WyRtc3zTD5mkExBLetee+KNS1rwxq1xp8Wo74iN6SSfMdvYH3rzJNYqd4vVHDhsNCrLkpy18yh4p/c635kQxEi7PYY7VzN5op1XUVktr2OG5ByQSckA8/pW3LNea4jFFLRn70oXHPpWPb2lzpmoW85B+QncxH3sjFelTulvqenioPkhRtd36dDc0a5HhrV7u402d5ZIEWJXQZBc9QfUda9Dnlh8a6RBsRLfVrfMixt/H1HX3ry7T1tZYZobmTbJIc5JwPbNaVhoGp6Ratf6ZeeVCh4YS5Y8ZOM9awq003zXtIwxdKdOpGaeiS1ZteFrqPR/FMcep27WxPy5deM+2e1dj4thht4pNY0nUhYXzKE3pyso7Bl7n3qnoHijQvGVuNM8QWsa3aAD96MbyO4NT3/wANNLuVdLbUb6OLbuWPzt6hh061x1Jx9p+8vF/emYzrQlUUquj+9M57RtY8XrdLKbVNTiI5CcHB71594rhvNE1ae61CxuLQTZIDDkk9ea9f8KeG9Z0ZWMcryLkrneCSAelUPFui6nqQV9SSSSNCcFlDBfwropVoRqNK1gqwpV52Vl5r/I8++Huiy6jYXerreCK6WUxxwr1YgcjPucV6RZaGmm2S3eqpjcdxdiCd2PSq/ga4Gl5jnhj+zqT5ewDgnvV/xFYXGt6UzW9+fK2svlhwrL7g/hiorVZSqWbsjGUqmGj7NO6Rs6XqWlzTJFC7eZ0yT7VtNJA9lKl2qyRspUhj1B4xXiukWFzojRMHPlrhcSNvz+NYfiPxFqMWoymW7kjhSVRFbxMRk9QxPcCo+o88vdkcsnpzTui5408CapDcD7MkghbJCKeFY/Q1g2mh3NnI/wBq81rkqIskYCIBnFepeAvGr6pNLb6m3mTIyrGUHQd8/hXc6jpWl31ysLxAkglmQc88da0eMnRfs6iO2niIxnGrUhd9z5z1e7CWcS7gNka5TP3mJ5x+ArN0m8s3kFxe2iXKpK3kxygsEYgchehYZ4OMjPGM10fjLwm+keM1hiH2u0kjLRlnCbePU+nf6Vx8iWluUtor1dm1tzqTzJ6g16EVCpDTW4niKiqzqS+Hpfr2L/jXxVdQaCthoqyzapqZMcEcKZZR0ZuPT+ZB7VQ+HXwu1Tw5qul6trszW7zSBBaRMCGU9RIehB9B7c16R8H9Htisepa3sVY4zGjlQC5DEjnrjnP1NdH4l1W31LXrCC2Qm2t2EjtnkAf/AF68+or1rb2NppVqqqSWy+S/4J1PhyDT5dZkNvbRwxqMRIoAGfX9K7Fox15/M1xGgWa6jqcF7DdKYITuKouMtnpXcSOiHLuACfpXl4n49GeZWfvWRla1osGq2zxS5ywxyeCK+e304aRr9/pV8u6JWPynPKn+VfTIAYcHNeLfHTT1tdX0rVIRgTkwS8dehH6V0YCs1P2b6nbltW83QntIp6ZoGl2UUstrgTumFkc7iM+npxVnR7C6TUJDjdgbM5654qjpbm2KwZJjYZTPUZ7Z9K0tU16Hw9AHdftE0+Uhgzgk+v4V3T523He5tU/2WDgtmcLqvgzV9Ouz5Jims8jynQgun1Neg2VxG+mLE/mGVgC+BgHgZ/WqOheJrbxBHPAf9HliX5kJJB6cj3qWaSOBHMxAVQSCOBj0p1JzlaM1qjkw9GDT5epzeuWuj2MUszFkkYFscbSM5yfyqt4I02Txtpeqix+7bSIsYK5D5OSx9ua6Xwv4XPi+HVbm5+SHyzHCMZGe38q4X4c3N7oY1q0hkmt5vtRjIXqQP69a0U3KMoxfvKx0OCjVWFpJa7/dsauv+G7XQtYWzgLT3mFWWd+SxJ6D0H+Fej6Nps4jhFs6xxquwNyQcDkfpXntyJF1mB7olizoxYtuznuTXs2i4Fj5MTr568hGGFI9c1z4qcowV3dmuNgqFKEImT8V7Ef20b4nBazjhA+kkh/rXCaFN5FwEJ+V8jg9K9D+LciC5gTPz+UCw/2dzV5jDKRKdp+UcgjnNVQV6epvgI82F5TtEAlLvtCjIXrXJeLNMnub5Z4Y3mtwBuCIXZcZxhffP6VvWN2LlE3Ahhg8k89q53VfEskeqSWls5xGcOQBx+dOhGUZOx5eKikuWZL4TtLhtTuNQvVe38xFjTcpDkDkswPIrQ8QThmS2iYPGeScdc05tQ3WUUy4Rz7/AIVkWzC8mwj7+Tkrzn2q0m5czOzAUlFKV9jsvClgLIxT7NruAeen0rjf2gpX1HxBohiYgeQykAc9ea9Z0DR2gt0kvNylgCEYcj/CqXjLwhZX9zZ3s7Oyw5UBffpXLSxEI1+d+ZxYySrzt1ueSXVi1v4WtwwAR3GQTzz0r2jwpfQWXhqzSRQhjhXIJx2rx/xE5k1+G3yREjgEA9OeK7a51pJbRrGz8yL92ULYDAjHStsRB1IpP1PSxUIqnTpE+q6lc6/q1tboPMt9wCKB2PU13epxpB4eaO1bARAnHpXkXh/WbjRrLzJIwzL8wLjJGM9Kh8QeLNRvrQxWrbFc7mCtxn0ArOeGlKSUdEgng5TlGMNIouatNGpgvIZWW5tH83KnBHuKnn+Ly2kcQFm13cY+aRm2L/nmvN5L3UJ4mRvT5j3P0qouk31zcxwWltJJMcFVXn3J5rreHhJe+tjvqYWjyc1bWx6FcfFy7nj8uGCO2ZiSXxvx34FY1z4h8QeKHS1Ms0kGeYwh5PbOKuQ6NZJbRJqNkqXB+aRwxz+Qrr9K8T6RpWmyQabp5N5geUQh2s+eMk1naFPWnC7Odyp0lejTv2OP8R+Hk0jSYVv9qXD/ADElQByelP8AA8lt4euINS0qWNxICsm0fKfbNYvjvVLzWbsf2teRTG2wZIVPlgkjgV1+pxw6J8H7Tcd2oysLmNccxjHHHXGMc981pK/JGE9XI4auOvLklFO27/yOvvvH8FvZCTytzjrh8j8e9cZpECeNdfEl3lo2k5IOML7Vy+qxy6HPBDezrd311FteMMGChlypGO+ak8I61f6ZqsJlj8q0Y/KpGeRwefWojhlCDlS3JhiqFOnzU01J6H0ZbaNp9pZC0gtY0t8Y2ha8x8V6PZad420yO5DDT5FeUqBn7or0DWvEKaXoFvqM0TEyhcIOMEjPNeS6n4sbXPF1qbmIRrFG0alSSuD15rgwcKrk5dNTnwU5e1cb73I5fA19r1tc6vprxxwyyuYbduCUBIHPrXOaZJeRXT6XfXMtrtygLDdtbPAx7nivXvh7rdvJoIt7iWKJrZyhZmA3cnFeZfECSC58SX11aYe3B2Bh0YgZJFdtGpOU5U5LbY9anKWIc8NWWnR/kM8P+HNR/tlhreYP3JaORzgocjbj/Cujg8TXUM0dqzvFcRtteRD8sg6AiuTv/EV9faT5U8z/AGhNqKxGMrxzkelSaVqUcetobqZGEiAhwODz3FbSg5+9NGFCh7D9xU1e6PRINQ8R+HNIu78Kl1ZDdOqS53Y5JA/WuYHxkn1KF4fstvGCvzNExJH4H8a9pthbahpUcZKPFJGvAOe3Fea+KPg1puoPNd2Mv2e8IyNqgKT7gV51Cth5yfto2Z5dWteXNyq/Y5rTH/4SHUrWezuF2yMASrkYx6V6ZFceGrG8e0vr+1W4XAeOSQLgn+VeWjwzeeBmtkDjzbhmAbG4KCOw9q5zWLTVIUeGOK3uhISXkmkJ3n1I6muydFV37stOhrW5+VSgm79j6DudB03VLTdGsJi+8hTkZ7HNZGpfDTRNVh/0lJFnXkOrYx+HpXkmi3Gq+GdJWIaorJO4/wBGRyURcfdzVu7+IGu6VOzQT+ZsP+rc5B46c1isLXi/3cyvqlSVLmk7eTPSPDHgG00e6kljA8lX+XDc/jmuqaKd2RoWQqnBC9fzrnfA3i6DxLbQrdhre6xl4iNuSR2ruUCouCNuOOK4MROopfvNzCtKcGoy6Hk3xkshN4ayYT9qU4Eq5+UHI/KvCkgu76606BLd4/s0YV0HO8jJ3DjvX0P48ik1LVrHdYXd1pdvuM4t13FjxxgcnpWDfWa3+siW0sJLCC3BZWnUozDGMEde9ephK3JTSZ106VOqoOputf8AgHH/ABO197DRNDsNGjeElN1w4wOB0FVND1JbrSJZEkZG8r5iBySSMnFdnJpum+IYoodQTDJlkKHDA/X864rxDbW3grUxbWdoLm2Mm9VeTOE/jHTqTW1Nxa5FuOpzwdRSfuNX9D0H4fa1NYaiLK4KN5hGxF67eMk/ia9TmtlnGJQ2Cc9a4HwVpum65bWGtaZuks3G3DDbtIPKkexr0ctztyM46d68XGSXtLx36nlq8RqBRGAuBjj615p8d0EnhRR5ZHlSiQN+n9a9MwCCOQexBxivNvi+v2HwELWSea5kJ2iWYjc59SQAKzwv8WPqdGCf7+PqcFZSi4062mBw6xjJ9axvF/mXdzZ3KRO/lReX8o5Vs5z+NdH8P7fSb+KO31O8kTy1CiNOOT6nsK6Pxd4RTSYvtlrO7WrOqkMclM9DnuP8a9pVo06qi9z1sW6NeboSet9zzzwu08JuLu5jPny4ABABx6/yrRulm1W+iiBOx2wQOgyelQ+JJotL02Yb91zKo8oKccHv+VP8NXUiaVZzujqQQeTyTn17/WtZa+/YWFVOjL2NPVpHufhfSk0bR47aMcj7wx1NeP8Aj+e3l8R3V1axBIkPl5QY3MBljXUp4ovH05yJ8YGMMOcfWuGuLj7VK8YVbhQrhlRgSC3VufeuHDUZxqOc3qLC0Z06rq1Grmeb+2FiWIZJ3ZWVyOCT0r0fShdJaxhS+WQHAxgjr/hXll0cafb2dwVjmgwrYJYyjd8uB0r1NLi9j8LxT2Ns7yhURhtyxxjOM8V0YlaK3c5Z4qdaD9otUyx8ZGX+3oFcfKbME/8Afb15ZZ6uslysTwEbmwCG6egr1f4wD/iewEgEG0VcHv8AM9eRW2mPBqCXEjKq5Py9zVYe3s9Tuwrn7GmonU22olY0SWMbAcBgKx/Emn/bbo3FsdhlISQLk7x/SteyQMSrqrYGQu71/wAinvLEJHhBAlHzADtTi+WV0XWpU6mk0VIYHisIbfzM7FKiuy+FPhlFu57y4UOlu37s5/jPf8BWBpEaGSR3XG1flB9+K9P8AtGfD0ZiwWZ2L9OtcuMquNNqPU5cbalStBW6fedNwxOVwfp+tY/iuZbTSJHGIznAJ6VpXkywx7nIwP1rzH4na7K9qIQNoHY9WJ9K87C0nUqLsedhKLqVF2Oa8M6MPEes37zOQgyqspI+b2PatIvY6LrDnUv36g7No4wcf4V23gDwpHp3hq2FwzC5nXzXwcYJ5A/CvKdT0y8i8ZXem3crQmWbEDypnehOARXpwqqtOUb6I9O9PFYiV3pFfkaN/Jo/kNP9pKwsSRCCScH29vWuRudW0mGdUjieZVbD4c4X/E16Prfwvt5NPkjttQlS5ZR8zw5Bb6Dsa4x/hX4nN4puIrYW5IGYVyPrg9K6KVai46zMqmNlFqNHbuyeS7tZraCS0hRISgDKBjnOc5qjFqkcd2GQFDt4bJB6+1dra+BYdM1a10+4zdWUkYzKq7drdz7Va8ZeC9P0i0S4tztV224J7cdalV6fMop7ndSx1KVoS3M7w9ay6spYia4bAGck4Geme9a1/ok1vH/q3jx0GcZrvfDmnW2j6bZ29uirlMse5OOtad2sNwjRyLv4z9K8+WNfPotDzp4/3/dWh88f8IrnWFnuAjRySbzHt6nryfSvQr3wpLrSh72WMWpj8s7V5xjhR7Vu3uhokT3LkAxHO0c59/8A61eWat8RtS0++NgYsQBiqY6OeODXWqlTEa03qjGrVpJLk0Len+H9O03x9ZxNdzagSA2ZcYQdMDAr1V/BOgyX8V49iheI7kUH5c5znFeL+G9bj1XxOs86/Z75STKrjHpjA9MV7/FODFGVfKuMqQOv+FYY11YSWrvYmvTjGnB09tSt4nsdPu9Hli1SRYrUc7icBT2Ir5w1zZp13JJbk3Stlo3JHyJk4GPXpXpPxu8QJpUFrEZhFlSVZlzz9O/FeJyXA1hTHZed5aupfzcKduMkn8eldWXUWqfNJ6MxpSlGa5Pi6GvpmoXRPmeYOpyqDjntyOOtegaJ4GvNZto3uJZImcZ2rwqg9q43Q7bGowqYysaMG2gdga+gvC8u2yJcBckcdMf5xRjK0qSvA93FV6mHpRV/e7njXivwFqOixBoA91bqvzFATgD1ribTTLpjhCNqnzfu/Ow6Yz6V9bI7OMKAeevb8a4H4padawabbalbwxxSW04yUULuDHnOPzrHDY+UmoSWrOWljViJRjWjdrZnnvgLXrnQ9SJumm+x9QD0J9PpXuttqS3ttFNDjypO4OT+lec+MdIgPgb7bpy5ukw7Ecnpk1wvhn4lX+k2MlsyqyPlUJBO1uvHPB+tOpR+tL2lNaoWKdPEtSWkttT0W52a94y8mbLRwEhe4A//AF/zrF8HaFbX2t6hFc5JhlIz2wPSoPCXiFbSG9vDNE08kbYRmGenJ+tdB8JIvOivL04EkznjOe/rRU5qUJW2VjSqpUYSa2SSRd1TwLbXVpNGJMcfJnkg/WvINU8OTWmqRRXxMkbMFD4ya+nPLUIy+vrXl/jURT6pcoig+S4I2+y5P9ayweKm5OLM8Di5zk4T1RFbeG7qKC31OzGdsYIKHB46HFZl/wDF2702U2M+kS3DA7TLuCg/T1rQ8D/Ee1+xrZX0EhVGIMi4PB9ql+IWiaZd2C6jE0Jicbg4I5PsavepyYiPoZTm68/Zyte+jOm0/wAY6EdMtbmO7jJlTcyoclT3B985qj4l1/Tb/RpJVb5d42knaa888Oiwh8NxWkVvDLqV5IQrKPmRc8knsBXUWWiWmm31vHdRCYKU8wt83uTUPD04Svrc0+q06T9691+J52t9eW9/cSW25lY5XAyAM1leJNPvLmeG9SWOdgh3FW5iJ45HrXo/j/U9O0XW7RrWyiuIJDuPlsO3sOnWkTxBoepaSYLywt4pwGVeRyM8fWu6NaSSmo6M3xFT6xSUOVpPc7r4WWA0vwJpdrs2ttLNz1JJ5rppo1kAByrDnI61xXwvuRNpFxbxXbPFbyER852g9v8APrXZRPLv2Eq7+ucV4VeMlVk/M8arD2c3FdBkk7w4UqGXHX1/zg1438YfFFjq3l6dYys81vJmVdpAxj9a9f12d7XRL+aMZdIHYD3ANfJHhhZr/WJruQl5BlcKCc+n6125dRjO9V9DfA64iKR1Xws8Ma7q8slzJaTw2LtlmkXasgPHfk/hXtHxBvE07witkQrTTlYEB9B1b8AP1rxiz8YeJtOtDbWM9zkPhY1tmbZx3PYdsV1+hW+o3tqupeLWMMr/AC7DwzKORgH7oNdeJpylUVSbVlsluGHpx9r7zvbXY4rxZo19JOLpVmkRlVcFNwxj9Kdp92ukabFBfJcSM4PkxAFnCg8nHoK9Mh1ZVD2MMRFsCNjBvmU54/wrjviFb39z4h0/UrFYHlhQwyxKw5U9x781rTrOdqclZGs41aU5Vqa1Ymm3g1HSXNhMSMbWP8Qz6ijQLf8As/UGubmZTBGCwhVSd7n+Qqr4VtbqzluLjUk82e62goSMIF7jHtxXTRQRXkS+ThkC5PHzY9/pSqSUW0tjrj+/hGVaNmF0beF7qO2W3SSXDiNyGCsRzg/iK1PBuviKEWl6yRuAecdxXPzabG90fsnztjgDuRWTfx39rdhCpiZixJbj+VZOnGpHlNnQhUjy33PaPHeiHUr6OUISFhC5AzjDE/1rybxDpP2a8S3E6M78kbegzXt3ifVI9O3F3CHy8hicY5NeH3OqNd63cXVtGrJnAZ/4u1Y4WU3fsjmy11XHyRetLBbGMPNLgHBHcn2q+BppG8xSNP034A4rKeSacK8jBtvGOv4U0TvBGQygnPX29DXQ436ndKN9ZGxdQ26Wu63UrlcHceQfWt3wEdjCO4yse35TngkmuGaWVx85AQ8da6SC4kt0VoRjA5wP1z61FWnePLcyr0nKHLfc9E1q80+z0+Wa6kj+6SOcnNeOmd/EXi3S4JWxE8gbjnCg8Vd8ZztFa2n+rImycdj6VW8Exk+N9JWXCs0RHHqAaijSVGnKfkzLDUFRpSnfWzPdSuzaVOAoxx6Vx3xNt7ZvDj6hOqJd2ro1tIQNwbeOB9a7IoNigjdn1NeS/Fzw7qQk/tm3nE1quAbdyTsY4AIHSvPwcVKqru39bHk4fl9onJ2R03hvW4dW10RtJ9xdyZ/jNdv2zzngV8raXrWqWOo208ZYurb1dBwrA42tjsa9jPjzWb+OOHSPDk7XbAbnlz5a+/FdOKwU4yThsbVqUarUqL0/I63xHPb2VlJKXijmONoY9fwxXlHinU5Ne1Wy0/T2lvHXDeXHkhW9z2HHWuzsPBl/qM323xVqDTzP/wAu8Pyont/+quv0nSbDSIfK061igTnO0cn6k8mohVp0Nvef4Dp1oYde770vwFtbaaPToEl2mdEAYjpkVDbk2ccj37ElmJzjoOwrRQsRyRnp+NNkQSKyHaCe3pXHd7M4+buZwRNRicoStvKgPPBIIODg9K8w8SfDB76/SNHLpI5KybsGNsdTXq6RlZ5FeQdBjNc7e+LdN0y6mW5eVxERgRRliTznpXVh6lWDfsjWNN1HZK5523ww1PRJBqIltpzABuMZIYjucHv+NdzZeLoYrdIWgbegCn/9Va3hzxXp/iK4ktYIriKRFDlJ4tuRnjFaOq6ZZ3gPnW8e8gjdgA1pUrub5cQtTaE1TiqNWOx578Q/Dui/EHToYHu5LO9iO6OQjvzwfzryWTwjq3hjXTb6g6XGIDtZZdwKDoxHbHavfdR8KAWDvYzbLhVyA3IzXD+LvB2qWNtLqnnrdRqmHIyCoxzx3HXpXXhK8YrkUtOzKpwoqoqlJ69CL4W6bFflrl2ILLtjBAx15P6163DHFbBemwjBx1LDua8c8AagunMoLBVIygB7n+tejw+ILZtjqwwvJbGOfSscZCcp+R1Y6lVlPU6RJfLlZQ4RCMjNeRfHXxg1lCNGt1jlJ2yz9S20HPAHSuz/AOEz063mkS9byiCSOQdwA5IrzD4mf2VrWqx6tpV9LFNPGIJ4zFlXUd8547UsFQ5aqdRafqcH1bEJp04u52Xw11xdR0O4sNSUFLaPeG/voRxXjWu6QINUvYdLlLiR8Kinjrn88V23gCznfUrm0tmaOH7I0GWU/NgcVR8PeHdUj18tp1gbqO0kBlVOmc9yTjNd9PlpTnJP5HdiqfLUcXG6e+trHCQWrW+pwpZLdpGQTP8AaDnLdyMcAe1fQvwagij0O8hBPnJNhuegxxx+dcp4q0i1v2YQ2tzpep53rDMBtkH+yRwar+APEQ0TW/Mv5T5UieRP6Z/hbj071niW8RSfLuaRw3+yOFNtvc90ZmVc7xgeteZ6Ht1bxPrTLgpGzxZI4OTgmulHinR2t2lGowuVUsRnr7Vg/Dy/to4PEOo+UfJkuWkWQclhj7uPrmvNpQlThJ210OKlTnShJ28jzbxj4Vg0K+SazuYxLn5oA2WI7Ypuqxala+Hl84usBG4pI3fPasjxlq9zqGq6tf2sDrBE6mWY8iEMcKufX6VY0h9Y8R6db2jAMOBluMr7k9uK9pKSgnJnoYR0lVaW637HW/DPw7c3d9DqdztW0h6IOSc812/iOOW21kSFNsUmCCBkcVh+DJbjTG+ywFyuAHV1xsxxkY9R3rrPENldX2n/ACBxOpBjYcha8ytN+2u9jDEVn7e8npscH8S9Isp0sr6xjEUkqN5gToT24+ua841u2u47B5ms2XKhWnVCRHjvxXY61c38Ewt75GZ0YjaOfyr0TwbqNhqPgu+MYjZY0fzoTg4+XuPSulVZYemn8SNcSpRw6i9Vfc4X9nW0nv7S81DzJktVby8dBJIO+O2BivbSjhgU4I7H1rlvhFYRWHgWyESKgnLzkAY+8x5P4AV1/IVuAM9M15WMq89aT+R4s272fQo6khn0yaO5T5JF2sT0weteA/D7SRp8+oSW53pDM2GIwCucV7b431T+yPDF9ck87CiZ/vHgV4vptzc2mnR2Fi2bm5G+QlfuDOcmuvAqXs5W6s9PL6N4SqW8v8zop5YbfMzsTdTnMVrGPmx6k9hSQ2148vmXFysMpyET7xXH16VHZWq2Tq29muGB8yVzyfbPai7v0SLIY72zx7V0eUTdzd+WAXelpI7XNzPNNK3y/wCsx+PGKcdM06WFc20assZJZjnfzx+NRQWesaqmbW3k8rGcrwD+JqK6sNb0yN/tFrMkYUguwyAO/Io125tQ5ZvRz17XLMWhxTRr9nuriN2XcFHzY9OvX8KZZXWoeHNRVrsxgSg7JNvDn0Ydj9afp1+NoZZPLdVKZ6Dnt3pdUX7baPFcSlUKgKSOc44I96nW/LLYSnNPlq6pne6TpVnqdrBqbRBGnjzti+UH1z+VWbvwppF0hSS12n+8rHP61y3wf1eWW0u9IuT+8tHLIcdQTyPz5/GtnxtqWo6W1rPZSDyXyrLs3ZNcM41VV9mpW7HmV+elUcb7GJ8YLe5u/EVvDG5W3WzVnHQfffP8q82ttVsVkEexhErhdzkLn6evrXsfxECNrUKt3t1z9NzV4tNoNxBf3NvdWp2+aGikC5bAJwcflXp4ZxlCzNJYqtCjCMNjqtYmtbHQY5bIKskrE7yf4RjnnvVHwmsWp3V7bXE0h8tQ0crkfvA2Oc/WtC60bztNt4/Mh3Qgkjqo3Dke/wCVULawOm2k04kR7hyqEAH5UHb86cbOFk9Re2rRnzXdiTWrBtInCtKjg87kYH3rbstTt722hRDtkxmTP+elcjcQ3V1qQtIbZJYSgZphJ9zjpt/xplndNY38QJwu4owx2q3DmW+p6uEqfXKb5lrE3vEkSS2sRO5v3nHPTnr7VRkuG0bxBoWoOCEilUMVOMqT/gTV/Vsvbo45hLjLH1rCvdQtNd0K5NkxL2rAgHrihRvGz2/zN1KKtBve59IQSJNbo8Tb42AIIOTioNUt472wmtZ4t0cqlCPrXPfDXWE1fwlaSqcSIuxwT0IrqhtDEnr35r5+SdOduqPmqkPZzcX0OY0XwTpml3AmEQmlA+TzF4T6D196XUfFem6TqEltceeZIxhzFFuC+g4rp/mwOceua8s1+6XT/F2qPldwKEBjkHK8100k8RJ87vobYWkq0nFnXaf458O3gIXU4kdBkpKCmPzFTz+L9GSznnivUm8pd22MEk49OK8W8aav/a0yS/YxEFO1nVf5Vn3OpRpC8MOQSuMocA5rsjl8HZ6ne8rThzK9+x0l58S7mHVHuJlla1aQKIlHQAdvfOOtWNJ+Ld5Pdxz3lios9xV0Q5ZB2yenbNcdp1np9/coL+/t4BM+WkJZljA9QR1I4q3J4Y0+LWZwt7JNE5BCxjCN355Oa65UMO9GtTz44bEN8vL956Frvjx7kKNNjaMYKlpO49a5aw1Kz1LWbOyeeM73wWz1bI4pmo6T9t0yX+zDI9xCpWWMjLAZ9B+NeZ2MCW91c3N4Jo2hJ7fxdsdqdGhT5Wo6HpQkqNoRXqfQl3qNvZfELTWWdBFcQ+UXBB5BPFd1cyllIjBOO+ev0r5mtPEp1mO2jdmguoHXy5AOSBxz78/419D6Ti+0u1neRi3ljJ6ZOOeK87F4f2fK36HNiKSUYzTutjj/AIja9daBBarBM0Mt4zZmIBVAATzngHOPzrhdA+I+s6rpl5pWrWhvbaWMql3GvllDjv2Ndp45toLnxdosWsSE6XO2w/w8eh+pwK7PxFDpujeEL1Ft4YLSKFtkaKAM44/HNXGdOEIRcbt9fmZRSU4N636I+dhe+TNFsUoYiN59QPUV0uiaZqmuW0t28rW1iuWGQcue2PWuf8KaNL4j8QwWoBETuGlJHYH9a+mtPsLW0tY4raJVjVQB8vWujF4lUbJbnt5jjFh7QitTwjUvDt0LI3lnFPLnIcMjN+IPbpWLp2kyXErRNNHG542uOv8AWvpnYAm04xXg/wAXdBnbVjeWEbkHCuE9zUYXFus+SWhx0MxqTTVtTa8IXQ8PX91pviCHbJKmIbjHyuccLntVz4c+IbLSJ77Srw+XumMqzE5Bz1yfbFef+JNfnudN0+2uRC11Am15JmIZhxjJ9RWUs9xYavam9RXvGAdFX51ZW9xx+dbPDe0i+br+hFd053hUlyydr32PfviStrL4MvLmQoQiiSGUc4bsQa808KaXBqujIzZMm794e+T3rDTX9Qk0ebTb+4V7d5NyQDBCkc446fSvQfhdJbNo2oW+EedX83kc7SOD/OsfZyw1Fq/UdFujhW4u7v0MLWfBJsrcalbI11aZ2yp0YDP3h2q9fxLpPhq3e3nU21xnci8MHxwPevR2kii0hlnAMQTDBu5xXiPiu4htLPG6VVJJQE/dOe3t0zU0KkqztLozXDVamJajJ7P7zC0rwVfeIb90g+SCUgyK3CttOea9S0n4eSWcCrc3+1xwPLTGfxrnPhd4ptdLZodQZ8z8B1X3r1nVdUsNMhWe/uo4Ym6bz1zRi69ZT5I7GWMnUoVpKCsn+JxEKy+HfEsNpqU6vazDfDcsCMEdVau/e9S4iiWHDb/mBzwcV598TjBrXhKK/wBNvIpdkpSMo3I3AggnrXmngrx3e+H9Q08XQaa0n6IXyV5xnHbtUfVniKftF8SOKrOM1GUnqenfFzQPL0lNWhV2khb9+FGcg9xXimhalrFlqU7W07QxuojuFYZOxzjOO4wc19X2s8Oo2yybVMbjOG5BBFcrdfDTw7LrEWpJbPHPFKJfLU5jdvcd6WGx0acHTqowVerCyizovDtkNN0KxsEfzPIhVN2MA4HWtJgSOCRnrmoTydwPseKp65qSaRpF3eP92JC2OuT2FeW05y82Qk5yt1Z5T8ZNb+061b6NGcwW4Es4Hdj0H5fzqHR7G00+GFrzVbK2v7tPM8uaQBiD0GM8DA71gaFbSatrb6lfl5A0nnzke/Qfyri9TkaPVdQk1kxi6Eru+8EMy5+UD2wfyr6GlQXKqUXtuerjav1SnGhD5nserK9su6dVUkZ3DnP+I6U3wF4dXWLqS7vwZLWI4weN7en0rmvDS3KeD3ju3aWIylrcv95UOMcdRXtXhWySy0CzjVfLZkEjj1Y8muPEzdCDinrexm8Q4Yfmjo5GjHEkMSRQoI404VVHGKoatOjxT27oXQxMWxjA+tXp4hKoUsQvXjiqsGn7Y5UaQlXDICBjGfSvLi0tWedFq93uedXekWd1p8kiKYpQQdobjn09elZGnE+fLBIxfYRgsce2Pzr0K08LWtsZWubh7lGGEDcbfpXB62P7K1DeqMqyu4XK5x1749q9SlVU7xiz1aNVVouD1GaNONB+INrP9y0vV2NnoGxg/wBK9a1ayhu7ZorgBkyDk84+leK6tF/adjvV/wB8uJYm7gjtXqfw81w694cgnkwLqE+VOAMYcd/xFZYyErKot1ozHGU24qp20ZS+JFt5mtQSb0iAt1Bdj/tNxiuPud6O3loZo05YAY4PSu78c+SNdt/OJObcADGf4m5xVNprebYksRCS8GTbjdjp9KqM3FLQmhUcYR0uc3p4t7y1DwyLHKSN0UrYAANXWtopVEsSjziCHQY2nHc1m6tZW9zLI9qwhbJx8ue/p6/SspIdZ05v3cYuFPDGFslh9D3+lb8vMrp2OpUoVFeMrPszoL0w2VtLPtVfcAfMPrXAuVuJ3Yj5i5b0rZa5n1SdIZ2w6/L5bcMPqK0bXw0gZ5JCVJ5XaM5x61tC1Ne9udmGjHDR956j5o2u9ASCZ9sKDd05Pt/OvLfCej6honi+eIxymwug67z8ylTyPpXsxtytoi/MoAIJC7uOmf8A61UL1LQXU0oVQsnZTgg880U6lk49zmlBVJqa3Tuv68zO+FniNfD2tXOkX42QyuTGzcANXuAkBRSpBVgCDXzp4g04XcAmjLLdo2Fz1Prk16z8MdVi1jwjbxXJEk0YMUqvySAep9eCK4sdRX8VfMzzLDxsq8fmdoFzjcwCj8K5rxh4Xs9diRoHW31BD+7lxwfZh3FdFuxwOg/GpFZQOMZx2HSvPp1HB80XqeTCcoS5ovU8Ulj+zC5s9VtxDcJkMNnD/wC0p7iuc0Tw/d6teGGwi2xyNtLkZ2r3PNe0fEG1UaDLfrGkk1qNwBH3l7ivNfhh4mNr4gFrrMP2RrkMsWTkDnpmvapV5ToucVqevTzC8Gl8R6dong/TLLR0sWtYnTHzFlyW9yayb74c6ZkSaZcT2xHLoG3KfoDXdqARnOR2/wDrUyd44Yi8zpHCoyzMdoA+teVHEVFK6Z5qxNVS5lLU8q1bw3c+Gp47rQNQb7S52uZgCr57H24qtdaPpniLwNcXk1uIdTaUiZgflVweeOgGKqePfG8N7OlvpigpG5DThuGHbFcT/aGoeTJbs9wsFxJvdP4HY169OnUlFSk7M9unhqtSmnN2f6GDpENlb+JXt57l5YN2GeIqCPfB+lfQGgwXeganp+nz332jSr9D9ndx80bgA7TjjkdDXhkOgC3uIRPdLDay3avPAqbpNuf4ePr3r3LULmfxBFa2Gm6VJDHaPHPHLO207U6Ae59c1WN96yvp1POtWV4zjyxLXxS0mzbwtd3LqTPCnyFjnv8ApXjV7qepala28F3fTTKp8tFkbKjsOO/413fxK8S3Oo6NNBYwsIIyPPYnO1uARx6HNeQwmd7+3tYmZiMyk9M8dRRg6UlTvI7MFNUEoVPib08j2/4YaKNPeSYnfKRywx8tbXiPxmdCkaJ7VyWP7s4+/wDSsT4Y6n/aEskbu8bImyRSMAnt/M/lWx460+81G3dIIkmhgTeSw5z3xXHNJ17VTGqlLEtVtSjL8RCwWCfTrm2eXhXYYGfw9au6Vc22qKTfvGBEucMecHpn9a4eeCa/spZb+82QW4RbdOOWPILc1dsLVmjgjDmTagi3Mfv+59a1dCCVo6Gzw1NK0NGZXxIvfB98LG1DLHdjKSSj5VGeMnjmqOr/AAyez0+G+sNUFzGVCgxyc49FznI56V20Hwz0/YJJp2V8fMuAR9Peup8MaHp2khbeCMsyHIkbnr6DoKbxUaUV7KTdjgnVTdnFNLvqz521TSXsIOdzMhCtvGCozyPUGqeka1eW14s9uskYOc7c5QDpyPoK+o/E/hvTvENoyXaKs+3CzqPmH+I9q8Lu9AOh6u8N9AZ7dGHzAdv/ANXNdGHxkK8bNanVhlDENOl7rXTudfosmueL7aOa8mCW0ZC/LwZCMZ/Q1m/F7RLSGws7mwlYNEcOj5OR2Jz3zW74M8Q6U9w0E9x9mhkOYBuwCR1H1rotd8OaV4ksTA+4Bj96NuciuV1PZVVdWiVOvPD1b2sl06HjXhXTYpz9q1Et9nkQiMwjhSO5HUVm6s99ceJUa5mF3GhHltPIyxsFBwDjn8q9lsfBtn4W0a4t4pN5uVWMiVtxUZ5NeT+K4hZaxPbW8heFSGD110a8akm4m0YxzJONR+ljK0HT7y01mDfH5pMvmKlud8bZOQgJ5P416FL8J38QavNqF2F0MSsJDBAA+5h3Pp9BXH6Fq8treefE0fyNldwOTjsMdP8A69elXfxd06IJDcWrx3oA3RE5x37VOJlXuvZLU5sXhY0EqcEnbu9UXdOvtX8HatYaXrgjudNnbyIL6JdpzjhWXNeirIj5ZGDEdhXleh399471yyu3hCWOnTecI2OCz9q9O3CJWLALnrgd68jFQs1zL3upw10tNr9bAqKrmRuuCu49hXmfxj14bINHtyGdh5kwAyQOazfH/iXUNYivrbS51tdNsztnkDfO5+nUCuQ0bztTnt3u3M0spCbs8lR2rrwuE5Wqs+nQ6MtpKdRzltE6bw/ai206JCwEz/O3oPYmtPU7e2lii+3WkEgUZVnRXIPXgn+lRfNbNm5/cw4CxhyBnFRaur3VtmNWZVw5xyDmtb3lc6JWq1Pe6ljSdKfX76Jo3KWucMwXGAP68V6xHGqRKinAAAFcp4fkEfh+0WwijX5MsCAPnFaGj395ei5W8RbfadoBHODXBiXKfojixLc3bZI1VmjkuzErhgFBKgg96cXCKWLfLjvXP6NpselXcjQFTE4IY988Y+ver1+0s9sohkH+swSDxgfSuZwSdk9DncFfQj1S/WF4mJUB2CgN+dc9rNnFf6ZctFG5LgsG/wBoHI+np+NaGoR/abqOFT5k6AMo/un1qvq8d7Z2I3JFFF0OwnJ9vrXTTtG1tzpp+4423PObCaSLbbCIfOeDjmtLwHqP/CPeMbu1uWYWd2hfC9AwGf8AGqm83eplgixmMkkds+tVPEUYjMN1ACzxZUn2NelKKneD6nrThGbdN/a/M9E+Kt01rqcBCnmBMMB3Dt3/ACrnbTWTdbUcLlTwFONxPeu88dLbT3ttb3BOXVT0yFG49R0//VXGaj4ZQeIIrDTSROF379hIH19K56coctpHnYapSdNRmrPuPSRFmE7gqwBOR0XP/wBakt76O51FVtGO2PGCM5Jz1rSi8KPqulsWuTDdBikikZXcDz7iuc1LQLzwzLa3M8iyxl8bgMc+hpwdObcU9TSkqU7rm16GxrGj6dc2yvcqZbwNjIbBUknnd2xWXb6drgcxaRepcIoyFnOMfRq1YlNxiXYvl7enOD/jWvNcWOmaC19rMqw27IQm0gFj6YFHPKKtuZvESpKzf3nNG/k886dq9vLaXGcFC2Ub/dIqS8jsU+0sbOJlVgdu3JAHcHP86js/EuieLLb7FPBNBcHGx5epA4GCO4644qhFPLaXElreMZLiMkLNjiRQcBv8a0UXs1ZrobUZxrR93Roje0JEcrJIIJsuMDbxngjPSofBWst4e8S3FtMN0V0dwLcYrZ1jVprmOKW5G4odm0L1BHX61w3jbNvJaXMY2vjqh6YrWMfaR5J9TupQdaDpT6n0Pby/a7RJUyA65GamjjIQB3YkDv3rK8DXkeoeFdNnQg7olH0IGMGtxowzZGRng+leFKPLJo+cnFwk4voZt/HFdRtayICjDB3HOa8u8aRabpmpDTxAhdl3q0hw2euRjv7163dKsakllUAZy2BivnLxfrd74k1+M3GUsreUxIVAy2OC3r/9avSy+LlJ9kF2knHc6PQPFXiUr9g027DqpKhp4w2z8a6y28IXeq+XP4p1S7vWbJ+zq+yP1HA4rnfDw+zxpiM7DjJA6fhXWTeJby4ja3SBpJcbRsjO7HT+tbVk+b92kvM9WUJpLkSv1ZX1WHS/sx0zSNNhK9PlQZZh3z1rC1bS4dMt9MUrJuVvMlBX5c9Rg9K63wrp8kWqF722eEFflEnBYnHSul8R21jPpsh1BI9iKSrN/CfWsPbqnNQ3RDxKpTUFqjJEGh+JNHK2n2Z2QfK4UbkI/UVxes+J7vT2l0ppVeSNcROnDEnjaTWJZ3E1n4v1NLVf3Mr4wp4xjrxWJ4s1BZLqeGK1E2wFWnAOVrppYdKVm7rc7KOEs9dVurnoXw01nRf7Im07U3ghvldhKJdp3evXj8KffaF4WttSjurB7baFYBUcMseewHbJ7V4VHp0cdvJKssqXRRgZAc5POAPbpUNtNMEia3XZdEqrqHLdMZPtXQ8H7zlGb1PNld17zg02e4S+GdXtLh9V0eVIp5Iwy2+3AYdhnvxV6P4lW9hbyWmsWksN2sZyQoILe49PzqH4feKp7zTY9PuJo0eDhHkPUdvyrhPHmmzNqX2uRifMbLlucjt+GcVzRp+0m4VlsdjpyqSdOqrtbFzUPEUR0mwFtpJW1Pytcy4+Zz/s9SORzXS+DikhtoWO4BiTjjBzmuL8P+HbnUbZ7i8unttLtQxm8wjc/f5fatbwj4lsrXUhb2vmvF5gZHcfeFb1YLlah0MMNUm4ypz36HtLujO0bZ/TipIbWNFEpYlT0IqiJQ6Bhv3sB8g6kY649KbLcTiJUZGCDqOgz2/CvF5Wcbi9kaHm7rlkXOFHHv2rj/iLAg0aW9lUYiX51/vKDnH1rorOWTpt+YjkH+dM8SW0Oo6LcWpUuZFIKn/ParpPkqJlUn7Oomj5y0w2OuO/kpPbckrxkcdzXWeDfFl7oWora6hJ50LDYrsenv7jivOrqx1Ky1m30sfaQjStEfKIDMmeg9Oo61ejgljttTgkWWNbaRXt2c/MFbP+Fe/VpRmrPVHoYfGyxEvq1da6/ee+6ZqNtqE095ql1DJbQIGC7wVOe5rxrxFeR6x4k1SeyhEVs0m2JRjHHGfxHNa2n6tZweCru3aWNr+4KoIQmdgx1z2rnbOxke48l5PJSZTyRgH1rmoUVTlJnbgaDp3nNWe1hvh3TrrVL94rKPkYZTjjHQgn8yK7LWvhtf8AnwzwKs/nKJZOMszgYwa4KPWbmwlMGmKWkibYCFywb8O1e6/CzUptS8N2/wBuEwvgSh8wkA47/SqxU6lFKcdjwa9WFerJxWhs+ANETRtHVNweaTDPj+H259K6Z0DKwHJ75rIKTRO/7xQOoUfzrQtxMUUvIuCvAC14NVucnNvcxmra3Pm74hyyx+K76yhTyxvIlwo5ycjrWtocMdnq2nRqQFSI4PbOOa1PGdtDfeOkt2lb7PbAvNJgda5e3h/s/XFu5HdoZJiFBbOEPSvejLnppeR7WEpKnT5UruSd/LsdDrWkanqVx5tmF8hGAXByD3xzVyxW50jTRFdsS7Nym7IHtg+9dBdXNvCYw8yxNIuRF0yfXH41laoWuoto2mIEtkoAR/8AWrmVRySi9jko017S7Oi0y1EFv9s83aZxuEY4AH9OtWftsgfcrNkdxiqPhzUIbzTobWYFZlJVXI4I9quXcTJc/ZreRA3UtkHaAM/nyK5Jr3mpBJWk1IRLucYIzgnnjIp9vfzINiJtdshfl5FH9kSqymBnnXGCWfBB/lUcJkivAZYgHifDbvSofK9iG4y2NDQ7qBbq4+0osNy+PnbgMo/lUnixrefRLu1knVJZUwmDznIIIridU1lbhp4rF8OSylWGQR6CqFt5t29tLMI1eFdgKHlunWrWG1U27FLDa+0bsVL6H+xLVJbp/MlJ2BFBznt/+uqRv4L21nRlETrt25IOBkdSK1dZij1FMzSuFBOccgfSudkaG3s5AqMtkrYJA+eQ/wCArvp2ktdzaDm6nPJ+6up7v4gtZL7UxbxyQRDyVLsy7nILHGB7EfrWVYS3OlX17Dco95PKvmRyoB8wxjB9Ku+JtSsLfXEtb6Xyne2DqQcE/M3GfwqhpdzLL9qexTexH7vzGJAA9TXmNOzvseZGMuS7WhCRqKafcXQcRC5kLPCoxt46g9845rLvYXvdD+yNc+cpjJj3Ejj1P48U/wC33LXOZpUYRkiNRyCSOa3dKsGS0jESYcgAEjIH0rTmdPVm9/Z2kcToV3PPImkzOVWEfMcfdz6/pWH8Vo7tpdOkghlmsLONo5VIOwvnOSO2c/pXoOpWSf8ACQeVuELXKhZnIwDkdB/jXJatq81rql5piAzJuHKZwePXvXVRneopRXT8zScPrb9zRnC/Dmxu77xLFO8H2a1t8ukrMcScdh+Nei3dok6Llgrq2VeIkMD9ajh8iHT2u0xGyjG0cdfYVgx6jdXF4wgm8yRiAAOB71vJyqyc9iaf+ze6ty/bXDWd8ttqSeYrn9zOq43eoI7HFUPEmi/b4JEgYIVLMAenTgZ966W706J7RpJk8yY7SHDY2HHUDqax7O7aWWSGRFE8LbGA6ZHQ/SphO/vI9ahVbfMt0an7P+uNNp95o1w+ZbZ/MiU/3CefyP8AOvXQwz1+or5jsb658HeOo76IfumYllH8cbH5h/n0r6TSZru1hnsnUxSoGDeoPTFefjaXLU5lszz80w/JV9otpBqMSXFnNDIRhgQK8B0bRZm15rSZdqi5POPlYE9+1e13OnzzMBJJuLck54rG13wrPqd/Bc6ZOtnNEgBl2nDEHjgfzq8LVVJON9zmpckN2Z2t6dNpU6hIx5bD5WHTNUtM1O4tX82U5Qc4A6fStDXdX1SxhWw8T2cRRyBBeW/Ks3oQehNY7RXEMIJVgnJUEduMf1reneULTPQov2kPfsdpd6+l1otxKlu7TRoWBHAU46/hXn/gmK/8Z3l7Hq+qTvZxncqxnAk/wFaVjfy2tu9uzAWtyChJHIyMfrVXwdqUXhyGaJbcM8jbVwMY59aI0+SElBa9DH6vKDfs/kO8WeHbfw2YUspZHluW/djGXU/l05xWLa6HFcarp2l+Y4lvJt1yW4IQc9fU4IrftGvNR8STapqUyPLGh+zpuwkQ9BSXUUtnrx1d5ITt24xgAHpWkZyS5W9bfidUZ1FH2betvxO7i8OaLYWXkpYwNAATh0DH868zuNMtNR8cXE+k2y/ZoogrYTjd3z+FdJrvjYXVgtnZKhuZhsJU9P8AAV0XgaxSw0MANFJLMxlkIYZyex+lcsZToRc57s5IuphoupU+J6f8E5ibwFaoqOJpFuZEJhCvtCt1xmvOtdmvYvN069bzJEyyyMcEgdvc9a9A3XPjbxPcW1xL5GlabIykI2GcdOo9cVf1b4b6bc28zWUX2ed8FCDnb+tbwr+zaVV6/kdNHEqi0q7v+hmaXf6Nq/hRdMt5TBM1tsdJB1JGCf0rzPTNHk0y9X7RKrQwS8OB820dhXT3HhHX/Dk7TSwC4thyGgJbj6dqp6rex3UMLROQ2SGHTmumlaN+R3TOilhqU588Hc9q8K3cM1inluGLKOT1+hrXmijNu6NwmPXp+NeV+AtVa3nFnK4JmAKtjP0I9+1d5JdrfCS3jnDt/EqEZUe/PH/168ivRcah5GJw7p1X2KumH7VfuFfAXgEfp+lauqWyrp9wyqzssZICnuBWfaxNazeYwCA9eOtXLnU4zGRlenIJHIqZXclymdROUlyniOojTPEFpfW+pfuNUt2E1vOnytIuACAR3FZEEFjo6BYrZpw7cRyPlpCF7tgCu01/wvYw3Kz2peMTTmXYeQvt7Cud8b6VLZSyopeNky8MoyNynGSPavapzi7JPRndh6c3Byil7R7PyM6DWtJtLV5b7R7pZ1GVeJR5YJ6Fj+YrsfDtlpd3HJPrX78MCUgUYZWPfPt/WvOdB0/W9bEWj2kQZJJvOJClQ+Om8+gx0r3/AMJeC4NItQ1/ILq6bl+PlB9BWeKqQpLfV/18iXKrSg/rMnfoup514I+HP2zxVPqNy8selxOxhXOfMOO59K9qisoLWFIbSJIlQYUKvSrHlIIvLUBV7YGMVk674j0zQ7eSTULlEZekeQXb0wK8qtiKmJl+h57vVm3TW/Qmu28i3klunChFO5mOBjsa5DxD8QbOC3+xaCrX+oOuAIwSqHHc+1cT4t8U3HiRlWcm00vOVQt80g9cU3RtWmikRNI0qVkUZIjiPT611U8FZKVTV9uh6dPA8i5qiu+3Ql0+wu7SC6nv2ze3wycjO31H15rV1Hw0lz4bZ4oQk+N4boT6Cue1DXLz+1FnvbWaJFOREQeB7muztfGdhc6VNDKSGIwFRS2fYmuip7WNmjqqKtDlnFetjnPDlyt7bpLdIj3dqfKYMM4xwDWs6MLYgxEhz/nr2rCh328z6jZ7m3EmSMDqM8H61uQ6p51v5lo5+bhhwee+aVRa3RjiIcsuaOxmWP26zu0WLc+DhC/CqPUeldSl5bNcwIZM3EhzlTkN2ya8m8ReKrw6vLBa3DQrHjbjjfnjqelbWlNf6jZCZnP2iL5d33c5q6lBuKlLQwjiIYmfK9LdT1+bVYxhRt8wfNwcg/X6Vn3k1vKkxguF891yURsk9f15rgI7C72qZJQrMSOGJOPU0i6Q/lowuQSThhjGK5VhoR+0XHDUov4yLT54otRuSEITBxu7Y61ydz4v1Aam6won2fJJyuSvbqK7K1s5IZpJbva2Vxkd65bVPD6NcSi1utqyAERkZY8967qfI5PmJxsalSa9jqbFnrEOp20cUcmH3BHC+nHIB5rZv9Gtr7TmhJKoSCpTKtke9UfC+ix6TbyXcsamQLkKF4xVK81y4vbjydPDljztVetRJXlansjopUZVKfI+m53Hxghca7a3AGVFsq5z0O9/8ay9E1xYLaeCWUojoRlF5z9f0rrfiKEk1RIpAuPs6sD3+81ea3do9sN5X90eNwOaypJTgoyMsJy1qMaczf8AD6zXU7XDlWjLbQG9P6V1ia3e28Qjt4FkjQjOTjb6jNcDoN8Fu4rRgBG5OT6ccV3Wl2Ru51SYN5MLchmzvJ7mssRFJ+9sZ4umoy95aFuJJNcv1nu4ljs4flXLffb1B9KjudNjgljt7eONPNbd8yBs9ehropUjgj8w/KqAe2O35VlagZ7t82rshQ/eGOmM5z6VyQm29NEcMJ2emxzF1p6XEE0aqIigCnHRj6CuItzJompzr5f705HzcjHtXprC4tdPFmyq8cj7jOTkqT7VW13QV1BpxcBVXAWJ0Pc12U6yWktmdeHqwUrVFdGBYzC+jDgHceCM9BWX4g054o55opWj3RmCaQdVzna/4E0tkJdG1ZrW8yoVwrHPT3ro7iETKWjxIHGB6flW1+SV1sdc17J6bM8Z8OzXniKzu9K1YEarpbYE/wDz0U5wT+Vej/DTx2+iumh68WFupxFMf4M9j7U3TbJbPULi0dYwWG9JABll9CR6Z/Ko/EmiQ3VoWYBLmLlGxgEdcGtKihUvCS0ZtTjGVJUKz5l0f5HrUuv6aJjG821UPzNjjP1rVtrmKeESQyo8Z6MpyK+ZrC4nnufIuJnCbect97HY/StT4ReMvsHie5tL+RxZSsQshO5c54//AF1yVcutByg72PAr03RqulLoe4eK9NXXdGn08o3z/Mr4+6ynIxXB3WpaidMi0m7hRbi3+UlVOXx0NenyXMVtbvNO4SFBkuTgYrzCT4g2E2vXRh0t7kk4hl4wcDGTx61jheZppRukdGFk07ct/wDM0fC3h+a/uI5tSVvJi5AI4JrodW8HabfxkIrQydmU9DXNnxZdqEkKAeYxIUZGPYYrs/D2qHULb9+NswGSvqKdZ1ovn2NK7rxftNjjb3wbfWtkUtpTKx9+a4W/sLnTLrF5bPtzguckZr6BkKqm5yAM9Saz9SsLXU7Z47mJJYyCCT/T3opY2S0mh0cxnF++rniV7Zxz3NvHAPLywyVJ6E16BaeBLGGRfInuwvdllK89sc1xGo2UunykwmRlU4+bsRXTWnxPto4oLaSFpbzIXYnU11VvayS9kdeIqznFOkxmoeDdU0GS4vtJuHniYb3jB/eBhzn/AGvcV2XhXxHa6zZxHPlXBUbozx83cCsfUPiPolrpcWoTSuke7a0JX5weRjFcIurWGq+KJP7Eb7HDdp5kaudn70EflmsVTnWi/aKzXU5dcQ/Z19JLZ/5nt7oskhVsYA5B715B8TvDNpaXC6lpcwUSOBJaoep7lfTjrXSXPhrXZlVpL888FUkIJ+lVLr4fXAty0FyWnVt4Ysc59KihyUZX5x4Vww81L2h5ZYarcCaOW2jMBg3YGdw9q0fDus3NlqsV9ZxxySM4in3feJDfNk+45qHxPavpetTRqcYchseuOo6c1t6fpeizR6DqbIEuppzBdW5cgSOF+VseuPzr1Jyhy3a0Z05jh3UhCcXd/wCZ63K8M0oV3AVwCOcfSoLi03yq+QVxg471Zlh+zuu6NSO2easwWXnKJZpGO7kKp4H+cfpXhKVtUeZzqOpj6hpdtqGk3HmFY/LBKsTjBHeuM1ORr/RNPu5lSQRgwsn8RxnP5iu/8Q2UUWiXkhkdQqb354IHavGrPUp7m+b7MHawS4RGUD7uTjP6npXZhVzpyT2OmhVjGHO3szQ0nUbnw/qDSaMY5bUZIt5pOVznKgj8K19c+JmtwKi6boKTSOM7lkMgX64A/WrPxXXQvD+j2FwyLDNLKsKFf4gR/EPT3rhbrUpEj+zWpYSSAJhf61vCEMQlUcTrjGnjVzRXvLv+pa1zxn4wu0SCe7isw5wyWqDf7jPWsnT9Eu726eSZ7hn6madtzk9ePTrXaeHPCUyBtRmUyhQC2OMjnOK6Wxt7dmSTGyKPkFeDjsD/AJ7U3WhT0pouWJp0FyUkm/I5XSdAtYLmGaeIyyHqH59ulZPi7xtqejT/AGfQI47aAOVMsgBdiPb09K6P+3DeeJYbF1iCswVJUHLc9TWvqvw903UriO6u9zCN9/3c7vrU+1hGSdc8nFV5Vle+pleGbi88W+HXuNQWBpoXCPLGhXzOM8j1zgVia9YaVY25urhzHK7FI/IbDMR1P0r1SDTY9J0iDT9KRYIgcYPcd68o+IXhbXxrFvdaLbtPbklHJO7y1JyeD71FCrGdRpOyCliKlKn7r1MTRbq5Z5Hs5ZJvLPK9nAGSD74roRHBfyJd6W/2a5fkqQdpPfd/jVXwnpep2PiSS8a1lhRImX96mAxPBYD6VYVRpeqNASyw3AJj/wBl/Qj3rpqSTlaJ34avUrU3z/F+Zhz6TFJc41MSWy78kKm5G78H0+tdRp7W62qJAyiMdCD71i6Tqc82smxuXlKtkOGXIGOhH5Vcl0GPUL4xWKN9obA3QkgE0T7TYqFOjUvJLlNCR1AfMi8jcDnG01Un1W3gjdZXViehzjNbll8Kt8aHUdYuwSOYojjH41cX4VaJDG+2e+kk/haSUED8AK5PrFBaOVxe1w0XrJv5HBSXlzqMqJDmOHpnPB/zitvT9LitpEQlTIwz5oOcivKfiV9v03xC+mWouIo7eQIGRiAxNdT4Vu7uPSWW+aTceFLnLD15rulS9xSi9Ga0sTGvN0qSasdfq1/a6bb/AGe3lkvb6QlfLAwqn/JqHRdHW1tWb/l5Y5dgBhc9hRoOnZHnTZ8xuQ/fH0rSuZFyeZETOcDpnpwK5W7e6gqTSTpwfr5l/wCLsOp2et2ur20ZlsEt1hlCjO0hmOfyIrnIp7fUbH90QRJ0C9jXuF7FHLlJVVgy4IbvXlXizwRLpMj6p4cQtbn5prPP3fVk/wAKxo14y9yWj6HHhcRGUVCWjWz/AMzi7i2ltpyJAcD0rrfBvi4WTyQ6iOGwVk9AB0rO0qSLUXTBXa4wQx5HbpUniTw8lrCj2seJFb5/mzx6101OWp7kz0pzhV/dVkdTP4iOtzSQWJCWcXzSO/Bf0Arbg1OzWOKFWyCuXOcZ7YNcP4btzFZlSFLM4bPGSa2xpsU+2W4CoZZDklsA4GfyrkqUoL3eiPLr04QlyR2OmM9nc2MscHlyT7D8uehI9aybWVbazikkb/R0XJYnOT7Vla0i20AMDeRJwWJPAJwBitixNnLpFvZo6yBQBuP8RGc1Chyxv0IdPljdanH+MLZtU1SK4sUbDKqnIP3vWrNlHDZ6fG99eRwIpwSTgfnWzd3rrJLBcugjXARTyWI4/CvLfiPJNdavEAhazjg2IEUkA55PHfkda7aMXVtB6JGtXEzjSUUtEdfM1tfxRPYXMMlxH8ybGyOc8H2IqNyNU05Xg6SZjkXujYxj86828N2Gum4tIoLW6iVX4ncbVK8dfWu9mKWOsXjFvLgmhM4x2ZfvY98YradLkdk7m2DruqnzKzRx2o2F/pV6r7AUY4UsMgmqduqX9pLp8ltBFeIp+zSZ2Bhn19RXaN4o0jX9VtbXT7SWMMOBIch2Hp71S8U6RFEouIV+ZGBwOx61rGo00pKzOiqqWZU1bSff9GbXhKSfxcLLw/qlx5v9nLiSWNjiRff1IxjNerx+HNIgKLHp8KlVwGC9hxXzx4R8aJ4e8cRySRLFbSIYpQB94HBz9c819LabfW2o2kdzaSrLBIMhlrzcdGdKSS0ieTV54RUU9tH6lW90ayurQweSsfGFZBgrXL3Xh/VrRnks5Q+PubTyK7vAJ/rRnjHFccKsoadCKeInDTf1PNL/AE3xBfWzm+MixwHcEV8lie+ParXhLxDDb2d3Yaoxhv4m2qrn74I4INdT4n16z8P6W93dMHcHakKn53Y9gK8QuNUl1vWGN0ptWwXDHso554ruoxeIg1JWR6OHi8VBqSskemaxpXl6eZ76SI4XcAANuf8AOa4K80yyTUYbqMW8dyvzRupy3NcDq/jOP7WkMTz3kQJCb5Nq/XFblhbNe6Ba6zbQPHbC4xK23hTn19K7IUJUl7z3NMP7CUuTnTfoXPF/h9nht5QXmSRQ8kfo2TyOxrjNHsfs15ceQk0kDElkkPQeo9DXsL+ONE0q9jtGK37RwhDLj5Fzzz+f61yOs21pFeLe6VcJPa3Yzt6deuBV0ak7cskaUpU8RUV9JLr+jJtH8da5opggeZrizjbKCXkgYPyk9e9djbfGC1lUCbTZ43PdSGFcfo+jHXNY/s+ySOSTyw7yHICAdR+tVfGfhe88M3MK3G2RJwfL8v1Hb9axnRoTnytanTUoYSpU5JK0mO8Vana6pfT3No74lJcq6kEH37f/AK6l8OXKjVrdpcrZzKFkIIwhx8rY9QQfwNJD4E8TG0ju0tEaORN3lh/mwfWobeNNM0i8e8ile6t2ES269d5OPm9q1Tg1yxd+g6/sHR0lpHse0aHrUDTS2uqShJ41Bjdz8sieoPr610MU8DKBFLGwGBhSD1GRXj1lDdX+hxT3hZZFPyxNwQPbvj61o29wipNFaIIZOMlTgA4rzamFTejPJlhI1PfgzqvGGpxT20unWzhpJI23YPA46Vg+EU0fT/Cl5f8A2dWnj3eYnVg2OmKybgJb6dJLcyxm55ICnvWdaSN9iM0JzKzBhgcZA6Y71rGglDkT6nSsJF0uRPqcJrLXniueG71SSV5IjyshysK56AfSvQfBvh1I4pNQnXEpAMaydQp6H61j6ks82qQ2tyiqzjdIFGPevUtLWWS2aYtEP3flxxhcgfWujE1nGCUdEZun9TpOzu5bsqHVZoIJU3EwgdCvbFcVqXiyPTnMcoVIXbYcZbHFbmpeGfFIvfOs7238gKNyPnBJ7Vr6V4Es3gsrrVFSSUKHkjUZUn2zXMpUaavJ3v2POlUf2ShYeDoZ5bXVYnILAMA3IUE5yK7ETK1x9ntzJIpO19qg7fxrUdIxEqIFCDgKBxiktokRSECqGOSMdTXn1K7qfEQpLUimiSFN4DMw4JOSanBjWEnI4BqQqOQSPyrOu49kyqhJVzkruxWUddBL3hbizS+jLP8AKvIU9/rXnus6ZHc2plaPG8kCTHDMD1rX+IHi1fD2niNCDJKpQKPvZxxjH+RWBoXxKsntkstc002qGIeXJncjZ4GeP1ruoUqqj7SKujWnWdJqz1MPTYRJNLHIc+Sfmb0GOpPpWvodwYGaSOQwsGyp9eff1rjfEV3JBDcC2kKpPKRuGRhR1HHrkVZ8PwXrWSvOsjjG1V3Hj0r05U7xuz2HWU6jpvax6XL4y8o7j5ZTjI7+9bUfirRpIFma+hjBydrHmvLG0ySRmw6qMdMGqL2LwMHMQKBsZAzXHLB0pbOxDwVCeidmbfiW3svEV6Lkx7mU5Dr2A5GfWseK28++iiyPLDYx0+UVfjuzJACzYjUdF4BP+FZ+lanb2OqRXNwNwQkmMDJbNdMVJRsuh0U6SpQlKK1sdmPLji2ID5ZAAIPYVWSJS7B0Lgndt654q0GtdRieSwbocugX7oPrjrXGeJPEuoxO8ehrBugIRy2CzdfXp/8AqrmpxlJ2W55LqxiuZn0Bcyx/bFh3AS7AwGeoyaUHggnIxnNcf4xv5bTxVCYeClqr/XLuMfpW/o9697GGcBe3H+fauCrScfe6M5HScYKXc5fxb4T8qZtY0GMLdJ801uPuyj2HY1zy6p/a0Hmnbnowx932xXq11L5MW4Lkema8p8SRQ2PizzLWPy1ucOyA8BjxkflXThajqe7LdbM7MNJ1VyS6bFy2QrZl0xkMDjPbpU6anNeXkYs4WihhUgN0XOO/1qbQbVLm9UylikYztHc4z/SuV8Z+LtQsbqHT9PWG3RZFdmC53E89K2jB1JcqVzKtUUHqdNqmmvq6iGebfPKclQMAYrT05E02OHT7pFBXlfl798VheBdfuNTtzqF3GjTiRkbbwGwB+Vbun3zaj40SOZAI4YGKqD3JAz+tZT5leD2RopuULdNyLXNPstQnjhKPHJK3zMDyMjr+dcLqNjeaDqSASCW3ZiEk2ZBHpXp2o2HmyOzSn5AGGBz+f41xfje5L21rGV4wWGOMc/8A1q0w822o9DpwlV3UN0y3bSLLGqDMh4x6r0rI1+GJ4xKFbEEgZs8/KeD+hrS0aZlsSe4UHPfPPeormUXSzRvGoVuGx3z/APrrWPuyKi/Z1Lva5keG/h2lrrVtrhuFbT4WEkUSrnLeh9q3fE9pDIwjEXlxz/NkcAVP8KdQlm0u+0+Yl4baRgmTzimeIZjNeIjDCk/KAeFpOpOVZqT2MqFL2NdxjseOato8cmqwh1DgttyG/LmvQfAXi2HwJYtp/iWcrag/u5gMjrx/WuJ8SO1t45jt4ziOWFHI9DmvonUPDWka9ocVpqlhDPE0Q6ryDjqD1rbF1YKMYVFdMWPcW/bRXxXT9U9zhLn4qWWr6lHH4auBLCgG5m+XJz0IqS98V+INQhdIPItIVGGdTluOp/SvNpvAVt4Q+JdvZ6ZeSG1mO/Y6fdGOmc17zp/hTT7WC3YBnfy8sW6MfpWFX2FFRaV7mdOpSjSTnH3jxS41qDTdViudWF3qF1G4dznKqufQ9K7HwvPpvjbxoZ7eDy7SO0+aIDBOSRzWR8QLCGDWrlIhsBQyrt7Y4x71D8Nv+JD4lsJ4PnF4pgdDxjgHP1rpqcsqXtIb2IjiKk5yj5Ox6DYfCXwbZXQuItKDyKcjzJGYflmtvxfDb2fgvUo4Y4oYIrc7VVQFXHtWubz5XOz7px96uC+JupS3UemaZjZb3l1Gk3Ody7un6V5VOVSrUXM72MKFJuasec+DvAut6tp0kDWVvFp877/tTty4I7e3evSLH4W6bpukCC1lmlukXh5G4z7DtXocESQxpFGoVEXaqjgAAcU6rq46rN6OyM4zcJucNDyLTdB8SeFNbe8stOTUIZAeI5ADg9jn866Cw8M33iDVBq3i1AgT/UWSPkJ/vHua709aOlRLFSnr179Toni5z1e/cjjhjjj2xrsUDHHYV4Zaz3mp+KNRNrbs6Xl8bdLhj8qsPX24zXtOuXTWWi39ygy0UDuBnGSFJry7wnNJa/Dawu7dtlzPeNIXxnB3Y/lWmFbjFy76HRgZOEZSWrdl+pl3+qR6JdNb312YrqOQKylt27/dHp061pXohvrq2u9MvYJTcp5jReYqs4UDkLnOfavI/GbSy6/NezytJNNIQ2an07RPsuoWVwl0+93UEhcEAkdDmvW+rrlUr6kTxlWnUaUVodtcQt57Q3QkUZPybdrDjrVOPUxN4ittN0+dI2t0LFG5DHHIP511fi/UGFus6xrkBI/m5JBx1NcTpGnw2WrLfIoMzZyenXr/ADqKb5o3Z6jlVrRi1tfU6LUZ4p/EtrbhCHRAZpBzn1P5Yr0bTIltnzFMSjKCpP8AX8K8wRGfzb/eRLkp+Fb/AIc1mb7G1syBhxlieSK5q9NyirdCcVRbgkuh3V/Pd/Z2WHoRjcG5x/jS22vQRpFFIxDBRnisiPUpRcxqqqFAAwefauAtbidtf1JjKSLaYgKejBscEVzQw3PFqXQ8araCs0e1xIrlZkyc9Cf8KlgkXdIhwGU9jxXNeC76a70yTzSP3L7QfY810YUbS/fOK4qkOWTizLcnYhh1yM/Sqt2A7ZA5X7vt/nFR3zG2TePmwp4NeL6r8T9Ulu5IY7eKKOOQJw2SfxxV4fCyrO8BpW1NLxzpT3l/DeyZkFvMwaIHkqe4rkEtdYvFkh1KG3isWYLAw4dUBztA7fWvQIZvtqpPIig+Xv2jp0rlNUu3xNOeWjztBPAxXr0ZNLl7Hdh8JGtU529EUNf2xi2ihibcnBfqAPX9K1fBx1K9S4M6iSGNsAdMe2a4iHWbi+uY45MAEF/yz0r1nRi0FiFgbZFJtkdOuTtz1rWunCFrakuq6tVyWyLT2URjV4yY+iuhOcHFZ6orKythtpxjPTHSp7lyj4XjzGUn2zWNJOyzAc/vGDEg471yQi2jqhByVx2oW5t0MsISSOTgqP4fwrnbq1DId44B+U5rsbYDyPLx0YjPqD1rK1ewSCKZ0Y7UbGztz3rWnPodeHrr+HI0vDF5DDYTIjsjFCGIGSx7Vnv4S1CeSe409YJrS4wZY5ML83Xr3rGila3uTtOcAfjRrGqX0l+9rBcy20ECpgRnkkjJyafJLmvF7nnZhQjS9Gf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal glomerulus. Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28164=[""].join("\n");
var outline_f27_32_28164=null;
var title_f27_32_28165="Magnesium oxide: Drug information";
var content_f27_32_28165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium oxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12820?source=see_link\">",
"    see \"Magnesium oxide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/5/5205?source=see_link\">",
"    see \"Magnesium oxide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mag-Ox&reg; 400 [OTC];",
"     </li>",
"     <li>",
"      MAGnesium-Oxide&trade; [OTC];",
"     </li>",
"     <li>",
"      Phillips'&reg; Laxative Dietary Supplement Cramp-Free [OTC];",
"     </li>",
"     <li>",
"      Uro-Mag&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F191006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement, Oral;",
"     </li>",
"     <li>",
"      Magnesium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Magnesium: Dosage is in terms of elemental magnesium (IOM, 1997):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     19-30 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 310 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 350 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactation: 310 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 400 mg daily",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     &ge;31 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 320 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 360 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactation: 320 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 420 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       OTC labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Antacid (dosage in terms of magnesium oxide salt):",
"     </b>",
"     Adults: Oral: Tablet: 1-2 tablets  (400-800 mg) daily or in divided doses; maximum: 2 tablets daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dietary supplement (dosage in terms of magnesium oxide salt):",
"     </b>",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Mag-Ox 400&reg;: Two tablets (800 mg) daily with food (maximum: 2 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Uro-Mag&reg;: 3-4 capsules (420-560 mg) daily with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Laxative (dosage in terms of elemental magnesium):",
"     </b>",
"     Children &ge;12 years, Adolescents, and Adults: Oral: Caplet: 2-4 caplets (1000-2000 mg) at bedtime or in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3013037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/5/5205?source=see_link\">",
"      see \"Magnesium oxide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Magnesium: Dosage is in terms of elemental magnesium (IOM, 1997):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: Adequate intake: 30 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: Adequate intake: 75 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: RDA: 80 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: RDA: 130 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: RDA: 240 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years: RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 360 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 400 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactation: 360 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 410 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       OTC labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Laxative (dosage in terms of elemental magnesium):",
"     </b>",
"     Children &ge;12 years and Adolescents: Oral: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F190998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, magnesium is renally excreted. Use with caution; accumulation in renal impairment may lead to magnesium toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: Elemental magnesium 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phillips'&reg; Laxative Dietary Supplement Cramp-Free: Elemental magnesium 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uro-Mag&reg;: 140 mg [equivalent to elemental magnesium 84.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 400 mg [equivalent to elemental magnesium 240 mg], 400 mg [equivalent to elemental magnesium 241.3 mg], 420 mg [equivalent to elemental magnesium 253 mg], 500 mg [equivalent to elemental magnesium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mag-Ox&reg; 400: 400 mg [scored; equivalent to elemental magnesium 240 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MAGnesium-Oxide&trade;: 400 mg [equivalent to elemental magnesium 240 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15152178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at least 2 hours apart from other medications. When used as a laxative, administer with at least 8 oz of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement; relief of acid indigestion and upset stomach; short-term treatment of  occasional constipation",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F191004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined: Gastrointestinal: Diarrhea (excessive oral doses)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     There are no contraindications in the manufacturer&rsquo;s labeling",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F190972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acid indigestion/upset stomach (self-medication, OTC use): Appropriate use: For occasional use only; serious side effects may occur with prolonged use. For use only under the supervision of a physician in patients with kidney dysfunction or who are pregnant or breast-feeding. Unless directed by a physician, do not use for &gt;2 weeks or exceed the recommended daily dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Constipation (self-medication, OTC use): Appropriate use: For occasional use only; serious side effects may occur with prolonged use. For use only under the supervision of a physician in patients with kidney dysfunction, sodium- or magnesium-restricted diets, abdominal pain/nausea/vomiting,a sudden change in bowel habits which has persisted for &gt;2 weeks, or who are pregnant or breast-feeding. If rectal bleeding develops or a bowel movement does not occur after use, discontinue use and consult healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3013029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Osada, 2002; Idama, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3013032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions. Magnesium requirements are the same in lactating and nonlactating females (IOM,1997).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F190988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food and at least 8 oz of water. Whole grains, legumes, and dark-green leafy vegetables are dietary sources of magnesium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4589104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Magnesium Oxide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $9.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Uro-Mag Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     140 mg (100): $18.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mag-200 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (120): $8.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Magnesium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $2.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Magnesium Oxide -Mg Supplement Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $3.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Magnesium Oxide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $2.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (120): $10.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 (240 Mg) mg (120): $8.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 (241.3 Mg) mg (120): $10.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     420 mg (100): $10.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $4.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (MAGnesium-Oxide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 (241.3 Mg) mg (100): $14.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (MagOx 400 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 (241.3 Mg) mg (60): $12.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Maox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     420 mg (250): $9.08",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F190982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum magnesium: 1.5-2.5 mg/dL; slightly different ranges are reported by different laboratories",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Magnez (PL);",
"     </li>",
"     <li>",
"      Oximag (PL);",
"     </li>",
"     <li>",
"      Plusssz Magnez (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3013033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium is important as a cofactor in many enzymatic reactions in the body involving protein synthesis and carbohydrate metabolism (at least 300 enzymatic reactions require magnesium). Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol and on sodium/potassium ATPase in promoting polarization (eg, neuromuscular functioning).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15157198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion: Urine (IOM, 1997)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bashuk RG and Krendel DA, &ldquo;Myasthenia Gravis Presenting as Weakness After Magnesium Administration,&rdquo;",
"      <i>",
"       Muscle Nerve",
"      </i>",
"      , 1990, 13(8):708-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28165/abstract-text/2385256/pubmed\" id=\"2385256\" target=\"_blank\">",
"        2385256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chernow B, Smith J, Rainey TG, et al, &ldquo;Hypomagnesemia: Implications for the Critical Care Specialist,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1982, 10(3):193-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28165/abstract-text/7037303/pubmed\" id=\"7037303\" target=\"_blank\">",
"        7037303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gams JG, &ldquo;Clinical Significance of Magnesium: A Review,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(3):240-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28165/abstract-text/3552543/pubmed\" id=\"3552543\" target=\"_blank\">",
"        3552543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Idama TO and Lindow SW, \"Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,\"",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1998, 105(3):260-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28165/abstract-text/9532984/pubmed\" id=\"9532984\" target=\"_blank\">",
"        9532984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride",
"      </i>",
"      , National Academy of Sciences, Washington, DC, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osada H, Watanabe Y, Nishimura Y, et al, \"Profile of Trace Element Concentrations in the Feto-Placental Unit in Relation to Fetal Growth,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 2002, 81(10):931-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28165/abstract-text/12366483/pubmed\" id=\"12366483\" target=\"_blank\">",
"        12366483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9583 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28165=[""].join("\n");
var outline_f27_32_28165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190993\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191006\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190996\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013037\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190997\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190998\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190981\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190969\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15152178\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190983\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191004\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190986\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190972\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299638\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190977\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013029\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013032\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190988\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589104\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190982\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038671\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013033\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15157198\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9583\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9583|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12820?source=related_link\">",
"      Magnesium oxide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/5/5205?source=related_link\">",
"      Magnesium oxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_32_28166="Mitomycin (systemic): Drug information";
var content_f27_32_28166=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mitomycin (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/33/10773?source=see_link\">",
"    see \"Mitomycin (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13895008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13895014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mitomycin For Injection;",
"     </li>",
"     <li>",
"      Mitomycin For Injection USP;",
"     </li>",
"     <li>",
"      Mutamycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13895019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antibiotic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13895060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stomach or pancreas adenocarcinoma (manufacturer&rsquo;s labeling):",
"     </b>",
"     I.V.: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 6-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anal carcinoma (unlabeled use):",
"     </b>",
"     I.V.: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as an I.V. bolus on days 1 and 29 (maximum: 20 mg/dose) in combination with fluorouracil and radiation therapy (Ajani, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bladder cancer, nonmuscle invasive (unlabeled use/route):",
"     </b>",
"     Intravesicular instillation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Low risk of recurrence (uncomplicated): 40 mg as a single dose postoperatively; retain in bladder for 2 hours (Hall, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Increased risk of recurrence: 20 mg weekly for 6 weeks, followed by 20 mg monthly for 3 years; retain in bladder for 1-2 hours (Friedrich, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13895061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13895062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The manufacturer&rsquo;s labeling states to avoid use in patients with serum creatine &gt;1.7 mg/dL, but no dosage adjustments are provided. The following adjustments have been used by some clinicians (Aronoff, 2007): Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 75% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 75% of dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13895063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F13895064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Leukocytes  2000 to &lt;3000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold  therapy until leukocyte count &ge;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; reduce to 70% of dose in subsequent cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Leukocytes &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold therapy until leukocyte count &ge;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; reduce to 50% of dose in subsequent cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Platelets 25,000 to &lt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold therapy until platelets &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; reduce to 70% of dose in subsequent cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold therapy until platelets &ge;100,000 mm",
"     <sup>",
"      3",
"     </sup>",
"     ; reduce to 50% of dose in subsequent cycles",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13895083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 5 mg, 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13895017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13895066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administer slow I.V. push or by slow (15-30 minute) infusion via a freely-running saline infusion. Consider using a central venous catheter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Intravesicular (unlabeled route): Instill into bladder and retain for up to 2 hours (Friedrich, 2007; Hall, 2007); rotate patient every 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13895049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, bleomycin, caspofungin, cisplatin, cyclophosphamide, doxorubicin, droperidol, fluorouracil, furosemide, granisetron, heparin, leucovorin calcium, melphalan, methotrexate, metoclopramide, ondansetron, teniposide, thiotepa, vinblastine, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aztreonam, cefepime, etoposide phosphate, filgrastim, gemcitabine, piperacillin/tazobactam, sargramostim, topotecan, vinorelbine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cisplatin, cyclophosphamide, doxorubicin, droperidol, fluorouracil, furosemide, heparin, leucovorin calcium, methotrexate, metoclopramide, vinblastine, vincristine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13895022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of adenocarcinoma of stomach or pancreas",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13895023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of anal carcinoma (nonmetastatic), bladder cancer, cervical cancer (recurrent or metastatic), esophageal cancer, gastric cancer, non small cell lung cancer (NSCLC)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13895009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       MitoMYcin (Systemic) may be confused with MitoMYcin (Ophthalmic), mitotane, mitoXANtrone",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13895033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting and anorexia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression (64%; onset: 4 weeks; recovery: 8-10 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS) (&le;15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, mucous membrane toxicity (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Stomatitis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Adult respiratory distress syndrome (ARDS), bladder fibrosis/contraction (intravesical administration), dyspnea, extravasation reactions, heart failure, hepatic sinusoidal obstruction syndrome (SOS, veno-occlusive liver disease), interstitial fibrosis, nonproductive cough, pulmonary infiltrates, rash, renal failure (irreversible)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13895029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mitomycin or any component of the formulation; thrombocytopenia; coagulation disorders, or other increased bleeding tendency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13895030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bladder fibrosis/contraction: With intravesical administration (unapproved administration route), bladder fibrosis/contraction has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Bone marrow suppression (thrombocytopenia and leukopenia) is common and may be severe and/or contribute to infections.",
"     </b>",
"     Fatalities due to sepsis have been reported; monitor for infections. Myelosuppression is dose-limiting, delayed in onset, and cumulative; therefore, monitor blood counts closely during and for &ge;8 weeks following treatment; treatment delay or dosage adjustment may be required for significant thrombocytopenia (platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) or leukopenia (WBC&lt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) or a progressive decline in either value.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolytic-uremic syndrome:",
"     <b>",
"      [U.S. Boxed Warning]: Hemolytic-uremic syndrome (HUS) has been reported (incidence not defined); condition usually involves microangiopathic hemolytic anemia (hematocrit &le;5%), thrombocytopenia (&le;100,000/mm",
"      <sup>",
"       3",
"      </sup>",
"      ), and irreversible renal failure (serum creatinine &ge;1.6 mg/dL). HUS may occur at any time, is generally associated with single doses &ge;60 mg, and HUS symptoms may be exacerbated by blood transfusion.",
"     </b>",
"     Other less common effects may include pulmonary edema, neurologic abnormalities, and hypertension. High mortality from HUS development has been reported, and is largely the result of renal failure. HUS may also be associated with cumulative doses &ge;50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potent vesicant:",
"     <b>",
"      Mitomycin is a potent vesicant, may cause ulceration, necrosis, cellulitis, and tissue sloughing if infiltrated.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: Cases of acute respiratory distress syndrome (ARDS) have been reported in patients receiving mitomycin in combination with other chemotherapy who were maintained at FIO",
"     <sub>",
"      2",
"     </sub>",
"     concentrations &gt;50% perioperatively; use caution to provide only enough oxygen to maintain adequate arterial saturation and avoid overhydration. Pulmonary toxicity has also been reported as dyspnea with nonproductive cough and appearance of pulmonary infiltrates on radiograph; discontinue therapy if pulmonary toxicity occurs and other potential etiologies have been ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Do not administer if serum creatinine is &gt;1.7 mg/dL;  monitor for renal toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vinca alkaloids: Shortness of breath and bronchospasm have been reported in patients receiving vinca alkaloids in combination with mitomycin or who received mitomycin previously; this acute respiratory distress has occurred within minutes to hours following the vinca alkaloid; may be managed with bronchodilators, steroids and/or oxygen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation therapy recipients: Use with caution in patients who have received radiation therapy or in the presence of hepatobiliary dysfunction; reduce dosage in patients who are receiving radiation therapy simultaneously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13895039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13895037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): May enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13895044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid black cohosh, dong quai in estrogen-dependent tumors.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13895025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13895027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13895028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if mitomycin is excreted in human milk; the manufacturer recommends against breast-feeding during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Mitomycin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $67.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $218.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (1): $300.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13895071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor CBC with differential (repeatedly during therapy and for &ge;8 weeks following therapy);  serum creatinine; pulmonary function tests; monitor for signs/symptoms of HUS",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13895087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ametycine (FR);",
"     </li>",
"     <li>",
"      Baxmicin (BR);",
"     </li>",
"     <li>",
"      Datisan (AR);",
"     </li>",
"     <li>",
"      Metomit (CN);",
"     </li>",
"     <li>",
"      Minazol (CO);",
"     </li>",
"     <li>",
"      Mitocyna (PY);",
"     </li>",
"     <li>",
"      Mitomicina-C (PT);",
"     </li>",
"     <li>",
"      Mitomycin (DE, DK, MY, SE);",
"     </li>",
"     <li>",
"      Mitomycin C (ES, HK, IL, IN, PL);",
"     </li>",
"     <li>",
"      Mitomycin-C (AT, BG, CH, GR, HN, ID, IT, NL, PH, RU, TH, TR, TW);",
"     </li>",
"     <li>",
"      Mitomycin-C Kyowa (AU, CZ, GB, HU, LU, NZ);",
"     </li>",
"     <li>",
"      Mitomycine (BE);",
"     </li>",
"     <li>",
"      Mitostat (FI);",
"     </li>",
"     <li>",
"      Mitotie (EC, MX);",
"     </li>",
"     <li>",
"      Mutamycin (DK, EE, FI, HR, NO, PT, UY);",
"     </li>",
"     <li>",
"      Mytomycin C (JP);",
"     </li>",
"     <li>",
"      Mytoxid (PH);",
"     </li>",
"     <li>",
"      Riptam (PE);",
"     </li>",
"     <li>",
"      Vetio (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13895050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts like an alkylating agent and produces DNA cross-linking (primarily with guanine and cytosine pairs); cell-cycle nonspecific; inhibits DNA and RNA synthesis; degrades preformed DNA, causes nuclear lysis and formation of giant cells. While not phase-specific",
"     <i>",
"      per se",
"     </i>",
"     , mitomycin has its maximum effect against cells in late G and early S phases.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13895052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 17-78 minutes; Terminal: 50 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ajani JA, Winter KA, Gunderson LL, et al, &ldquo;Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2008, 299(16):1914-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28166/abstract-text/18430910/pubmed\" id=\"18430910\" target=\"_blank\">",
"        18430910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 101.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Au JL, Badalament RA, Wientjes MG, et al, &ldquo;Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2001, 93(8):597-604.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28166/abstract-text/11309436/pubmed\" id=\"11309436\" target=\"_blank\">",
"        11309436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      El-Ghazal R, Podoltsev N, Marks P, et al, &ldquo;Mitomycin-C-Induced Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome: Cumulative Toxicity of an Old Drug in a New Era,&rdquo;",
"      <i>",
"       Clin Colorectal Ca",
"      </i>",
"      , 2011, 10(2):142-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28166/abstract-text/21859568/pubmed\" id=\"21859568\" target=\"_blank\">",
"        21859568",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flam M, John M, Pajak TF, et al, &ldquo;Role of Mitomycin in Combination With Fluorouracil and Radiotherapy, and of Salvage Chemoradiation in the Definitive Nonsurgical Treatment of Epidermoid Carcinoma of the Anal Canal: Results of a Phase III Randomized Intergroup Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(9):2527-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28166/abstract-text/8823332/pubmed\" id=\"8823332\" target=\"_blank\">",
"        8823332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedrich MG, Pichlmeier U, Schwaibold H, et al, &ldquo;Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence Rate Compared With Short-Term Intravesical Chemotherapy and Short-Term Therapy With Bacillus Calmette-Gu&eacute;rin (BCG) in Patients With Non-Muscle-Invasive Bladder Carcinoma,&rdquo; Eur Urol, 2007, 52(4):1123-29. PMID: 17383080",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28166/abstract-text/17383080/pubmed\" id=\"17383080\" target=\"_blank\">",
"        17383080",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall MC, Chang SS, Dalbagni G, et al, &ldquo;Guideline for the Management of Nonmuscle Invasive Bladder Cancer (stages Ta, T1, and Tis): 2007 Update,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      ,  2007, 178(6):2314-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28166/abstract-text/17993339/pubmed\" id=\"17993339\" target=\"_blank\">",
"        17993339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lesesne JB, Rothschild N, Erickson B, et al, &ldquo;Cancer-Associated Hemolytic-Uremic Syndrome: Analysis of 85 Cases From a National Registry,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1989, 7(6):781-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28166/abstract-text/2497229/pubmed\" id=\"2497229\" target=\"_blank\">",
"        2497229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Medina PJ, Sipols JM, and George JN, &ldquo;Drug-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome,&rdquo;",
"      <i>",
"       Curr Opin Hematol",
"      </i>",
"      , 2001, 8(5):286-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/32/28166/abstract-text/11604563/pubmed\" id=\"11604563\" target=\"_blank\">",
"        11604563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83318 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28166=[""].join("\n");
var outline_f27_32_28166=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895008\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895014\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895019\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895060\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895061\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895062\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895063\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895064\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895083\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895017\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895066\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895049\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895022\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895023\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895009\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895033\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895029\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895030\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895039\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895037\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895044\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895025\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895027\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895028\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570436\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895071\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895087\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895050\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895052\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83318\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83318|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/33/532?source=related_link\">",
"      Mitomycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/62/14307?source=related_link\">",
"      Mitomycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/33/10773?source=related_link\">",
"      Mitomycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_32_28167="Transmyocardial laser revascularization for management of refractory angina";
var content_f27_32_28167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transmyocardial laser revascularization for management of refractory angina",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28167/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28167/contributors\">",
"     Roger J Laham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28167/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28167/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28167/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28167/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28167/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28167/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28167/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/32/28167/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the increasing success of conventional medical therapeutic approaches and the continued development and improvement of mechanical revascularization approaches (eg, drug-eluting stents), a significant number of patients with ischemic heart disease and angina pectoris cannot be successfully managed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a substantial proportion of patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG) do not achieve complete revascularization and, despite maximal medical therapy, many of these patients continue to experience residual anginal symptoms or myocardial ischemia requiring hospitalization. The outcome with medical therapy is poor and one study of 59 such patients found that the one year rate of myocardial infarction or death was 25.5 and 17 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several novel therapeutic strategies that are currently being evaluated for treating patients with refractory angina [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/2\">",
"     2",
"    </a>",
"    ]. In 2002, a report from the European Society of Cardiology reviewed these strategies, including transmyocardial and percutaneous laser revascularization, and summarized the strength of the evidence supporting their use (",
"    <a class=\"graphic graphic_table graphicRef61088 \" href=\"UTD.htm?1/61/2012\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of transmyocardial laser revascularization will be found here. Other modalities, including medical therapies, such as antagonism of endothelin-1 and chelation, and invasive modalities such as promotion of angiogenesis, spinal chord stimulation, and external balloon counterpulsation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/4/6216?source=see_link\">",
"     \"Therapeutic angiogenesis for management of refractory angina\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=see_link\">",
"     \"New therapies for angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TMLR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmyocardial laser revascularization (TMLR) is a technique that uses laser ablation to create transmural channels in the ischemic myocardium in order to restore myocardial perfusion. It shows promise in patients who have angina that is refractory to medical therapy and who are not candidates for surgery or angioplasty. It has also been used as an adjunctive therapy with minimally invasive CABG to achieve more complete revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/4\">",
"     4",
"    </a>",
"    ]. Animal studies have shown that TMLR reduces infarct size and preserves myocardial function after an infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\"",
"    </a>",
"    .) However, despite FDA approval of some of the laser devices for treatment of intractable angina, these techniques are in the early stages of their development; while they offer much promise, there is substantial risk associated with their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic premise behind the application of TMLR is based upon the work of early investigators who were seeking to emulate reptilian circulation in the mammalian heart by creating direct conduits for blood flow from the left ventricular cavity into the myocardium (",
"    <a class=\"graphic graphic_figure graphicRef68481 \" href=\"UTD.htm?11/58/12195\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/6\">",
"     6",
"    </a>",
"    ]. A variety of techniques, including needle acupuncture, mechanical drilling of the left ventricular conduits, and insertion of T-tubes into the myocardium, were attempted with variable success. Development of the clinical high power CO2, holmium:yttrium-aluminum garnet (YAG), and excimer laser systems led to FDA approval of laser myocardial revascularization as a stand-alone therapy in patients with intractable angina. This decision was based upon the demonstration of significant reduction in anginal symptoms as assessed by angina class scale and improvement in exercise capacity. However, there has been little objective evidence of improvements in myocardial perfusion as assessed by nuclear perfusion imaging.",
"   </p>",
"   <p>",
"    Further studies in large animal models have shown that the original premise of TMLR, passive myocardial perfusion of oxygenated blood via newly created channels, is almost certainly",
"    <strong>",
"     false",
"    </strong>",
"    . Essentially all channels are closed by 24 hours, possibly within the first hour, and direct measurement of channel-supplied myocardial blood flow suggests that the increase in myocardial blood flow is minuscule [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The lack of improved blood flow has also been observed clinically. As an example, one study performed positron emission tomography prior to and at 7.5 and 34.6 weeks after TMLR in seven patients; despite a reduction in angina, there was no change in myocardial blood flow at rest and during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    infusion or in coronary vasodilator reserve in lasered and unlasered regions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, the mechanism of the observed clinical benefit, ie, reduction in symptom intensity, following TMLR remains uncertain. A number of possibilities have been proposed to explain these results:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myocardial angiogenesis resulting from the upregulation and release of vascular endothelial growth factors and inflammatory mediators [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Myocardial sympathetic denervation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/6,13,14\">",
"       6,13,14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Myocardial fibrosis that results in a tethering action to improve myocardial function and promote favorable remodeling",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the mechanism, there is usually a delay in clinical benefit; improvement in anginal class is often not evident for at least three months postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/15\">",
"     15",
"    </a>",
"    ]. This situation places patients at high risk for perioperative morbidity and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials have reported encouraging results following TMLR in patients with refractory angina who had lesions not amenable to revascularization or who were at high risk for revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/16-23\">",
"     16-23",
"    </a>",
"    ]. The following reports illustrate the major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial involved 192 patients with refractory angina and left ventricular free-wall ischemia that was not amenable to direct coronary revascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/16\">",
"       16",
"      </a>",
"      ]. After a one year follow-up, more patients undergoing TMLR improved by at least two Canadian Cardiovascular Society (CCS) classes (72 versus 13 percent for continued medical therapy) (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      ) and more had a significant improvement in quality of life. Myocardial perfusion, as assessed by thallium scanning, improved by 20 percent in the TMLR group compared to a 27 percent worsening in the medical group (",
"      <a class=\"graphic graphic_figure graphicRef79231 \" href=\"UTD.htm?2/3/2110\">",
"       figure 2",
"      </a>",
"      ). Overall survival at one year was the same in the two groups (85 versus 79 percent) but there was a marked reduction in hospitalization for unstable angina with TMLR (",
"      <a class=\"graphic graphic_figure graphicRef79521 \" href=\"UTD.htm?13/42/13998\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Similar findings were noted in a trial of 275 patients with refractory angina [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/17\">",
"       17",
"      </a>",
"      ]. At one year, more patients undergoing TMLR had an improvement in angina (76 versus 32 percent with medical therapy) (",
"      <a class=\"graphic graphic_figure graphicRef72331 \" href=\"UTD.htm?17/45/18142\">",
"       figure 4",
"      </a>",
"      ), a higher rate of survival free of cardiac events that was primarily due to freedom from cardiac related hospitalizations (61 versus 31 percent) (",
"      <a class=\"graphic graphic_figure graphicRef59592 \" href=\"UTD.htm?27/59/28605\">",
"       figure 5",
"      </a>",
"      ), and higher exercise tolerance and quality of life scores. There was no difference in myocardial perfusion with thallium imaging or in one year survival (84 versus 89 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At five years, patients treated with TMLR continued to have more frequent improvement in angina than those treated medically (88 versus 44 percent improved by two or more angina classes) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/24\">",
"     24",
"    </a>",
"    ]. The survival rate was also significantly higher for patients initially assigned to TMLR; however, this difference disappeared when patients crossing over were analyzed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a long-term follow-up of a Norwegian trial of 100 patients, anginal symptoms and hospitalization for unstable angina were still significantly reduced at 43 months [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/23\">",
"       23",
"      </a>",
"      ]. There were no differences in the number of myocardial infarctions or mortality (22 versus 24 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These benefits have not been confirmed in all trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. One trial randomly assigned 188 patients with refractory angina due to severe coronary disease not amenable to revascularization to TMLR plus usual medication or to medical management only [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/25\">",
"     25",
"    </a>",
"    ]. The perioperative mortality was 5 percent. After a one year follow-up, patients who underwent TMLR had better relief of angina than the medically treated patients, but there was no difference in exercise capacity as assessed with treadmill exercise testing and a nonsignificant trend toward reduced survival (89 versus 96 percent in the medically treated patients).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limitation to these observations is that the surgical trials were not blinded, thereby permitting a possible placebo effect. The DIRECT trial, which is the only major",
"    <strong>",
"     blinded",
"    </strong>",
"    study of laser myocardial revascularization, failed to show any benefit compared to continued medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'DIRECT trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications after TMLR are almost exclusively cardiac-related and include myocardial infarction, left ventricular failure, atrial fibrillation, and ventricular arrhythmias. Risk factors for an adverse event include CCS class IV status, unprotected left main stenosis, and diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported perioperative mortality has ranged from 3 to 5 percent in most reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/16,25,29\">",
"     16,25,29",
"    </a>",
"    ], but rates as high as 12 percent have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/26,30\">",
"     26,30",
"    </a>",
"    ]. As noted above, however, the increase in short-term mortality does not appear to result in reduced survival at follow-up at one to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/16,17,23,25\">",
"     16,17,23,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The perioperative mortality may be related to acute adverse effects of TMLR on the myocardium that might lead to reduced myocardial blood flow, regional ischemia, and diastolic dysfunction, a result of an increase in regional myocardial edema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, the risk of both perioperative and long-term mortality may be reduced in patients with good blood flow to at least one region of the heart through a native artery or a patent vascular graft (5 versus 25 percent postoperative mortality in patients who did not have adequate blood flow to any region, a benefit that persisted at one year) (",
"    <a class=\"graphic graphic_figure graphicRef56163 \" href=\"UTD.htm?18/53/19293\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Use in refractory unstable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unstable angina that is refractory to medical therapy are at high risk for myocardial infarction and death. Although such patients are usually referred for revascularization by either angioplasty or bypass surgery, there are patients in whom revascularization is not feasible, including those with failed prior procedures, diffuse coronary artery disease, distal stenosis, or small coronary arteries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Long lesions or diffuse disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Small coronary arteries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of TMLR as an alternative approach for treatment of such patients was evaluated by a series of 76 patients with unstable angina of seven days duration who had three failed attempts at weaning from intravenous antianginal drugs; the outcome of these patients was compared to 91 patients with chronic stable angina who underwent TMLR [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/32\">",
"     32",
"    </a>",
"    ]. The ICU and hospital stay after TMLR was the same in both groups. Although perioperative mortality (&le;30 days post-TMLR) was higher in the unstable angina group (16 versus 3 percent), the late mortality (up to one year after TMLR) was the same (13 versus 11 percent). Among the survivors, 82 percent had a reduction of angina by two or more classes at one year, which was similar to the outcome in patients with chronic stable angina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Combined TMLR and CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of TMLR combined with coronary artery bypass grafting (CABG) in patients with coronary disease not amenable to complete revascularization with bypass surgery was evaluated in a study of 263 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients were randomly assigned to bypass grafting of suitable vessels plus TMLR of areas not graftable or bypass surgery alone, with nongraftable areas left unrevascularized.",
"   </p>",
"   <p>",
"    The operative mortality was lower with the combined approach (1.5 versus 7.6 percent for bypass surgery alone) and the need for inotropic support or use of an intra-aortic balloon pump was less after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/33\">",
"     33",
"    </a>",
"    ]. At thirty days, freedom from major adverse cardiac events (death or MI) was significantly greater with TMLR (97 versus 91 percent), but this difference was no longer significant at one year. There was also no significant difference in relief of angina at one year.",
"   </p>",
"   <p>",
"    At five years, patients treated with TMLR had significantly greater relief of angina by several measures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/34\">",
"     34",
"    </a>",
"    ]. However, survival at this time was not significantly different between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PERCUTANEOUS TMLR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to reduce the perioperative mortality associated with surgical TMLR, percutaneous TMLR has been performed in the catheterization laboratory using a holmium:YAG laser, which can channel energy through flexible fibers, unlike the CO2 laser, creating channels in the presence of blood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Preliminary phase I and open label phase II studies of percutaneous TMLR found similar results to those seen with the open chest CO2 TMLR studies: an improvement in angina class and exercise capacity with minimal or no change in nuclear perfusion scans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The PACIFIC trial randomly assigned 221 patients with refractory angina (CCS class III or IV) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) to percutaneous TMLR or conventional medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/39\">",
"     39",
"    </a>",
"    ]. At 12 months, those undergoing percutaneous TMLR had a greater median increase in exercise tolerance (89 versus 12.5 seconds [14.4 versus 5.5 percent]) and the angina was more likely to be class II or lower (34 versus 13 percent of patients). There was no difference in survival or the combined end point of death, myocardial infarction, or hospital admission between the two groups.",
"   </p>",
"   <p>",
"    However, neither symptomatic nor survival benefits from percutaneous TMLR were noted in a trial of 141 patients with class III or IV angina (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) due to one or more chronically occluded coronary arteries who had failed previous percutaneous coronary intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/40\">",
"     40",
"    </a>",
"    ] or in the DIRECT trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     DIRECT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DIRECT trial is the only major",
"    <strong>",
"     blinded",
"    </strong>",
"    study of laser myocardial revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/27\">",
"     27",
"    </a>",
"    ]. In this trial, 298 patients with refractory angina who were suboptimal candidates for CABG or PCI were randomly assigned to electromechanical mapping, using the Biosense Laser system, with low-dose or high-dose laser channels or no laser channels, blinded as a sham procedure. There was no benefit of TMLR compared to continued medical therapy in terms of patient survival, angina class, quality of life assessment, exercise duration, or nuclear perfusion imaging.",
"   </p>",
"   <p>",
"    These findings raise doubt about previous positive studies, since they underscore the powerful placebo effect in patients with end-stage cardiac disease that can lead to physiologic benefits as well as improved symptoms. The placebo effect can persist for 30 months or more [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Combined with PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of a percutaneous coronary intervention (PCI), including angioplasty, stenting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atherectomy, combined with percutaneous TMLR performed in the same myocardial territory served by the treated vessel was addressed in a pilot study of 26 patients with class",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    angina [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/42\">",
"     42",
"    </a>",
"    ]. Major periprocedural adverse events, due to subacute vessel closure or tamponade, occurred in 11.5 percent. At six months, 19 percent of patients required repeat PCI for restenosis, 12 percent had class",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    angina, and the mortality was 19 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the availability of drug-eluting stents and novel devices for chronic total occlusion, the number of patients who are truly not amenable to CABG or PCI is shrinking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Chronic total occlusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom which concluded that neither TMLR nor percutaneous TMLR should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28167/abstract/43\">",
"     43",
"    </a>",
"    ]. This is based on evidence of an absence of benefit (no significant improvement in myocardial function or survival) and the presence of safety concerns (both may be associated with an increase in periprocedural complications).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/1\">",
"      Mukherjee D, Comella K, Bhatt DL, et al. Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. Am Heart J 2001; 142:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/2\">",
"      Kim MC, Kini A, Sharma SK. Refractory angina pectoris: mechanism and therapeutic options. J Am Coll Cardiol 2002; 39:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/3\">",
"      Mannheimer C, Camici P, Chester MR, et al. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J 2002; 23:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/4\">",
"      Trehan N, Mishra Y, Mehta Y, Jangid DR. Transmyocardial laser as an adjunct to minimally invasive CABG for complete myocardial revascularization. Ann Thorac Surg 1998; 66:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/5\">",
"      Horvath KA, Smith WJ, Laurence RG, et al. Recovery and viability of an acute myocardial infarct after transmyocardial laser revascularization. J Am Coll Cardiol 1995; 25:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/6\">",
"      Roethy W, Yamamoto N, Burkhoff D. An examination of potential mechanisms underlying transmyocardial laser revascularization induced increases in myocardial blood flow. Semin Thorac Cardiovasc Surg 1999; 11:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/7\">",
"      Kohmoto T, Fisher PE, Gu A, et al. Does blood flow through holmium:YAG transmyocardial laser channels? Ann Thorac Surg 1996; 61:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/8\">",
"      Kohmoto T, Fisher PE, Gu A, et al. Physiology, histology, and 2-week morphology of acute transmyocardial channels made with a CO2 laser. Ann Thorac Surg 1997; 63:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/9\">",
"      Burkhoff D, Fisher PE, Apfelbaum M, et al. Histologic appearance of transmyocardial laser channels after 4 1/2 weeks. Ann Thorac Surg 1996; 61:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/10\">",
"      Rimoldi O, Burns SM, Rosen SD, et al. Measurement of myocardial blood flow with positron emission tomography before and after transmyocardial laser revascularization. Circulation 1999; 100:II134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/11\">",
"      Hughes GC, Lowe JE, Kypson AP, et al. Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia. Ann Thorac Surg 1998; 66:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/12\">",
"      Horvath KA, Chiu E, Maun DC, et al. Up-regulation of vascular endothelial growth factor mRNA and angiogenesis after transmyocardial laser revascularization. Ann Thorac Surg 1999; 68:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/13\">",
"      Sundt TM 3rd, Kwong KF. Clinical experience with the holmium:YAG laser for transmyocardial laser revascularization and myocardial denervation as a mechanism. Semin Thorac Cardiovasc Surg 1999; 11:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/14\">",
"      Al-Sheikh T, Allen KB, Straka SP, et al. Cardiac sympathetic denervation after transmyocardial laser revascularization. Circulation 1999; 100:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/15\">",
"      Hughes GC, Landolfo KP, Lowe JE, et al. Perioperative morbidity and mortality after transmyocardial laser revascularization: incidence and risk factors for adverse events. J Am Coll Cardiol 1999; 33:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/16\">",
"      Frazier OH, March RJ, Horvath KA. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 1999; 341:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/17\">",
"      Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 1999; 341:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/18\">",
"      Burkhoff D, Schmidt S, Schulman SP, et al. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial. ATLANTIC Investigators. Angina Treatments-Lasers and Normal Therapies in Comparison. Lancet 1999; 354:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/19\">",
"      Horvath KA, Cohn LH, Cooley DA, et al. Transmyocardial laser revascularization: results of a multicenter trial with transmyocardial laser revascularization used as sole therapy for end-stage coronary artery disease. J Thorac Cardiovasc Surg 1997; 113:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/20\">",
"      Diegeler A, Schneider J, Lauer B, et al. Transmyocardial laser revascularization using the Holium-YAG laser for treatment of end stage coronary artery disease. Eur J Cardiothorac Surg 1998; 13:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/21\">",
"      Burns SM, Sharples LD, Tait S, et al. The transmyocardial laser revascularization international registry report. Eur Heart J 1999; 20:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/22\">",
"      March RJ. Transmyocardial laser revascularization with the CO2 laser: one year results of a randomized, controlled trial. Semin Thorac Cardiovasc Surg 1999; 11:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/23\">",
"      Aaberge L, Rootwelt K, Blomhoff S, et al. Continued symptomatic improvement three to five years after transmyocardial revascularization with CO(2) laser: a late clinical follow-up of the Norwegian Randomized trial with transmyocardial revascularization. J Am Coll Cardiol 2002; 39:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/24\">",
"      Allen KB, Dowling RD, Angell WW, et al. Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. Ann Thorac Surg 2004; 77:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/25\">",
"      Schofield PM, Sharples LD, Caine N, et al. Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial. Lancet 1999; 353:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/26\">",
"      N&auml;gele H, Stubbe HM, Nienaber C, R&ouml;diger W. Results of transmyocardial laser revascularization in non-revascularizable coronary artery disease after 3 years follow-up [ssee comments]. Eur Heart J 1998; 19:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/27\">",
"      Leon MB, Kornowski R, Downey WE, et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol 2005; 46:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/28\">",
"      Tjomsland O, Aaberge L, Almdahl SM, et al. Perioperative cardiac function and predictors for adverse events after transmyocardial laser treatment. Ann Thorac Surg 2000; 69:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/29\">",
"      Aaberge L, Nordstrand K, Dragsund M, et al. Transmyocardial revascularization with CO2 laser in patients with refractory angina pectoris. Clinical results from the Norwegian randomized trial. J Am Coll Cardiol 2000; 35:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/30\">",
"      Burkhoff D, Wesley MN, Resar JR, Lansing AM. Factors correlating with risk of mortality after transmyocardial revascularization. J Am Coll Cardiol 1999; 34:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/31\">",
"      Hughes GC, Shah AS, Yin B, et al. Early postoperative changes in regional systolic and diastolic left ventricular function after transmyocardial laser revascularization: a comparison of holmium:YAG and CO2 lasers. J Am Coll Cardiol 2000; 35:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/32\">",
"      Hattler BG, Griffith BP, Zenati MA, et al. Transmyocardial laser revascularization in the patient with unmanageable unstable angina. Ann Thorac Surg 1999; 68:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/33\">",
"      Allen KB, Dowling RD, DelRossi AJ, et al. Transmyocardial laser revascularization combined with coronary artery bypass grafting: a multicenter, blinded, prospective, randomized, controlled trial. J Thorac Cardiovasc Surg 2000; 119:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/34\">",
"      Allen KB, Dowling RD, Schuch DR, et al. Adjunctive transmyocardial revascularization: five-year follow-up of a prospective, randomized trial. Ann Thorac Surg 2004; 78:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/35\">",
"      Kim CB, Oesterle SN. Percutaneous transmyocardial revascularization. J Clin Laser Med Surg 1997; 15:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/36\">",
"      Kornowski R, Hong MK, Haudenschild CC, Leon MB. Feasibility and safety of percutaneous laser revascularization using the Biosense system in porcine hearts. Coron Artery Dis 1998; 9:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/37\">",
"      Lauer B, Junghans U, Stahl F, et al. Catheter-based percutaneous myocardial laser revascularization in patients with end-stage coronary artery disease. J Am Coll Cardiol 1999; 34:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/38\">",
"      Shawl FA, Domanski MJ, Kaul U, et al. Procedural results and early clinical outcome of percutaneous transluminal myocardial revascularization. Am J Cardiol 1999; 83:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/39\">",
"      Oesterle SN, Sanborn TA, Ali N, et al. Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial. Potential Class Improvement From Intramyocardial Channels. Lancet 2000; 356:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/40\">",
"      Stone GW, Teirstein PS, Rubenstein R, et al. A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions. J Am Coll Cardiol 2002; 39:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/41\">",
"      Rana JS, Mannam A, Donnell-Fink L, et al. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol 2005; 95:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/42\">",
"      Stone GW, St Goar FG, Taussig A, et al. First experience with hybrid percutaneous transmyocardial laser revascularization and angioplasty in patients with lesions at high risk for restenosis: Results of a phase I feasibility study. Am Heart J 2001; 142:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28167/abstract/43\">",
"      Schofield PM, McNab D, National Institute for Health and Clinical. NICE evaluation of transmyocardial laser revascularisation and percutaneous laser revascularisation for refractory angina. Heart 2010; 96:312.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1568 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.25.216.6-E05BAE8337-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28167=[""].join("\n");
var outline_f27_32_28167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TMLR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Use in refractory unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Combined TMLR and CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PERCUTANEOUS TMLR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIRECT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Combined with PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1568\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1568|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/58/12195\" title=\"figure 1\">",
"      Schematic of transmyocardial laser revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/3/2110\" title=\"figure 2\">",
"      TMLR  improves left ventricular myocardial perfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/42/13998\" title=\"figure 3\">",
"      TMLR event free survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/45/18142\" title=\"figure 4\">",
"      TMLR improvement angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/59/28605\" title=\"figure 5\">",
"      TMLR freedom rehospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/53/19293\" title=\"figure 6\">",
"      Unobstructed blood flow predicts TMLR outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1568|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/61/2012\" title=\"table 1\">",
"      Treatment options for refractory angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=related_link\">",
"      New therapies for angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/4/6216?source=related_link\">",
"      Therapeutic angiogenesis for management of refractory angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_32_28168="Drug-induced lupus";
var content_f27_32_28168=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug-induced lupus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28168/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28168/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28168/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28168/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28168/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28168/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28168/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/32/28168/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain drugs induce autoantibodies in a significant number of patients, most of whom do not develop signs of an autoantibody associated disease. As examples,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    and anti-tumor necrosis factor therapies often cause increased levels of antinuclear antibodies (ANA) in serum, yet few develop clinical symptoms such as rash, serositis, arthritis suggesting drug induced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are two ways in which certain drugs may interact with lupus: they might exacerbate underlying lupus or induce lupus in a predisposed patient; or they might cause the separate syndrome of drug-induced lupus. Although some studies suggested that penicillin and anticonvulsant drugs might exacerbate underlying lupus, current opinion suggests that these patients had lupus and were receiving appropriate medications. However, many investigators feel that sulfonamide antibiotics may exacerbate lupus.",
"   </p>",
"   <p>",
"    Drug-induced lupus has similarities to spontaneous systemic lupus erythematosus (SLE), but also has some different clinical and immunologic features (",
"    <a class=\"graphic graphic_table graphicRef69467 \" href=\"UTD.htm?14/62/15341\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will review features of drug-induced lupus, particularly those that distinguish it from native or idiopathic SLE. The clinical manifestations and diagnosis of SLE in adults and in children are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"     \"Systemic lupus erythematosus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are an estimated 15,000 to 30,000 cases of drug-induced lupus per year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/2\">",
"     2",
"    </a>",
"    ]. It is generally equally common in males and females, is more common in older people, and Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. An exception is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    -induced lupus, which is mostly observed in young women treated for acne.",
"   </p>",
"   <p>",
"    The risk for developing lupus is quite varied for different medications, ranging from 15 to 20 percent of those taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , 7 to 13 percent of those taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , to as low as 2 per 1000 for those taking anti-TNF and 5 per 10,000 of those taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism or mechanisms involved in drug-induced lupus remain uncertain. However, various theories have been developed regarding the pathogenesis of drug-induced lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/4\">",
"     4",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormalities in oxidative drug metabolism",
"     </li>",
"     <li>",
"      Drugs act as haptens or agonists for drug-specific T cells",
"     </li>",
"     <li>",
"      Cytotoxic drug metabolites cause pathology",
"     </li>",
"     <li>",
"      Drugs non-specifically activate lymphocytes",
"     </li>",
"     <li>",
"      Drug metabolites disrupt central immune tolerance",
"     </li>",
"     <li>",
"      Abnormalities in thymus function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the mechanism, the result has the hallmarks of enhanced autoimmunity and clinical manifestations (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Clinical manifestations'",
"    </a>",
"    below) represent immune-mediated organ damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1339498\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the pathogenesis of drug-induced lupus is not well understood, genetic predisposition may play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1339415\">",
"    <span class=\"h3\">",
"     Acetylator status",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of certain drugs, particularly those agents that are metabolized by acetylation such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Etiology'",
"    </a>",
"    below), the disease is more likely to develop, and to develop sooner, in patients who are slow acetylators because of a genetically mediated decrease in the hepatic synthesis of N-acetyltransferase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, acetylation rate is not a risk factor for spontaneous lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/8\">",
"     8",
"    </a>",
"    ]. Acetylation rate seems unlikely to be related to the etiopathogenesis of disease related to other agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    and those that inhibit tumor necrosis factor-alpha action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1339422\">",
"    <span class=\"h3\">",
"     Other genetic risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other genetic risk factors include HLA-DR4, HLA-DR0301, and the complement C4 null allele [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;One important immunologic characteristic of drug-induced lupus is the presence of autoantibodies. In disease related to certain drugs there are antinuclear antibodies that have specificity for histone proteins. With disease due to other agents, antibodies more often associated with idiopathic SLE (eg, anti-double stranded DNA) or with systemic vasculitis (eg, anti-neutrophil cytoplasmic antibodies) are present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Antihistone antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihistone antibodies are present in more than 95 percent of cases overall; this percentage is representative for those taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ; however, antihistone antibodies have been found in a smaller proportion of patients with drug-induced lupus associated with other medications, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    , propylthiouracil, and statins (32, 42, and &lt;50 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Other autoantibodies are uncommon in this disorder. Antihistone antibodies are also seen in up to 80 percent of patients with idiopathic lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]; however, patients with idiopathic SLE also form a variety of other autoantibodies, including those directed against DNA and small ribonucleoproteins (",
"    <a class=\"graphic graphic_table graphicRef69467 \" href=\"UTD.htm?14/62/15341\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The antihistone antibodies in drug-induced lupus are primarily formed against a complex of the histone dimer H2A-H2B and DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/11-13\">",
"     11-13",
"    </a>",
"    ] and, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , to the H1 and H3-H4 complex [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/9\">",
"     9",
"    </a>",
"    ]. DNA is required either to stabilize the complex or perhaps to contribute part of the antigenic epitope [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/13\">",
"     13",
"    </a>",
"    ]. Although the drugs that can cause drug-induced lupus are markedly heterogeneous, there may be a common pathway for disease induction since the autoantibodies produced in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , hydralazine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37047?source=see_link\">",
"     acebutolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , isoniazide, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    are in most, but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/12\">",
"     12",
"    </a>",
"    ], cases nearly identical [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, the antihistone antibodies in idiopathic lupus are primarily directed against the H1 and H2B histone subunits [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of IgG antibodies to the complex of H2A-H2B and DNA soon after starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    is associated with a high risk of developing drug-induced lupus; by comparison, autoantibodies to single-stranded DNA or histones alone do not distinguish between symptomatic or asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/14\">",
"     14",
"    </a>",
"    ]. It is not known if these observations apply to other causes of drug-induced lupus.",
"   </p>",
"   <p>",
"    It remains unclear, however, what the particular characteristic is of those drugs that induce autoantibody formation. One possibility is that the offending drugs are capable of serving as substrates for myeloperoxidase in activated neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/15\">",
"     15",
"    </a>",
"    ]. This has been demonstrated in vitro with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , and to a lesser extent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    , and PTU. This interaction results in the formation of reactive drug metabolites, which may directly affect lymphocyte function.",
"   </p>",
"   <p>",
"    An alternative hypothesis is that drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    decrease T cell DNA methylation, leading to overexpression of LFA-1 (lymphocyte function-associated antigen-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/9,16,17\">",
"     9,16,17",
"    </a>",
"    ]. Consistent with this hypothesis is the observation in an animal model that hydralazine acted by inhibiting the extracellular signal-regulated kinase (ERK) pathway, with resulting interference with DNA methyltransferase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/18\">",
"     18",
"    </a>",
"    ]. The T cells with hypomethylated DNA may then become autoreactive, leading to autoantibody formation. Ultraviolet light has the same effect, which may explain its ability to induce exacerbations of primary lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/16\">",
"     16",
"    </a>",
"    ]. It is also possible that genetic differences in cytochrome P450 enzymes, which facilitate the metabolism of many medications, results in the generation of toxic metabolites that facilitate the development of autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon in vitro and in vivo murine studies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    hydroxylamine (PAHA, a reactive metabolite of procainamide) has been implicated in the development of drug-induced lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. As an example, antibodies to the histone (H2A-H2B)-DNA complex can be induced in mice by the intrathymic injection of PAHA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/20\">",
"     20",
"    </a>",
"    ]. In another study, the incubation of PAHA with T cell clones resulted in resistance to anergy induction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/21\">",
"     21",
"    </a>",
"    ]. Taken together, these observations suggest that PAHA induces autoimmunity via the emergence of autoreactive T cells followed by the production of antihistone antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Anti-double stranded DNA antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-double stranded DNA antibodies are typically absent in drug-induced lupus due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , such antibodies are associated with drug-induced disease with other agents, particularly with interferon-alfa and anti-TNF agents. With the latter class of anti-cytokine therapies, although patients may develop autoantibodies, relatively few patients, including those with anti-DNA antibodies, develop clinical, drug-induced lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Anti-TNF agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Antineutrophil cytoplasmic antibodies (ANCA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced ANCA are sometimes associated with necrotizing vasculitis. The pathogenetic significance of drug-induced ANCA is discussed in detail elsewhere. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'ANCA-positive vasculitis and renal disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Drug-induced ANCA-associated vasculitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of drugs have been identified as being definite, probable, or possible causes of lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/5,6,13,23-37\">",
"     5,6,13,23-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definite &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       Procainamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      (INH),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      , anti-tumor necrosis factor alpha therapy (with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ), interferon-alfa,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      , and practolol [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. INH induces antinuclear antibodies in approximately 15 percent of patients but symptomatic lupus is rare. Diltiazem may result in the induction of subacute cutaneous lupus [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/27\">",
"       27",
"      </a>",
"      ]. Interferon-alpha induced lupus is characterized by anti-nuclear antibodies, including antibodies to dsDNA.",
"      <br/>",
"      <br/>",
"      Anti-tumor necrosis factor alpha therapy with infliximab,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      , and etanercept has been associated with the development of positive test results for antinuclear (13 to 83 percent), anti-DNA (3 to 32 percent),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antihistone antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. Four patients who developed definite or probable drug-induced lupus while receiving etanercept had resolution of symptoms within two to six weeks of discontinuing therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"       \"Overview of biologic agents in the rheumatic diseases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"       \"Infliximab in Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Probable &mdash; Anticonvulsants (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , mephenytoin, trimethadione,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/54/13158?source=see_link\">",
"       ethosuximide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ), antithyroid drugs, antimicrobial agents (sulfonamides,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      ), beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , paraaminosalicylate,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      , interferon gamma,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"       terbinafine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      , hydrazine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/24,31-36\">",
"       24,31-36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      One report described seven patients who developed a drug-induced lupus-like syndrome (characterized clinically by malaise, arthralgias, arthritis, and edema) in association with therapy with rifampin for mycobacterial infection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/32\">",
"       32",
"      </a>",
"      ]. Despite over 20 years use with the rifampin class (including rifampin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      ), this complication had not been noticed previously. All patients in this report were also treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      . It was suggested that inhibition of hepatic cytochrome P450 enzymes by these medications might have raised serum rifampin levels or that rifampin might have affected the metabolism of clarithromycin or ciprofloxacin.",
"      <br/>",
"      <br/>",
"      Subacute cutaneous lupus erythematosus (SCLE) may be associated with systemic (oral) use of the antifungal agent, terbinafine. New onset or exacerbation of preexisting SCLE was noted after exposure to terbinafine in five patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A component of alfalfa sprouts, L-canavanine, induces a lupus-like syndrome in monkeys. There is, however, no definite evidence that this occurs in humans.",
"     </li>",
"     <li>",
"      Possible &mdash; Gold salts, penicillin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"       reserpine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , statins (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      )",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"       griseofulvin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      , valproate, ophthalmic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"       timolol",
"      </a>",
"      , and 5-aminosalicylate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Those drugs associated with the highest risk of inducing lupus in an individual patient are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    . Oral contraceptives, on the other hand, may contribute to a relapse of idiopathic lupus but are unlikely to produce drug-induced disease. Postmenopausal estrogen replacement therapy has also been associated with an increased risk of developing idiopathic lupus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H35#H35\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Other possible risks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Procainamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lupus-like syndrome is most commonly seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    which, as noted above, may be mediated by the reactive metabolite procainamide hydroxylamine. A positive antinuclear antibody (ANA) titer occurs in almost all patients given the drug for more than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/38\">",
"     38",
"    </a>",
"    ]; they are more likely to develop in slow acetylators [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/11\">",
"     11",
"    </a>",
"    ]. Symptoms, however, develop in about one-third of those who have taken procainamide for more than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/38\">",
"     38",
"    </a>",
"    ]; the determining factors for susceptibility to symptomatic disease are not known [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Risk factors include HLA-DR6Y, but not DR4 or DR3 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to this high risk, there is little or no ANA formation or symptomatic lupus following the administration of N-acetylprocainamide (NAPA), the major active metabolite of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/40\">",
"     40",
"    </a>",
"    ]; furthermore, remission of procainamide-induced lupus can be achieved by switching to NAPA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/41\">",
"     41",
"    </a>",
"    ]. These observations suggest an important pathogenetic role for the aromatic amino group on procainamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hydralazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of clinical disease is generally lower with drugs other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , averaging 5 to 10 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , being infrequent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , and rarely occurring with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. With hydralazine, for example, a number of risk factors have been identified including drug dose (more than 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cumulative dose of more than 100 g), female sex, slow hepatic acetylation, the HLA-DR4 genotype, and the null gene for the fourth component of complement, C4 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/38,42-44\">",
"     38,42-44",
"    </a>",
"    ]. In one study, lupus developed in 19 percent of women taking 200 mg of hydralazine per day as compared to 13 of 13 who also had the HLA-DR4 genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/43\">",
"     43",
"    </a>",
"    ]. It is possible that slow acetylation increases free drug levels while low levels of C4 might prevent clearance of any immune complexes that are formed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/43\">",
"     43",
"    </a>",
"    ]. Even low doses may not be safe as clinical disease can develop in up to 5 percent of slow acetylators taking 100 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Minocycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    , in contrast to other tetracyclines, appears to cause a drug-induced lupus syndrome, particularly among young women being treated for acne [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/37,45-48\">",
"     37,45-48",
"    </a>",
"    ]. Symptoms include arthralgia (73 to 100 percent), arthritis (12 to 45 percent), fever (38 percent), and rash (29 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/47\">",
"     47",
"    </a>",
"    ]. Other clinical features that have been described are morning stiffness, myalgia, and cutaneous vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/37\">",
"     37",
"    </a>",
"    ]. A positive ANA and P-ANCA have been found in 92 and 83 percent of tested sera, respectively; by comparison, antihistone antibodies are uncommon (0 to 13 percent). Although the risk of developing drug-induced lupus is relatively low (hazard ratio 2.6-3.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/49\">",
"     49",
"    </a>",
"    ], we recommend that minocycline not be used in patients with SLE. Although most cases of minocycline-induced lupus resolve within a relatively short time after drug discontinuation, young children may be at increased risk for prolonged disease following minocycline exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anti-TNF agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of drug-induced lupus are characterized by skin and pleuropericardial abnormalities, along with the formation of autoantibodies such as those to dsDNA, the Sm antigen, or histones. Renal and neurological manifestations are extremely rare. Most cases of drug-induced lupus associated with TNF inhibitor use resolve completely upon discontinuation of the TNF inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2120?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with drug-induced lupus can develop a variety of systemic symptoms, including fever, myalgias, rash, arthralgias, arthritis, and serositis (",
"    <a class=\"graphic graphic_table graphicRef69467 \" href=\"UTD.htm?14/62/15341\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The frequency of these manifestations may vary with the drug. As an example, pleuritis occurs in approximately half of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    -induced lupus patients, 22 percent of those with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    -induced disease, and less than 1 percent of those with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematologic abnormalities and more severe manifestations, such as kidney disease and central nervous system involvement, are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/2,5\">",
"     2,5",
"    </a>",
"    ], although they may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/44,51,52\">",
"     44,51,52",
"    </a>",
"    ]. Liver function abnormalities may occur and have been noted in 32 to 54 percent of patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    -induced lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypocomplementemia and anti-DNA antibodies are also unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/43\">",
"     43",
"    </a>",
"    ], with the exceptions noted above (eg, anti-DNA often present in disease associated with use of interferon-alfa and anti-TNF therapies).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Skin disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As is the case with nondrug-induced, native lupus, a variety of skin manifestations may be seen. As mentioned, one of the more specific is the polycyclic scaling erythematous rash in sun exposed areas, typical of subacute cutaneous lupus erythematosus (SCLE). This type of rash has been associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , calcium channel blockers, angiotensin-converting enzyme inhibitors, the antifungal agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    , statins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37047?source=see_link\">",
"     acebutolol",
"    </a>",
"    , and interferons [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/2,3,33,53-55\">",
"     2,3,33,53-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H7#H7\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Subacute cutaneous lupus erythematosus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rash of SCLE has also been noted in drug-induced disease due to anti-TNF agents and with some forms of chemotherapy. The rash of SCLE has been noted in patients reported with lupus following initiation of treatment with the anti-TNF agents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/2,37,56\">",
"     2,37,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar photo-distributed rash, autoantibody formation, and histopathologic findings characteristic of SCLE have been noted in some patients receiving chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=see_link&amp;anchor=H14#H14\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Photosensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     ANCA-positive vasculitis and renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2003 review reported a 15 to 20 percent prevalence of ANCA in patients with idiopathic SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/57\">",
"     57",
"    </a>",
"    ]. The various subtypes of ANCA in idiopathic SLE were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      P-ANCA &mdash; 10 to 42 percent",
"     </li>",
"     <li>",
"      C-ANCA &mdash; 0 to 6 percent",
"     </li>",
"     <li>",
"      Anti-myeloperoxidase (anti-MPO) &mdash; 0 to 24 percent",
"     </li>",
"     <li>",
"      Anti-proteinase 3 (anti-PR3) &mdash; 0 to 13 percent",
"     </li>",
"     <li>",
"      Other ANCA specificities (eg, lactoferrin, elastase) &mdash; 0 to 59 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The renal disease in drug-induced lupus is most often due to a necrotizing glomerulonephritis with little or no immune complex deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/52,58,59\">",
"     52,58,59",
"    </a>",
"    ], although an immune complex-mediated glomerulonephritis can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/51\">",
"     51",
"    </a>",
"    ]. The patients with a necrotizing glomerulonephritis usually show a P-ANCA pattern on immunofluorescence microscopy with anti-MPO plus either anti-lactoferrin or anti-elastase (the latter antibodies are called atypical P-ANCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/52,57-59\">",
"     52,57-59",
"    </a>",
"    ]. This combination of ANCAs appears to be relatively specific for this form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    -induced vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/60\">",
"     60",
"    </a>",
"    ]. These patients may also have anti-double-stranded DNA antibodies, which are uncommon in the typical form of hydralazine-induced lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of drug-induced lupus should be suspected when a patient taking one or more of the above drugs for at least one month, and usually much longer, presents with some combination of arthralgia, myalgia, malaise, fever, rash,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serositis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Confirming the diagnosis is difficult, however, because of the clinical overlap with the more common idiopathic disease. If available, the finding of antihistone antibodies in the absence of other autoantibodies strongly suggests that a drug is responsible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. The \"gold standard\" is spontaneous resolution of the disease within one to seven months after the offending drug has been discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28168/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is focused on stopping the medication. Nonsteroidal antiinflammatory drugs and antimalarials can be temporarily used if constitutional and musculoskeletal symptoms do not clear rapidly. Corticosteroids are infrequently required but can induce quick resolution of serositis. In contrast, patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    -induced vasculitis often require cytotoxic therapy as in other ANCA-positive vasculitides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/1\">",
"      Olsen NJ. Drug-induced autoimmunity. Best Pract Res Clin Rheumatol 2004; 18:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/2\">",
"      Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007; 1108:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/3\">",
"      Vasoo S. Drug-induced lupus: an update. Lupus 2006; 15:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/4\">",
"      Rubin RL. Drug-induced lupus. Toxicology 2005; 209:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/5\">",
"      Hess E. Drug-related lupus. N Engl J Med 1988; 318:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/6\">",
"      Fritzler MJ. Drugs recently associated with lupus syndromes. Lupus 1994; 3:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/7\">",
"      Grant DM, M&ouml;rike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990; 85:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/8\">",
"      Reidenberg MM, Drayer DE, Lorenzo B, et al. Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. Arthritis Rheum 1993; 36:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/9\">",
"      Yung RL, Johnson KJ, Richardson BC. New concepts in the pathogenesis of drug-induced lupus. Lab Invest 1995; 73:746.",
"     </a>",
"    </li>",
"    <li>",
"     Merola JF. Lupus-like syndromes related to drugs. In: Lupus erythematosus: Clinical evaluation and treatment, Schur PH, Massarotti E.  (Eds), Springer, New York. in press.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/11\">",
"      Totoritis MC, Tan EM, McNally EM, Rubin RL. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N Engl J Med 1988; 318:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/12\">",
"      Burlingame RW, Rubin RL. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 1991; 88:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/13\">",
"      Rubin RL, Bell SA, Burlingame RW. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 1992; 90:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/14\">",
"      Rubin RL, Burlingame RW, Arnott JE, et al. IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus. J Immunol 1995; 154:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/15\">",
"      Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994; 266:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/16\">",
"      Yung R, Powers D, Johnson K, et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996; 97:2866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/17\">",
"      Lu Q, Kaplan M, Ray D, et al. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum 2002; 46:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/18\">",
"      Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003; 48:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/19\">",
"      McKinnon RA, Nebert DW. Possible role of cytochromes P450 in lupus erythematosus and related disorders. Lupus 1994; 3:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/20\">",
"      Kretz-Rommel A, Duncan SR, Rubin RL. Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus. J Clin Invest 1997; 99:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/21\">",
"      Kretz-Rommel A, Rubin RL. A metabolite of the lupus-inducing drug procainamide prevents anergy induction in T cell clones. J Immunol 1997; 158:4465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/22\">",
"      De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus 2006; 15:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/23\">",
"      Love LA. New environmental agents associated with lupus-like disorders. Lupus 1994; 3:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/24\">",
"      Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/25\">",
"      De Rycke L, Kruithof E, Van Damme N, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/26\">",
"      Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000; 43:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/27\">",
"      Crowson AN, Magro CM. Diltiazem and subacute cutaneous lupus erythematosus-like lesions. N Engl J Med 1995; 333:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/28\">",
"      Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 2005; 1051:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/29\">",
"      Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 2006; 18:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/30\">",
"      De Rycke L, Baeten D, Kruithof E, et al. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005; 14:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/31\">",
"      Laversuch CJ, Collins DA, Charles PJ, Bourke BE. Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease. Br J Rheumatol 1995; 34:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/32\">",
"      Berning SE, Iseman MD. Rifamycin-induced lupus syndrome. Lancet 1997; 349:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/33\">",
"      Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol 2001; 137:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/34\">",
"      Sheikhzadeh A, Sch&auml;fer U, Schnabel A. Drug-induced lupus erythematosus by amiodarone. Arch Intern Med 2002; 162:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/35\">",
"      Spiera RF, Berman RS, Werner AJ, Spiera H. Ticlopidine-induced lupus: a report of 4 cases. Arch Intern Med 2002; 162:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/36\">",
"      Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 2004; 31:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/37\">",
"      Mor A, Pillinger MH, Wortmann RL, Mitnick HJ. Drug-induced arthritic and connective tissue disorders. Semin Arthritis Rheum 2008; 38:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/38\">",
"      Yung R, Richardson B. Drug-induced rheumatic syndromes. Bull Rheum Dis 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/39\">",
"      Adams LE, Mongey AB. Role of genetic factors in drug-related autoimmunity. Lupus 1994; 3:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/40\">",
"      Reidenberg MM, Drayer DE. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus. Angiology 1986; 37:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/41\">",
"      Stec GP, Lertora JJ, Atkinson AJ Jr, et al. Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy. Ann Intern Med 1979; 90:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/42\">",
"      Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J (Clin Res Ed) 1984; 289:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/43\">",
"      Batchelor JR, Welsh KI, Tinoco RM, et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980; 1:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/44\">",
"      Speirs C, Fielder AH, Chapel H, et al. Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus. Lancet 1989; 1:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/45\">",
"      Gough A, Chapman S, Wagstaff K, et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996; 312:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/46\">",
"      Elkayam O, Levartovsky D, Brautbar C, et al. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med 1998; 105:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/47\">",
"      Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 1999; 159:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/48\">",
"      Lawson TM, Amos N, Bulgen D, Williams BD. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 2001; 40:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/49\">",
"      Margolis DJ, Hoffstad O, Bilker W. Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol 2007; 157:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/50\">",
"      El-Hallak M, Giani T, Yeniay BS, et al. Chronic minocycline-induced autoimmunity in children. J Pediatr 2008; 153:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/51\">",
"      Shapiro KS, Pinn VW, Harrington JT, Levey AS. Immune complex glomerulonephritis in hydralazine-induced SLE. Am J Kidney Dis 1984; 3:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/52\">",
"      Short AK, Lockwood CM. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. QJM 1995; 88:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/53\">",
"      Callen JP. Drug-induced cutaneous lupus erythematosus, a distinct syndrome that is frequently unrecognized. J Am Acad Dermatol 2001; 45:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/54\">",
"      Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003; 139:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/55\">",
"      No&euml;l B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007; 21:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/56\">",
"      Mohan AK, Edwards ET, Cot&eacute; TR, et al. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002; 360:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/57\">",
"      Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus 2003; 12:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/58\">",
"      N&auml;ssberger L, Johansson AC, Bj&ouml;rck S, Sj&ouml;holm AG. Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment. J Intern Med 1991; 229:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/59\">",
"      Cambridge G, Wallace H, Bernstein RM, Leaker B. Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994; 33:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/60\">",
"      N&auml;ssberger L, Sj&ouml;holm AG, Jonsson H, et al. Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol 1990; 81:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28168/abstract/61\">",
"      Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoimmunity 2005; 38:507.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4677 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28168=[""].join("\n");
var outline_f27_32_28168=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1339498\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1339415\">",
"      - Acetylator status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1339422\">",
"      - Other genetic risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Antihistone antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Anti-double stranded DNA antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Antineutrophil cytoplasmic antibodies (ANCA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Procainamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hydralazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Minocycline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anti-TNF agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Skin disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANCA-positive vasculitis and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/4677\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4677|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/62/15341\" title=\"table 1\">",
"      Features of drug induced LE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2120?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_32_28169="Chorionic villus sampling: Risks, complications, and techniques";
var content_f27_32_28169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chorionic villus sampling: Risks, complications, and techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28169/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28169/contributors\">",
"     Alessandro Ghidini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28169/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28169/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28169/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28169/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/32/28169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorionic villus sampling (CVS) refers to a procedure for the prenatal diagnosis of genetic disorders in which small samples of the placenta are obtained for chromosome or DNA analysis. It is generally performed during the first trimester (after 10 weeks), thus reducing the at-risk couple's period of anxious waiting for test results and permitting access to pregnancy termination at a safer and more discreet time. A larger amount of DNA is derived from CVS than from cells obtained at amniocentesis, thereby allowing reliable DNA analysis within hours or days of sampling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Introduction of first trimester screening programs has led to a decrease in the utilization of CVS, particularly among women 35 years or older [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CVS is performed as an ambulatory procedure, without analgesia or local anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/4\">",
"     4",
"    </a>",
"    ]. A transvaginal sonographic examination should precede the procedure to determine the number of embryos and chorionicity, document fetal viability, and detect major fetal structural anomalies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sonographer and the physician performing the CVS should be coordinated with one another. Coordination comes from experience; a learning curve for safe and successful performance of the procedure has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/5\">",
"     5",
"    </a>",
"    ]. An assistant trained in the sonographic appearance of a transcervical catheter or transabdominal needle is also essential to ensure smooth performance. A second trained assistant with an on-site microscope can provide rapid evaluation of sample adequacy, assess the quality of the specimen obtained, and select the chorionic villi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two approaches are available for obtaining chorionic tissue: transcervical (TC) and transabdominal (TA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Transcervical chorionic villus sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervicovaginal cultures should be obtained prior to a transcervical procedure to identify any potential pathogens (gonorrhea, chlamydia, group B streptococcus), which we treat with appropriate antibiotics. The TC technique requires the following materials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      26 cm long polyethylene cannula with outer diameter of 1.5 mm and a soft stainless steel blunt obturator",
"     </li>",
"     <li>",
"      Sterile speculum",
"     </li>",
"     <li>",
"      Metal sound",
"     </li>",
"     <li>",
"      20-mL syringe containing nutrient medium; the medium can be supplemented with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      when only chromosome analysis is performed. If DNA analysis is planned, saline solution should be used instead of heparin to avoid heparin's interference with the process of DNA extraction (",
"      <a class=\"graphic graphic_figure graphicRef56383 \" href=\"UTD.htm?27/58/28580\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Single-toothed tenaculum or ring forceps (optional).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The woman is placed in the lithotomy position, the external and internal genitalia are prepped with an antiseptic solution, and a speculum is inserted into the vagina. A single-toothed tenaculum or ring forceps is used to grasp the anterior lip of the cervix and gently pull it toward the operator to bring the uterus into a more axial configuration. If the uterus is sharply anteverted, filling the bladder may help to straighten the angle between the endocervical canal and the anterior uterine wall. Next, under direct transabdominal ultrasound visualization, a metal sound is introduced into the endocervical canal to define its course and curvature. The TC cannula is bent to assume a similar curve and then inserted under ultrasound guidance through the canal and into the placenta. The obturator of the cannula is removed and a 20-mL syringe containing medium is attached to the catheter. Chorionic villi are aspirated as the catheter is moved back and forth inside the placenta. After an adequate specimen is obtained, the catheter is withdrawn while keeping the syringe under negative pressure.",
"   </p>",
"   <p>",
"    An alternative transcervical method uses a biopsy forceps to obtain the placental sample [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A review of randomized trials comparing different instruments for TC CVS found that use of a cannula was associated with significantly greater risk of an inadequate sample (RR 3.81, 95%CI 1.52-9.56), but no greater need for instrument reinsertion (RR 2.44, 95% CI 0.83-7.20) compared to forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/6\">",
"     6",
"    </a>",
"    ]. There was no difference in miscarriage when the use of a cannula was compared with biopsy forceps (RR 1.00; 95% CI 0.14-6.96). The authors did not conclude that forceps should be used instead of a cannula because the evidence was not strong enough to support change in practice for clinicians who have become familiar with an aspiration cannula.",
"   </p>",
"   <p>",
"    Physicians learning CVS may want to consider developing their expertise in the forceps technique. In either case, the sample material is placed onto a plastic tissue culture dish and the content evaluated at a nearby microscope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Transabdominal chorionic villus sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TA technique uses the following materials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sterile pocket for the ultrasound probe and sterile gel",
"     </li>",
"     <li>",
"      20 gauge needle, 9 or 12 cm long, with stylet",
"     </li>",
"     <li>",
"      20 to 30 mL syringe containing nutrient medium; as noted above, the medium can be supplemented with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (if only chromosome analysis is performed) or saline solution (if DNA analysis is indicated).",
"     </li>",
"     <li>",
"      Holder to mount the syringe, which makes aspiration easier (",
"      <a class=\"graphic graphic_figure graphicRef78345 \" href=\"UTD.htm?25/38/26212\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The woman is placed in the supine position, the placenta is localized by transabdominal ultrasonography, and her lower abdomen is prepped with antiseptic solution. The needle is then inserted using either a free-hand technique or a needle-guide attached to the ultrasound probe. The needle is advanced at an angle that allows it to penetrate along the long axis of the placenta. The stylet is removed, the medium-containing syringe mounted on the holder, and the holder is then attached to the hub of the needle. The needle tip is moved back and forth inside the placenta until an adequate sample has been aspirated by the vacuum created in the syringe. The sampling system is then withdrawn under negative pressure. The medium is flashed onto a plastic tissue culture dish and the content evaluated at a nearby microscope.",
"   </p>",
"   <p>",
"    A 2013 Cochrane review concluded there is no difference in clinically important outcomes with the use of a continuous compared with a discontinuous negative pressure needle aspiration system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/6\">",
"     6",
"    </a>",
"    ]. A pilot randomized trial compared the traditional CVS technique (using vacuum manually created in a syringe) with the use of a 4 mL Vacutainer directly connected to the needle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/8\">",
"     8",
"    </a>",
"    ]. The two techniques had similar rates of success, number of passes of the needle within the chorion, and amount of villi retrieved between the two groups. The advantage of use of Vacutainer seems to be the lack of need for a second operator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Handling the tissue sample",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a large amount of maternal blood is present in the sample, the blood should be removed promptly to avoid inclusion of villi in blood clots. Blood clots are removed and villi separated from maternal decidua with forceps under a dissecting microscope. The cleaned villi can be transferred to appropriate medium, such as Chang complete media (Irvine Scientific, Irvine, CA), or Amniomax media (GIBCO-BRL, Rockville, MD) for overnight or long-term culture, FISH studies, or AF-PCR for rapid prenatal results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/9\">",
"     9",
"    </a>",
"    ]. Use of array comparative genomic hybridization (aCGH) appears to increase diagnostic yield because it can identify microdeletions and microduplications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7208?source=see_link&amp;anchor=H1897463#H1897463\">",
"     \"Use of array comparative genomic hybridization (aCGH) in obstetrics\", section on 'Clinical indications for aCGH in obstetrics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Multiple gestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the chorionicity of multiple gestations is essential prior to CVS, as chorionicity determines the number of samples to be taken. An ultrasound examination can evaluate the placental implantation site(s), the thickness of the septal membrane, and the presence of a lambda or twin peak sign (ie, a triangular projection of placental tissue on the chorionic surface and extending between the layers of the intertwin membrane) to differentiate monochorionic from dichorionic placentas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, an accurate map of the fetal to placental relationship in multiple gestations is critical for accurate performance of selective termination later in pregnancy.",
"   </p>",
"   <p>",
"    CVS can be performed by a TA, TC, or a combined TA and TC (TA for one twin, TC for the other) approach. One or two samplings are required, irrespective of the technique.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only a single sample is required in the presence of monochorionic twins (ie, only one distinct placental site with either an absent dividing membrane or a \"non-peaked\" membrane insertion site and thin dividing membranes).",
"     </li>",
"     <li>",
"      If there are separate placentas, the procedure is similar to CVS for a singleton pregnancy (but with two separate needle insertions). Combined TA and TC-CVS may be necessary in some cases to avoid twin-twin contamination: the most typical example is when one placenta is anterior and the other posterior. If access to the posterior placenta with a TA approach requires passing through the anterior placenta, a TC-CVS to the posterior placenta should be employed. The cytogenetic results and DNA polymorphism, if required, will confirm the separate origin of chorionic tissue from each twin.",
"     </li>",
"     <li>",
"      If the placentas are fused and either dichorionic or of uncertain chorionicity, the tip of the aspirating device should be inserted either close to the insertion of the umbilical cord or at the placental margin, far away from the area of fusion, to minimize the possibility of sampling the same fetus twice. The device should not pass through the placenta of one twin to reach the other twin's placenta. The cytogenetic results and DNA polymorphism may permit differentiation between the samples. However, if the results are identical and chorionicity remains uncertain, confirmation that each fetus has been sampled is advisable; this can be achieved by amniocentesis later in pregnancy. Follow-up amniocentesis is required in up to 6 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Uncertain results requiring further investigation are more frequent in multiple gestations assessed by CVS than by amniocentesis. As an example, a study of 500 women with multiple pregnancies who underwent amniocentesis or CVS had uncertain results in one or both samples requiring further investigation in 5 percent of CVS specimens compared to 0.3 percent of amniotic fluid samples [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, sampling one fetus twice (erroneous sampling) was seen once among 163 pregnancies and cross contamination due to mixed sampling was discovered in two of seven pregnancies that underwent DNA diagnosis. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Multiple gestation'",
"    </a>",
"    below.) Maternal cell contamination caused a diagnostic problem once among the amniotic fluid samples. Despite these limitations, CVS offers the advantage of earlier, and therefore safer, selective fetal reduction if requested because of abnormal results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CVS enables prenatal diagnosis of conditions in which diagnostic cytogenetic or DNA analysis is possible. Rapid karyotyping can be achieved within 48 hours of sampling by examining cytotrophoblastic cells in metaphase (direct method). However, due to the risk of false positive results (about 0.04 to 0.12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]), long-term cultures should be performed concurrently. Prenatal diagnosis via DNA extraction from chorionic cells is performed primarily when there is a family history of a mendelian disorder.",
"   </p>",
"   <p>",
"    The most common indication for cytogenetic testing by CVS is an increased risk of fetal aneuploidies due to advanced maternal age, family history, or abnormal first trimester screening for Down syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link\">",
"     \"Sonographic findings associated with fetal aneuploidy\"",
"    </a>",
"    .) As an example, a report of 10,000 consecutive CVS procedures by a single operator found women were referred for chromosomal risk in 89 percent, assessment of mendelian disorders in 11 percent, and DNA investigations for paternity or infectious agents in 0.4 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/18\">",
"     18",
"    </a>",
"    ]. CVS will also be useful for obtaining a fetal karyotype when sonographic fetal survey for congenital anomalies in the first trimester becomes more sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ALTERNATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniocentesis is an alternative to CVS as both procedures provide the same information. The choice of procedure depends upon the woman's personal appraisal of the risks and benefits of each technique. Amniocentesis for prenatal diagnosis can be performed in the first trimester (ie, early amniocentesis, typically at 11 to 13 weeks of gestation but before 15 weeks) or early second trimester (ie, typically at 16 weeks but always after 15 weeks). Early amniocentesis is not recommended for most women because it is associated with a higher rate of pregnancy loss and complications than either CVS or midtrimester procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to CVS may relate to one or both sampling routes.",
"   </p>",
"   <p>",
"    Contraindications to TC-CVS include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vaginismus",
"     </li>",
"     <li>",
"      Cervical stenosis",
"     </li>",
"     <li>",
"      Cervical myomas",
"     </li>",
"     <li>",
"      Cervical infection",
"     </li>",
"     <li>",
"      Lower uterine segment myomas obstructing access to a fundal placenta",
"     </li>",
"     <li>",
"      Severe anteflexion or retroflexion of the uterus that renders the placenta inaccessible to the catheter despite uterine manipulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contraindications to TA-CVS rarely occur:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extreme uterine retroflexion with intestinal loops between the abdominal wall and uterus",
"     </li>",
"     <li>",
"      Fetal position obstructing access to a posterior placenta.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative contraindications to either type of CVS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal isoimmunization. Fetomaternal hemorrhage has been documented after CVS. Thus, unsensitized Rh negative women should receive anti-D immunoglobulin after the procedure. Women already sensitized appear to be at increased risk for an augmented maternal antibody response following CVS, which may result in more severe fetal erythroblastosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=see_link\">",
"       \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Presence of an intrauterine device.",
"     </li>",
"     <li>",
"      Risk factors for neural tube defects. Alpha-fetoprotein testing cannot be performed on CVS tissue samples or those obtained by first trimester amniocentesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious complications from CVS are fetal damage or loss. Other concerns relate to bleeding, infection, and uncertain results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fetal loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of cohort studies on procedure-related complications of CVS calculated a pregnancy loss rate of 0.7 percent within 14 days of a TA CVS procedure, 1.3 percent within 30 days, and 2 percent for loss anytime during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the best estimates of the incidence of fetal loss come from a few large randomized clinical trials in which women with indications for prenatal genetic testing were assigned to undergo either CVS or amniocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/14,23-25\">",
"     14,23-25",
"    </a>",
"    ]. The analysis below takes into account all patients eligible for the procedure (ie, excluding those not eligible at randomization, such as nonviable fetus, multiple pregnancy, or gestation beyond 12 weeks).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Total fetal loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because CVS is performed approximately four to six weeks earlier in gestation than amniocentesis, simply comparing the rate of spontaneous loss after CVS versus after amniocentesis is not an appropriate method of determining the procedure-related risk of loss. It is more appropriate to assess the total fetal loss rate after patient allocation, since this will account for spontaneous losses occurring at the end of the first trimester and early second trimester in both groups.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two randomized trials comparing CVS by any route versus amniocentesis noted a significant increase in total fetal losses after CVS (",
"      <a class=\"graphic graphic_table graphicRef58539 \" href=\"UTD.htm?14/63/15355\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/14,23\">",
"       14,23",
"      </a>",
"      ]. Transcervical procedures accounted for 72 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/23\">",
"       23",
"      </a>",
"      ] and 50 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/14\">",
"       14",
"      </a>",
"      ] percent of CVS in the two trials.",
"     </li>",
"     <li>",
"      Four randomized trials provided data specifically comparing TC CVS with amniocentesis (",
"      <a class=\"graphic graphic_table graphicRef71354 \" href=\"UTD.htm?35/60/36811\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/14,23-25\">",
"       14,23-25",
"      </a>",
"      ]. The total fetal loss rate was significantly higher with TC CVS than with amniocentesis, with an average difference in fetal loss of 3.5 percent.",
"     </li>",
"     <li>",
"      One randomized trial specifically compared TA CVS and amniocentesis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/14\">",
"       14",
"      </a>",
"      ]. The total fetal loss rate was similar for both groups (6.3 and 7.0 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these trials suggest that CVS is less safe than second trimester amniocentesis, and the excess risk seems to be confined to TC CVS. This conclusion is supported by three randomized trials comparing TC CVS and TA CVS where each trial recruited over 100 patients (",
"    <a class=\"graphic graphic_table graphicRef53439 \" href=\"UTD.htm?26/24/27019\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/14,26,27\">",
"     14,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cohort studies have also reported TC CVS is associated with higher rates of spontaneous losses among euploid fetuses than TA CVS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Perinatal mortality rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cumulative perinatal mortality rate (PNM) is not significantly higher after CVS than amniocentesis (7 versus 6 per 1000 live births), independent from the type of CVS (TC or TA) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Surviving children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only one of the above trials described the rate of surviving children, which was 4.6 percent lower in women undergoing CVS compared to amniocentesis (86 versus 91 percent, p&lt;0.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/23\">",
"     23",
"    </a>",
"    ]. This difference primarily reflected more spontaneous fetal deaths before 28 weeks of gestation (2.9 percent), which may have been procedure-related, and more terminations of pregnancies for chromosomal anomalies (1 percent), which may have reflected a higher detection rate of abnormal diagnoses due to earlier sampling with CVS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Predictors of fetal loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the effect of sampling route on fetal loss rates (see above), the following additional predictors have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small for gestational age fetuses have a higher loss rate after the procedure compared to normal-sized fetuses [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The number of times the sampling device has to be introduced before obtaining adequate tissue affects the overall fetal loss rate [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/18,32-34\">",
"       18,32-34",
"      </a>",
"      ]. Introduction of the sampling device three times or more is associated with a significant increase in fetal loss [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The operator's skill and experience play an important role in the rate of fetal loss [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/35\">",
"       35",
"      </a>",
"      ]. Surveillance of fetal loss rates has been recommended for self-evaluation of expertise. It has been estimated that expertise is usually achieved after 250 procedures and maintained by systematic sampling [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/36\">",
"       36",
"      </a>",
"      ]. The learning rate for TA-CVS is faster than that for TC-CVS [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective study over a 20-year period found that pregnancy loss after CVS declined significantly over time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/37\">",
"     37",
"    </a>",
"    ], although the authors did not specify the route of CVS in their practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of CVS in multiple gestation has been addressed only by small case-control or cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/11-13,38,39\">",
"     11-13,38,39",
"    </a>",
"    ]. In a systematic review, the rate of pregnancy loss before 20 weeks was 2.75 percent (95% CI 1.28&ndash;4.75; n = 3) and before 28 weeks it was 3.44 percent (95% CI 1.67&ndash;5.81; n = 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/40\">",
"     40",
"    </a>",
"    ]. Only two studies included a control group, and the overall fetal loss rate, as well as that before 20 weeks, did not differ between CVS subjects and the controls. The small number of study subjects, the heterogeneity of the published data, and the lack of matching between CVS subjects and controls prevent any meaningful conclusion on excess risk of CVS in twins.",
"   </p>",
"   <p>",
"    The risk of a sampling error in twin gestation, though small (0.6 to 0.8 percent), is higher than that with amniocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/11,12,39-41\">",
"     11,12,39-41",
"    </a>",
"    ] and it seems to be even greater in triplets and higher order gestations (1.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Confined placental mosaicism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term placental cultures of CVS samples reveal the presence of rare trisomies not present in the conceptus in 1 to 2 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/15,16,43,44\">",
"     15,16,43,44",
"    </a>",
"    ]. The risk is twice as high using the direct method and increases with advancing gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/45\">",
"     45",
"    </a>",
"    ], although after the first trimester the aneuploid placental line is lost in 30 to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/46\">",
"     46",
"    </a>",
"    ]. Since the false negative rate with CVS is extremely low (0.03 percent in one series of over 62,000 procedures) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/16,47\">",
"     16,47",
"    </a>",
"    ], the woman can be reassured that her fetus is not affected if the abnormal karyotype is confined to direct preparations (ie, trophoblastic cells) and the long-term cultures (ie, mesenchymal cells) have a normal complement. In contrast, it is prudent to perform an amniocentesis to rule out a false positive test (which occurs in 0.15 to 1.3 percent of tests) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/16,48\">",
"     16,48",
"    </a>",
"    ] when the abnormal karyotype is also found in mesenchymal cells. The need for follow-up samples is significantly higher after CVS than after amniocentesis because the certainty that the established karyotype represents that of the fetus is lower [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/48\">",
"     48",
"    </a>",
"    ]. If the chorionic villi material is not enough for both direct preparations and long-term cultures, a choice must be made between the two karyotyping strategies. Preliminary evidence suggests that when CVS is indicated by abnormal ultrasound findings, long-term culture may be preferable to direct preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of normal results from amniocytes confirms a normal fetal karyotype. However, the couple should be informed that there is an increased risk of intrauterine growth restriction and fetal death in these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Depending upon the chromosome involved in the chorionic mosaicism (chromosomes 5, 6, 7, 15 or 16), there may be a risk of uniparental disomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/51\">",
"     51",
"    </a>",
"    ]. Further molecular studies may help to resolve this issue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link\">",
"     \"Overview of causes of and risk factors for fetal growth restriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of data from several studies published in different years estimated that the sensitivity of amniocentesis and CVS were both 99.6 percent (false negative 0.4 percent) for detection of nonlethal chromosomal aneuploidies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/6\">",
"     6",
"    </a>",
"    ]. The specificity of amniocentesis was 99.93 percent (false positive 0.07 percent) and the specificity of CVS was 99.90 percent (false positive 0.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/52\">",
"     52",
"    </a>",
"    ]. The different rates of false-positive results in direct CVS preparations, long-term CVS cultures, and amniocentesis reflect the distance in relationship between the tissue sampled and the embryo proper. The trophoblast, from which CVS direct preparation metaphases are prepared, is the first lineage to differentiate from the totipotent cells of the morula. Mesenchymal cells, which produce metaphases for cultured CVS preparations, are more closely related to the embryo than trophoblast because they are derived from the more recently separated lineage of the extraembryonic mesoderm. Thus, an abnormal karyotype found only in the trophoblastic cells usually represents confined placental mosaicism, with no effect on fetal phenotype. An abnormal karyotype in the mesenchymal cells is more likely to reflect a true abnormal fetal karyotype. Amniotic fluid cells, which originate from the epiblast of the inner cell mass from which the embryonic tissues arise, closely reflect the constitution of the embryo. Confined placental mosaicism, a term referred to any case of abnormality restricted to the placenta (trophoblast or mesenchyme), and not involving the fetus, is associated with greater risk of fetal growth restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Limb-reduction defects and oromandibular hypogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased rate of transverse limb abnormalities has been reported when CVS is performed at less than nine weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. This risk is independent of the expertise of the operator, the route of the procedure (TA versus TC), or gauge of the needle or cannula used [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. It appears to be higher when CVS is performed during the embryonic development phase and diminishes with advancing gestation, approaching the background rate at or beyond 11 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/57\">",
"     57",
"    </a>",
"    ]. Thus, 10 weeks is the generally accepted lower limit for CVS procedures. In some cases, the limb reduction is associated with oromandibular hypogenesis (called the oromandibular-limb hypogenesis syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of factors have been implicated in the genesis of these abnormalities. Most commonly, the damage is thought to be mediated by trauma to the placenta, leading to disruption of terminal arteries (ie, arteries supporting the development of embryonic extremities) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Failure at obtaining sample",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sampling success rate in the majority of the studies is at least 99 percent after fewer than three insertions; it is not different for TC- versus TA-CVS. However, the sampling success rate at the first attempt is significantly higher with TA- than TC-CVS (98 versus 96 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/14\">",
"     14",
"    </a>",
"    ]. Moreover, TC CVS is associated with significantly more multiple insertions than TA CVS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal spotting after CVS is reported in up to one-third of women, but frank bleeding occurs in less than 6 percent and is more common after the TC- than TA- CVS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/18,23,26,30,33\">",
"     18,23,26,30,33",
"    </a>",
"    ]. A subchorionic hematoma is detected by ultrasound following up to 4 percent of TC-CVS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare cases of clinically-evident infectious complications including chorioamnionitis (0 to 0.5 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/18,33\">",
"     18,33",
"    </a>",
"    ], maternal septic shock (three cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/61-63\">",
"     61-63",
"    </a>",
"    ], and maternal intestinal perforation (during TA-CVS) leading to peritonitis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/18\">",
"     18",
"    </a>",
"    ]. TC-CVS appears to carry a higher risk of infection than TA-CVS. Of greater concern is the possibility that subclinical intrauterine infection is the cause of part of the excess fetal losses reported after TC-CVS compared to TA-CVS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/24,64\">",
"     24,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A new sterile catheter should be used for each insertion and the TA route chosen, whenever possible, to minimize infectious complications. This is especially true when difficulties are expected or observed with the TC approach.",
"   </p>",
"   <p>",
"    There is also a risk of vertical transmission of maternal infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnostic amniocentesis\", section on 'Vertical transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Fetomaternal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetomaternal hemorrhage (FMH) has been documented based upon an increase in maternal serum alpha-fetoprotein (MSAFP) following CVS. It occurs in a substantial percent of cases; reported results vary widely depending upon the criteria and method of FMH assessment used [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/65-69\">",
"     65-69",
"    </a>",
"    ]. The amount of fetal hemorrhage is small in relation to the total fetoplacental blood volume. TA-CVS is associated with a greater risk of FMH than TC-CVS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/68\">",
"     68",
"    </a>",
"    ]. FMH has been proposed as one cause of fetal loss after CVS, particularly when MSAFP is very high or continues to rise after CVS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/68,70\">",
"     68,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Release of fetal blood into the maternal circulation can cause isoimmunization; therefore, Rh- negative women should receive at least mini-dose (50 mcg) anti-D Rh immunoglobulins following the procedure. CVS-related FMH may augment the maternal immune response in women already sensitized and lead to early, severe erythroblastosis fetalis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Obstetric complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large population-based cohort study including 1984 women undergoing CVS and 47,854 unexposed controls found that rates of pregnancy complications (placental abruption, placenta previa, preterm delivery, hypotonic uterine dysfunction) and rates of operative vaginal or abdominal delivery were not significantly higher in women undergoing CVS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/71\">",
"     71",
"    </a>",
"    ]. In contrast, a nationwide Finnish study including 887,439 births, of which 3346 were complicated by abruption, found that exposure to CVS in pregnancy was significantly more frequent among women with abruption than in those without (OR 1.48, 95% CI 1.12-1.96) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More controversial is whether CVS is associated with increased risk of subsequent preeclampsia. Several studies have reported that undergoing CVS is associated with a significantly increased risk of developing preeclampsia, especially severe preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/73-75\">",
"     73-75",
"    </a>",
"    ], but others have not found this association [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. If an association exists between placental disruption due to CVS and subsequent preeclampsia, it is likely modest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survey by questionnaire of 1509 women who had TC CVS, with an 87 percent response rate and an average infant age of 4.2 years at follow-up, found no increase in rates of congenital malformations, neonatal morbidity, pediatric morbidity requiring hospital admission or outpatient treatment, functional disturbance, and physical growth below the 10th centile compared with control women undergoing second trimester amniocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/78\">",
"     78",
"    </a>",
"    ]. Of interest, only 10 percent of all congenital malformations had been detected at the routine follow-up shortly after birth. A population-based cohort study of women 35 to 49 years old has compared the infant morbidity of those exposed to CVS versus those not exposed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28169/abstract/79\">",
"     79",
"    </a>",
"    ]. No increase in fetal and infant mortality, prematurity, low birthweight, nonreassuring fetal status, or limb reduction defects was found in association with CVS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=see_link\">",
"       \"Patient information: Chorionic villus sampling (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/7/2161?source=see_link\">",
"       \"Patient information: Chorionic villus sampling (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CVS is the procedure of choice for first trimester prenatal diagnosis of genetic disorders.",
"     </li>",
"     <li>",
"      Compared with amniocentesis, CVS is associated with a greater risk of sampling and technical failures.",
"     </li>",
"     <li>",
"      The safety and efficacy of CVS have been documented, although the procedure carries a slightly, but significantly, increased risk of fetal loss compared to second trimester amniocentesis. Because CVS is performed approximately four to six weeks earlier in gestation than amniocentesis, simply comparing the rate of spontaneous loss after CVS versus after amniocentesis is not an appropriate method of determining the procedure-related risk of loss.",
"     </li>",
"     <li>",
"      TA-CVS is preferable to TC-CVS because TA-CVS is associated with fewer procedure-related fetal losses, lower risk of bleeding and infectious complications, lower need for multiple insertions, and higher sampling success rate at the first attempt.",
"     </li>",
"     <li>",
"      Pooled data from cohort studies reveal a pregnancy loss rate of 0.7 percent within 14 days of a TA CVS procedure and 1.3 percent within 30 days",
"     </li>",
"     <li>",
"      Procedure-induced limb defects are negligible when the procedure is performed after 10 weeks of gestation",
"     </li>",
"     <li>",
"      Rh(D) negative nonsensitized women should receive anti-D Rh immunoglobulin prophylaxis after the procedure",
"     </li>",
"     <li>",
"      Second trimester amniocentesis is the prenatal diagnostic technique associated with the lowest risk of pregnancy loss; chorionic villus sampling is safer than early (ie, before 15 weeks) amniocentesis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/1\">",
"      Benn PA, Egan JF, Fang M, Smith-Bindman R. Changes in the utilization of prenatal diagnosis. Obstet Gynecol 2004; 103:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/2\">",
"      Chasen ST, McCullough LB, Chervenak FA. Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population? Am J Obstet Gynecol 2004; 190:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/3\">",
"      Wray AM, Ghidini A, Alvis C, et al. The impact of first-trimester screening on AMA patients' uptake of invasive testing. Prenat Diagn 2005; 25:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/4\">",
"      Mujezinovic F, Alfirevic Z. Analgesia for amniocentesis or chorionic villus sampling. Cochrane Database Syst Rev 2011; :CD008580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/5\">",
"      Wijnberger LD, van der Schouw YT, Christiaens GC. Learning in medicine: chorionic villus sampling. Prenat Diagn 2000; 20:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/6\">",
"      Young C, von Dadelszen P, Alfirevic Z. Instruments for chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev 2013; 1:CD000114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/7\">",
"      von Dadelszen P, Sermer M, Hillier J, et al. A randomised controlled trial of biopsy forceps and cannula aspiration for transcervical chorionic villus sampling. BJOG 2005; 112:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/8\">",
"      Battagliarin G, Lanna M, Coviello D, et al. A randomized study to assess two different techniques of aspiration while performing transabdominal chorionic villus sampling. Ultrasound Obstet Gynecol 2009; 33:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/9\">",
"      Brown L, Abigania M, Warburton D, Brown S. Validation of QF-PCR for prenatal aneuploidy screening in the United States. Prenat Diagn 2006; 26:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/10\">",
"      Rode ME, Jackson M. Sonographic considerations with multiple gestation. Semin Roentgenol 1999; 34:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/11\">",
"      Pergament E, Schulman JD, Copeland K, et al. The risk and efficacy of chorionic villus sampling in multiple gestations. Prenat Diagn 1992; 12:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/12\">",
"      Wapner RJ, Johnson A, Davis G, et al. Prenatal diagnosis in twin gestations: a comparison between second-trimester amniocentesis and first-trimester chorionic villus sampling. Obstet Gynecol 1993; 82:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/13\">",
"      van den Berg C, Braat AP, Van Opstal D, et al. Amniocentesis or chorionic villus sampling in multiple gestations? Experience with 500 cases. Prenat Diagn 1999; 19:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/14\">",
"      Smidt-Jensen S, Permin M, Philip J, et al. Randomised comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling. Lancet 1992; 340:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/15\">",
"      Los FJ, van den Berg C, Van Opstal D, et al. Abnormal karyotypes in semi-direct chorionic villus preparations of women with different cytogenetic risks. Prenat Diagn 1998; 18:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/16\">",
"      Hahnemann JM, Vejerslev LO. Accuracy of cytogenetic findings on chorionic villus sampling (CVS)--diagnostic consequences of CVS mosaicism and non-mosaic discrepancy in centres contributing to EUCROMIC 1986-1992. Prenat Diagn 1997; 17:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/17\">",
"      van den Berg C, Van Opstal D, Brandenburg H, et al. Accuracy of abnormal karyotypes after the analysis of both short- and long-term culture of chorionic villi. Prenat Diagn 2000; 20:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/18\">",
"      Brambati B, Tului L, Cislaghi C, Alberti E. First 10,000 chorionic villus samplings performed on singleton pregnancies by a single operator. Prenat Diagn 1998; 18:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/19\">",
"      Chitty LS, Pandya PP. Ultrasound screening for fetal abnormalities in the first trimester. Prenat Diagn 1997; 17:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/20\">",
"      Canick JA, Kellner LH. First trimester screening for aneuploidy: serum biochemical markers. Semin Perinatol 1999; 23:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/21\">",
"      Moise KJ Jr, Carpenter RJ Jr. Increased severity of fetal hemolytic disease with known rhesus alloimmunization after first-trimester transcervical chorionic villus biopsy. Fetal Diagn Ther 1990; 5:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/22\">",
"      Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007; 110:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/23\">",
"      Medical Research Council European trial of chorion villus sampling. MRC working party on the evaluation pf chorion villus sampling. Lancet 1991; 337:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/24\">",
"      Lippman A, Tomkins DJ, Shime J, Hamerton JL. Canadian multicentre randomized clinical trial of chorion villus sampling and amniocentesis. Final report. Prenat Diagn 1992; 12:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/25\">",
"      Borrell A, Fortuny A, Lazaro L, et al. First-trimester transcervical chorionic villus sampling by biopsy forceps versus mid-trimester amniocentesis: a randomized controlled trial project. Prenat Diagn 1999; 19:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/26\">",
"      Jackson LG, Zachary JM, Fowler SE, et al. A randomized comparison of transcervical and transabdominal chorionic-villus sampling. The U.S. National Institute of Child Health and Human Development Chorionic-Villus Sampling and Amniocentesis Study Group. N Engl J Med 1992; 327:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/27\">",
"      Brambati B, Terzian E, Tognoni G. Randomized clinical trial of transabdominal versus transcervical chorionic villus sampling methods. Prenat Diagn 1991; 11:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/28\">",
"      Papp C, Beke A, Mezei G, et al. Chorionic villus sampling: a 15-year experience. Fetal Diagn Ther 2002; 17:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/29\">",
"      Scott F, Peters H, Boogert T, et al. The loss rates for invasive prenatal testing in a specialised obstetric ultrasound practice. Aust N Z J Obstet Gynaecol 2002; 42:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/30\">",
"      Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev 2003; :CD003252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/31\">",
"      Wilson RD, Gibson W, Bebbington M, et al. First trimester fetal heart rate: response to chorionic villus sampling in the chromosomally normal fetus. Fetal Diagn Ther 1997; 12:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/32\">",
"      Evans MI, Drugan A, Koppitch FC 3rd, et al. Genetic diagnosis in the first trimester: the norm for the 1990s. Am J Obstet Gynecol 1989; 160:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/33\">",
"      Williams J 3rd, Wang BB, Rubin CH, Aiken-Hunting D. Chorionic villus sampling: experience with 3016 cases performed by a single operator. Obstet Gynecol 1992; 80:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/34\">",
"      WHO Consultation on First Trimester Fetal Diagnosis. Risk evaluation in chorionic villus sampling. Prenat Diagn 1986; 6:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/35\">",
"      Silver RK, MacGregor SN, Sholl JS, et al. An evaluation of the chorionic villus sampling learning curve. Am J Obstet Gynecol 1990; 163:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/36\">",
"      Kuliev A, Jackson L, Froster U, et al. Chorionic villus sampling safety. Report of World Health Organization/EURO meeting in association with the Seventh International Conference on Early Prenatal Diagnosis of Genetic Diseases, Tel-Aviv, Israel, May 21, 1994. Am J Obstet Gynecol 1996; 174:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/37\">",
"      Caughey AB, Hopkins LM, Norton ME. Chorionic villus sampling compared with amniocentesis and the difference in the rate of pregnancy loss. Obstet Gynecol 2006; 108:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/38\">",
"      Brambati B, Tului L, Lanzani A, et al. First-trimester genetic diagnosis in multiple pregnancy: principles and potential pitfalls. Prenat Diagn 1991; 11:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/39\">",
"      Brambati B, Tului L, Guercilena S, Alberti E. Outcome of first-trimester chorionic villus sampling for genetic investigation in multiple pregnancy. Ultrasound Obstet Gynecol 2001; 17:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/40\">",
"      Agarwal K, Alfirevic Z. Pregnancy loss after chorionic villus sampling and genetic amniocentesis in twin pregnancies: a systematic review. Ultrasound Obstet Gynecol 2012; 40:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/41\">",
"      De Catte L, Liebaers I, Foulon W. Outcome of twin gestations after first trimester chorionic villus sampling. Obstet Gynecol 2000; 96:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/42\">",
"      Eddleman KA, Stone JL, Lynch L, Berkowitz RL. Chorionic villus sampling before multifetal pregnancy reduction. Am J Obstet Gynecol 2000; 183:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/43\">",
"      Sikkema-Raddatz B, Bouman K, Verschuuren-Bemelmans CC, et al. Four years' cytogenetic experience with the culture of chorionic villi. Prenat Diagn 2000; 20:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/44\">",
"      Stetten G, Escallon CS, South ST, et al. Reevaluating confined placental mosaicism. Am J Med Genet A 2004; 131:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/45\">",
"      Carroll SG, Davies T, Kyle PM, et al. Fetal karyotyping by chorionic villus sampling after the first trimester. Br J Obstet Gynaecol 1999; 106:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/46\">",
"      Wilkins-Haug L, Quade B, Morton CC. Confined placental mosaicism as a risk factor among newborns with fetal growth restriction. Prenat Diagn 2006; 26:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/47\">",
"      van den Berg C, Van Opstal D, Polak-Knook J, Galjaard RJ. (Potential) false-negative diagnoses in chorionic villi and a review of the literature. Prenat Diagn 2006; 26:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/48\">",
"      Los FJ, van Den Berg C, Wildschut HI, et al. The diagnostic performance of cytogenetic investigation in amniotic fluid cells and chorionic villi. Prenat Diagn 2001; 21:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/49\">",
"      Wilkins-Haug L, Roberts DJ, Morton CC. Confined placental mosaicism and intrauterine growth retardation: a case-control analysis of placentas at delivery. Am J Obstet Gynecol 1995; 172:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/50\">",
"      Toutain J, Labeau-Ga&uuml;zere C, Barnetche T, et al. Confined placental mosaicism and pregnancy outcome: a distinction needs to be made between types 2 and 3. Prenat Diagn 2010; 30:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/51\">",
"      Van Opstal D, Van den Berg C, Deelen WH, et al. Prospective prenatal investigations on potential uniparental disomy in cases of confined placental trisomy. Prenat Diagn 1998; 18:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/52\">",
"      Heckerling PS, Verp MS. A cost-effectiveness analysis of amniocentesis and chorionic villus sampling for prenatal genetic testing. Med Care 1994; 32:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/53\">",
"      Mastroiacovo P, Botto LD, Cavalcanti DP, et al. Limb anomalies following chorionic villus sampling: a registry based case-control study. Am J Med Genet 1992; 44:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/54\">",
"      Dolk H, Bertrand F, Lechat MF. Chorionic villus sampling and limb abnormalities. The EUROCAT Working Group. Lancet 1992; 339:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/55\">",
"      Report of National Institute of Child Health and Human Development Workshop on Chorionic Villus Sampling and Limb and Other Defects, October 20, 1992. Am J Obstet Gynecol 1993; 169:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/56\">",
"      Olney RS, Khoury MJ, Alo CJ, et al. Increased risk for transverse digital deficiency after chorionic villus sampling: results of the United States Multistate Case-Control Study, 1988-1992. Teratology 1995; 51:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/57\">",
"      Firth H. Chorion villus sampling and limb deficiency--cause or coincidence? Prenat Diagn 1997; 17:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/58\">",
"      Firth HV, Boyd PA, Chamberlain PF, et al. Analysis of limb reduction defects in babies exposed to chorionic villus sampling. Lancet 1994; 343:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/59\">",
"      van der Zee DC, Bax KM, Vermeij-Keers C. Maternoembryonic transfusion and congenital malformations. Prenat Diagn 1997; 17:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/60\">",
"      Jahoda MG, Pijpers L, Reuss A, et al. Evaluation of transcervical chorionic villus sampling with a completed follow-up of 1550 consecutive pregnancies. Prenat Diagn 1989; 9:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/61\">",
"      Infection and chorionic villus sampling. Lancet 1985; 2:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/62\">",
"      Barela AI, Kleinman GE, Golditch IM, et al. Septic shock with renal failure after chorionic villus sampling. Am J Obstet Gynecol 1986; 154:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/63\">",
"      Leschot NJ, Wolf H, Verjaal M, et al. Chorionic villi sampling: cytogenetic and clinical findings in 500 pregnancies. Br Med J (Clin Res Ed) 1987; 295:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/64\">",
"      Goldberg JD, Porter AE, Golbus MS. Current assessment of fetal losses as a direct consequence of chorionic villus sampling. Am J Med Genet 1990; 35:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/65\">",
"      Warren RC, Butler J, Morsman JM, et al. Does chorionic villus sampling cause fetomaternal haemorrhage? Lancet 1985; 1:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/66\">",
"      Mariona FG, Bhatia R, Syner FN, Koppitch F. Chorionic villi sampling changes maternal serum alpha-fetoprotein. Prenat Diagn 1986; 6:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/67\">",
"      Blakemore KJ, Baumgarten A, Schoenfeld-Dimaio M, et al. Rise in maternal serum alpha-fetoprotein concentration after chorionic villus sampling and the possibility of isoimmunization. Am J Obstet Gynecol 1986; 155:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/68\">",
"      Smidt-Jensen S, Philip J, Zachary JM, et al. Implications of maternal serum alpha-fetoprotein elevation caused by transabdominal and transcervical CVS. Prenat Diagn 1994; 14:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/69\">",
"      Katiyar R, Kriplani A, Agarwal N, et al. Detection of fetomaternal hemorrhage following chorionic villus sampling by Kleihauer Betke test and rise in maternal serum alpha feto protein. Prenat Diagn 2007; 27:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/70\">",
"      Fuhrmann W, Altland K, K&ouml;hler A, et al. Feto-maternal transfusion after chorionic villus sampling. Evaluation by maternal serum alphafetoprotein measurement. Hum Genet 1988; 78:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/71\">",
"      Cederholm M, Haglund B, Axelsson O. Maternal complications following amniocentesis and chorionic villus sampling for prenatal karyotyping. BJOG 2003; 110:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/72\">",
"      Minna T, Mika G, Tiina L, et al. Risk for placental abruption following amniocentesis and chorionic villus sampling. Prenat Diagn 2011; 31:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/73\">",
"      Silver RK, Wilson RD, Philip J, et al. Late first-trimester placental disruption and subsequent gestational hypertension/preeclampsia. Obstet Gynecol 2005; 105:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/74\">",
"      Adusumalli J, Han CS, Beckham S, et al. Chorionic villus sampling and risk for hypertensive disorders of pregnancy. Am J Obstet Gynecol 2007; 196:591.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/75\">",
"      Grobman WA, Auger M, Shulman LP, Elias S. The association between chorionic villus sampling and preeclampsia. Prenat Diagn 2009; 29:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/76\">",
"      Odibo AO, Singla A, Gray DL, et al. Is chorionic villus sampling associated with hypertensive disorders of pregnancy? Prenat Diagn 2010; 30:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/77\">",
"      Khalil A, Akolekar R, Pandya P, et al. Chorionic villus sampling at 11 to 13 weeks of gestation and hypertensive disorders in pregnancy. Obstet Gynecol 2010; 116:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/78\">",
"      Schaap AH, van der Pol HG, Boer K, et al. Long-term follow-up of infants after transcervical chorionic villus sampling and after amniocentesis to compare congenital abnormalities and health status. Prenat Diagn 2002; 22:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28169/abstract/79\">",
"      Cederholm M, Haglund B, Axelsson O. Infant morbidity following amniocentesis and chorionic villus sampling for prenatal karyotyping. BJOG 2005; 112:394.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 449 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28169=[""].join("\n");
var outline_f27_32_28169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Personnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Transcervical chorionic villus sampling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Transabdominal chorionic villus sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Handling the tissue sample",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Multiple gestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ALTERNATIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fetal loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Total fetal loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Perinatal mortality rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Surviving children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Predictors of fetal loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Confined placental mosaicism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Limb-reduction defects and oromandibular hypogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Failure at obtaining sample",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Obstetric complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/449\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/449|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/58/28580\" title=\"figure 1\">",
"      Transcervical CVS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/38/26212\" title=\"figure 2\">",
"      Transabdominal CVS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/449|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/63/15355\" title=\"table 1\">",
"      Total fetal loss rate1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/60/36811\" title=\"table 2\">",
"      Total fetal loss rate2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/24/27019\" title=\"table 3\">",
"      Total fetal loss rate3",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=related_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=related_link\">",
"      Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=related_link\">",
"      Overview of causes of and risk factors for fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/7/2161?source=related_link\">",
"      Patient information: Chorionic villus sampling (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=related_link\">",
"      Patient information: Chorionic villus sampling (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7208?source=related_link\">",
"      Use of array comparative genomic hybridization (aCGH) in obstetrics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_32_28170="Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma";
var content_f27_32_28170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28170/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28170/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28170/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28170/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/32/28170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/32/28170/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/32/28170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection of localized renal cell cancer (RCC) can be curative for localized disease, but many patients recur after surgery. In addition, many RCCs are clinically silent until metastatic disease is present. The long-term prognosis for advanced RCC is generally poor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RCCs can evoke an immune response, which occasionally results in dramatic, sustained remissions. Various immunotherapeutic strategies have been used to treat advanced disease. High-dose, bolus interleukin-2 (IL-2) induces durable complete remissions in about 10 percent of patients, but its use is limited by severe toxicity and the need for specialized care during treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link\">",
"     \"Immunotherapy of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Understanding the molecular pathogenesis of RCC has identified targets for therapeutic intervention (",
"    <a class=\"graphic graphic_figure graphicRef65979 \" href=\"UTD.htm?14/4/14408\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef76708 \" href=\"UTD.htm?24/51/25406\">",
"     algorithm 1",
"    </a>",
"    ). Molecularly targeted agents and their application in patients with advanced RCC will be reviewed here. Other aspects of the prognosis and management of RCC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21528?source=see_link\">",
"     \"Overview of the treatment of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link\">",
"     \"Immunotherapy of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 65 to 75 percent of renal epithelial tumors are clear cell carcinomas; other important subtypes include papillary (chromophilic), chromophobe, collecting duct, and medullary carcinomas, as well as oncocytomas. The different RCC subtypes are increasingly being characterized by unique genetic abnormalities and associated gene expression patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The pathogenesis of clear cell carcinoma is the best understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=see_link\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial insights into the molecular pathogenesis of clear cell RCC came from studies in von Hippel-Lindau (VHL) disease. VHL is characterized by the development of cerebellar and spinal hemangioblastomas, retinal angiomas, pheochromocytomas, and renal cysts and tumors. Clear cell RCCs develop in 40 to 60 percent of patients with VHL disease; these tend to be multicentric and bilateral with an unusually early age of onset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic analyses of VHL-associated RCCs showed loss of heterozygosity at the VHL locus on chromosome 3p25, and the same abnormality is present in 75 to 80 percent of sporadic clear cell RCCs. These findings implicated the VHL gene in the pathogenesis of clear cell RCCs. This abnormality results in the overproduction of vascular endothelial growth factor (VEGF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=see_link\">",
"     \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VEGF is probably the most important growth factor that is involved in tumor angiogenesis, and it plays a significant role in the growth and progression of many types of human cancer, including RCC. Elucidation of the downstream pathways from the VEGF receptor has defined a number of targets for interruption of the signaling that results in angiogenesis (",
"    <a class=\"graphic graphic_figure graphicRef65979 \" href=\"UTD.htm?14/4/14408\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef76708 \" href=\"UTD.htm?24/51/25406\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of angiogenesis inhibitors\", section on 'VEGF receptors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two different approaches have clinical activity in blocking the VEGF pathway: small molecule tyrosine kinase (TK) inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    ) that block the intracellular domain of the VEGF receptor; and a monoclonal antibody (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ) that binds circulating VEGF and prevents activation of the VEGF receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative pathway is mediated by the mammalian target of rapamycin (mTOR), which is downstream of the phosphoinositide 3-kinase and Akt and is regulated by the PTEN tumor suppressor gene. Inhibition of this pathway by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    leads to decreased protein translation and inhibition of both angiogenesis and tumor cell proliferation.",
"   </p>",
"   <p>",
"    Most data with these agents are derived from patients with clear cell RCC. Although data are more limited, these approaches appear to have activity in other types of RCC as well. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Non-clear cell carcinoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350645694\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid development of agents blocking the vascular endothelial growth factor (VEGF) pathway (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ) or the mTOR pathway (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    ) has established molecularly targeted therapy as the preferred treatment approach for most patients with advanced clear cell RCC. Currently there are no trials that provide data comparing different molecularly targeted agents, and the agents have been evaluated in different clinical settings. Despite this, there is no reason to assume that a given agent will not be active in other settings.",
"   </p>",
"   <p>",
"    The choice of therapy can be stratified by whether patients were or were not treated for advanced renal cell carcinoma:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350646080\">",
"    <span class=\"h2\">",
"     Untreated patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a good Karnofsky performance status (KPS) (&ge;80 percent) (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 1",
"      </a>",
"      ) and intact organ function, we suggest high-dose interleukin-2 (IL-2) rather than targeted therapy, provided there is access to this treatment. IL-2 can induce durable long-term remissions in approximately 10 percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H2#H2\">",
"       \"Immunotherapy of renal cell carcinoma\", section on 'Interleukin-2'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who decline or who are not candidates for IL-2 (including those patients without access to IL-2 therapy), treatment can be stratified by the presence of prognostic factors: poor KPS, serum lactic dehydrogenase (LDH) level &gt;1.5 times the upper limit of normal, corrected serum calcium &gt;10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      hemoglobin concentration less than the lower limit of normal, and absence of nephrectomy (ie, no disease-free interval) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link\">",
"       \"Prognostic factors in patients with renal cell carcinoma\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with none of these factors (favorable risk) or &le;2 factors (intermediate risk), we suggest a VEGF TK inhibitor. Both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      are reasonable options. An ongoing",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT00720941\">",
"       randomized phase III trial",
"      </a>",
"      will hopefully help determine which agent should be preferentially used. A reasonable alternative to these TK inhibitors include the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      plus interferon-alfa (IFNa). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pazopanib'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H4\">",
"       'Sunitinib'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H24\">",
"       'Bevacizumab'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"     <li>",
"      For patients with &ge;3 factors (poor risk), we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"      rather than other targeted therapies. A reasonable alternative to temsirolimus is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      , which also has shown activity in patients with poor risk features. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Temsirolimus'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H4\">",
"       'Sunitinib'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350645850\">",
"    <span class=\"h2\">",
"     Previously treated patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who progressed after cytokine therapy (ie, IL-2 or interferon-alfa), we recommend treatment with a TK inhibitor. We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      rather than other agents in this class. For patients without access to axitinib, alternative options include:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      . A choice between these agents is based on patient considerations (ie, comorbidities) and drug availability. (See",
"      <a class=\"local\" href=\"#H104724963\">",
"       'Axitinib'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients who have progressed after a VEGF pathway inhibitor, both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      are reasonable options. In the absence of prospective trials, a decision to use either agent is based on individual patient considerations, such as tumor response to the prior VEGF pathway inhibitor. (See",
"      <a class=\"local\" href=\"#H104724963\">",
"       'Axitinib'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H31\">",
"       'Everolimus'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence to support these recommendations is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VEGF TK INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple VEGF tyrosine kinase (TK) inhibitors are active against RCC. These agents are reviewed below. Although there are differences among these agents, some toxicities are common to this class. The toxicity observed with VEGF TK inhibitors is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    inhibits the VEGF receptor tyrosine kinase (TK), as well as other TKs associated with the platelet-derived growth factor (PDGF) receptor and c-kit oncogene. The benefit of sunitinib was shown in a phase III trial of 750 patients with largely good- or intermediate-prognosis metastatic clear cell RCC who had not received prior systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Patients were randomly assigned to six-week cycles of sunitinib (50 mg daily for four weeks, followed by two weeks off) or interferon alfa (IFNa 9 million units three times per week). Key results include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The objective response rate (ORR) was significantly increased with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      (47 versus 12 percent with IFNa).",
"     </li>",
"     <li>",
"      Median progression-free survival (PFS) was significantly prolonged (11 versus 5 months, hazard ratio [HR] 0.54).",
"     </li>",
"     <li>",
"      Overall survival (OS) was prolonged with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      (median 26.4 versus 21.8 months, HR 0.82, 95% CI 0.67-1.00). Over one-half of all patients on both arms were treated with VEGF pathway inhibitors after completion of the trial. Multivariate analysis of survival based upon the pretreatment stratification parameters and treatment assignment found that initial treatment with sunitinib was a statistically significant predictor of prolonged survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The schedule of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    used in the phase III trial above was compared with continuous daily treatment (37.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in a randomized trial that included 292 patients with advanced RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/7\">",
"     7",
"    </a>",
"    ]. Preliminary results from that trial suggest that continuous dosing results in a lower time to progression compared with the six-week dosing schedule (median 7.1 versus 9.9 months, HR 0.77, 95% CI 0.57-1.04). OS and adverse events profiles were similar with the two regimens. Whether this represents a dose (pharmacokinetic) effect or a schedule effect and how these results influence schedule considerations for other VEGFR TKIs remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104724963\">",
"    <span class=\"h2\">",
"     Axitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     Axitinib",
"    </a>",
"    is an orally available inhibitor of the VEGF receptors 1, 2, and 3. In January 2012, axitinib was approved by the US Food and Drug Administration (FDA) for the treatment of patients with advanced RCC after one systemic therapy.&nbsp;Preliminary results also suggest that it may be equally effective to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    in the first-line setting. These data are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H465740478\">",
"    <span class=\"h3\">",
"     First-line setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    in previously untreated patients with metastatic RCC was evaluated in a multicenter randomized trial in which 288 patients were randomly assigned to treatment with axitinib (5 mg twice a day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (400 mg twice a day) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/8\">",
"     8",
"    </a>",
"    ]. As reported at the 2013 Genitourinary Cancers Symposium, compared to sorafenib, axitinib resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An improvement in PFS (10 versus 6.5 months, HR 0.77, 95% CI 0.56-1.05).",
"     </li>",
"     <li>",
"      Higher ORR (32 versus 15 percent, p=0.02)",
"     </li>",
"     <li>",
"      Higher rates of toxicity (all grades) including diarrhea (50 versus 40 percent), hypertension (49 versus 29 percent), weight loss (37 versus 24 percent), fatigue (33 versus 26 percent), and anorexia (29 versus 19 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these data, it appears that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    is an another first line option for treatment of patients with metastatic RCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H465740471\">",
"    <span class=\"h3\">",
"     Second-line setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original approval in the US was based on the AXIS phase III trial that included 723 patients with metastatic clear cell RCC who were randomly assigned treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    (5 mg twice a day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (400 mg twice a day) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/9\">",
"     9",
"    </a>",
"    ]. All patients had prior treatment with a cytokine (35 percent) or other&nbsp;anti-VEGF or molecularly targeted treatment (eg, 54 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ). Quality of life (with a time to deterioration endpoint) was prospectively assessed using standardized questionnaires.",
"   </p>",
"   <p>",
"    Compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant improvement in PFS (median, 7 versus 5 months, HR for PFS, 0.67, 95% CI 0.54-0.81).",
"     </li>",
"     <li>",
"      The benefit in PFS was higher in patients previously treated with cytokines (median 12 versus 7 months, HR 0.46, 95% CI 0.32-0.68) than in patients previously treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      (median 5 versus 3 months, HR 0.74, 95% CI 0.57-0.96).",
"     </li>",
"     <li>",
"      A significant increase in ORR (19 versus 9 percent).",
"     </li>",
"     <li>",
"      A higher rate of stable disease &gt;20 weeks (27 versus 20 percent).",
"     </li>",
"     <li>",
"      Higher rates of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      adverse event including diarrhea (11 versus 7 percent), hypertension (16 versus 11 percent), and fatigue (11 versus 5 percent).",
"     </li>",
"     <li>",
"      A lower rate of hand-foot syndrome (27 versus 51 percent).",
"     </li>",
"     <li>",
"      A statistically significant improvement in the time to symptom deterioration (median, 3.1 versus 2.8 months, HR for symptom worsening 0.83, 95% CI 0.70-0.98).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    increases the treatment options for patients who have progressed after one systemic treatment. The AXIS trial shows it is superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , particularly among patients previously treated with cytokine therapy. For patients previously treated with vascular endothelial growth factor&nbsp;pathway&nbsp;inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ), axitinib and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    are reasonable options. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Everolimus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The ability to titrate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    to clinical parameters may be important to maximize treatment outcomes. An example of this was presented at the 2012 ASCO annual meeting. In a randomized phase II study, 213 patients were treated with axitinib (5 mg twice daily) for four weeks, after which eligible patients were randomly assigned further treatment with axitinib dose titration (stepwise from 5 to 7 to 10 mg twice a day based on tolerability) or axitinib with placebo dose titration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients who did not meet eligibility criteria were treated in a separate arm (axitinib &le;5 mg twice daily without dose titration).",
"   </p>",
"   <p>",
"    Eligibility criteria for randomization after completion of the first four weeks included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No severe hypertension (blood pressure",
"      <span class=\"nowrap\">",
"       &le;150/90",
"      </span>",
"      mmHg and &le;2 concurrent antihypertensive medications)",
"     </li>",
"     <li>",
"      No grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      related toxicities",
"     </li>",
"     <li>",
"      No dose reductions required during the first four weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main results of this study were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among all patients, the median PFS was 14.5 months and ORR was 48 percent.",
"     </li>",
"     <li>",
"      A higher",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      exposure (&ge;150",
"      <span class=\"nowrap\">",
"       ng-h/mL)",
"      </span>",
"      was associated with a higher ORR (59 versus 40 percent) and an improvement in PFS (14 versus 11 months).",
"     </li>",
"     <li>",
"      An increase in diastolic blood pressure (DBP) on day 15 of the first cycle was associated with improvements in outcomes (ORR and PFS). Compared to those patients with a lower DBP, patients with a DBP &ge;90",
"      <span class=\"nowrap\">",
"       mm/Hg",
"      </span>",
"      had a higher ORR (65 versus 50 percent) and median PFS (23 versus 14 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We await the final results of dose titration to determine if the titration strategy was associated with changes in DBP and clinical outcomes to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    is a potent small molecule inhibitor of multiple TKs including VEGF receptor 2, FLT3, PDGF receptor, and fibroblast growth factor receptor-1 (FGFR1) (",
"    <a class=\"graphic graphic_figure graphicRef65979 \" href=\"UTD.htm?14/4/14408\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef76708 \" href=\"UTD.htm?24/51/25406\">",
"     algorithm 1",
"    </a>",
"    ). It also inhibits C-raf and both mutant and wild-type B-raf. Raf kinase is an important mediator of the",
"    <span class=\"nowrap\">",
"     Ras/Raf/MEK",
"    </span>",
"    pathway. Although activating mutations in B-raf (BRAF) have not been identified in RCC, constitutive activation in the B-raf pathway (Raf, MEK, and ERK) has been observed in approximately 50 percent of tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H803309751\">",
"    <span class=\"h3\">",
"     Previously treated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    in advanced RCC was demonstrated in the phase III TARGET trial, in which 903 patients with advanced RCC who had failed prior standard therapy were randomly assigned to sorafenib (400 mg orally twice daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key findings included [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median PFS was significantly longer in those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      compared with placebo (5.5 versus 2.8 months, HR 0.44, 95% CI 0.35-0.55).",
"     </li>",
"     <li>",
"      OS with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      was not significantly prolonged compared to placebo (median 17.8 versus 15.2 months, HR 0.88, 95% CI 0.74-1.04). However, the study allowed patients originally assigned to placebo to cross over and receive sorafenib, potentially obscuring differences in survival.",
"     </li>",
"     <li>",
"      In a separate analysis from this trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      appeared to be effective in carefully selected older patients (&ge;70 years), as evidenced by a significant improvement in PFS (26 versus 14 weeks with placebo) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The toxicity observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and other VEGF TK inhibitors is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H803309767\">",
"    <span class=\"h3\">",
"     Untreated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    in previously untreated patients is less clear.",
"   </p>",
"   <p>",
"    In a phase II trial in good- and intermediate-risk patients with previously untreated advanced RCC, patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (400 mg orally twice a day) or IFNa (9 million units three times per week) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/15\">",
"     15",
"    </a>",
"    ]. At progression, patients originally assigned to sorafenib were allowed to dose escalate the dose of sorafenib to 600 mg orally twice a day, while those who had been assigned to IFNa could be crossed over to sorafenib (400 mg twice a day).",
"   </p>",
"   <p>",
"    Key results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the initial treatment phase, quality of life and percentage of patients achieving tumor shrinkage were greater with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      than IFNa.",
"     </li>",
"     <li>",
"      There was no increase in PFS with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      compared with IFNa (5.7 versus 5.6 months, HR 1.14, 95% CI 0.61-1.27).",
"     </li>",
"     <li>",
"      Dose escalation to 600 mg twice a day was well tolerated in patients who were tolerating 400 mg twice a day and associated with an additional period of PFS of four months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional phase II studies have suggested that dose escalation is a feasible approach that may be associated with clinical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, further study is required to determine whether this approach has a role in the management of patients with advanced RCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    is an oral agent that inhibits the TKs associated with the VEGF, PDGF, and Kit receptors. In 2009, it was approved by the",
"    <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/druginfo/fda-pazopanibhydrochloride\">",
"     US",
"    </a>",
"    FDA for patients with previously untreated advanced renal cell carcinoma and for patients who had progressed on cytokine therapy.",
"   </p>",
"   <p>",
"    In a phase III trial, 435 patients, who were previously untreated or had received only cytokine therapy, were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/17\">",
"     17",
"    </a>",
"    ]. Almost all patients were good or intermediate risk.",
"   </p>",
"   <p>",
"    There was a significant increase in PFS with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    compared with placebo (median 9.2 versus 4.2 months, HR 0.46, 95% CI 0.34-0.62), with improvement in PFS seen in both untreated patients and in those who had received cytokine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/17\">",
"     17",
"    </a>",
"    ]. In the final analysis of the trial presented at the 2010 European Society of Medical Oncology meeting, there was a nonsignificant improvement in OS (median 22.9 versus 20.5 months, HR 0.91, 95 % CI 0.71-1.16) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/18\">",
"     18",
"    </a>",
"    ]. Any potential effect on OS is likely confounded by the high rate of crossover and other treatment after initial evidence of progressive disease in patients enrolled on the placebo arm of the trial. Treatment was generally well tolerated.",
"   </p>",
"   <p>",
"    In the PISCES phase III randomized trial, the tolerability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    was compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    to determine if differences in toxicity affected patient preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/19\">",
"     19",
"    </a>",
"    ]. All patients (n=168) were randomly assigned to treatment with a ten-week course (phase 1) of pazopanib (800 mg daily) or sunitinib (50 mg for four weeks",
"    <span class=\"nowrap\">",
"     on/two",
"    </span>",
"    weeks off) followed by a two-week washout period. Patients were then crossed over to the alternative agent for an additional ten weeks (phase 2). Following the double blind phase (total of 22 weeks), patients were allowed to continue on treatment based on which agent they preferred. Major results presented at the 2012 ASCO annual meeting were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A similar number of patients withdrew from the study during phase 1 (18 patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      versus 14 receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ) and phase 2 (4 versus 6, respectively).",
"     </li>",
"     <li>",
"      Among the patients who completed the study questionnaires and received one dose or more of treatment during each study phase (n=114), significantly more patients preferred",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      (70 versus 22 percent, respectively).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"       Pazopanib",
"      </a>",
"      was associated with significantly better health related quality of life compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      . In addition, pazopanib resulted in less fatigue and less dysgeusia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these data suggesting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    is better tolerated, there are no data to inform whether one is more effective than the other. We await the results of an ongoing",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT00720941\">",
"     randomized phase III trial",
"    </a>",
"    comparing pazopanib to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    to determine which should be the preferred agent for these patients.",
"   </p>",
"   <p>",
"    The most frequent toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341047316\">",
"    <span class=\"h2\">",
"     Tivozanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tivozanib is an orally active inhibitor of VEGFR 1, 2, and 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/20\">",
"     20",
"    </a>",
"    ]. At the 2012 ASCO annual meeting, the preliminary results of a phase III trial comparing tivozanib to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    as first-line treatment in metastatic renal cell carcinoma were presented [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/21\">",
"     21",
"    </a>",
"    ]. In this trial, 517 patients were randomly assigned to treatment with tivozanib (1.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    on a three weeks",
"    <span class=\"nowrap\">",
"     on/one",
"    </span>",
"    week off schedule) or to sorafenib (400 mg twice a day without a treatment break). Compared to sorafenib, tivozanib resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant improvement in PFS (HR 0.80; median 12 versus 10 months, respectively; p=0.04).",
"     </li>",
"     <li>",
"      A significantly higher ORR (33 versus 23 percent).",
"     </li>",
"     <li>",
"      A higher occurrence of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      hypertension (26 versus 17 percent, respectively). Other toxicities (all grades) that were more commonly encountered with tivozanib included dysphonia (21 versus 5 percent) and back pain (14 and 7 percent). However, tivozanib resulted in less diarrhea (24 versus 38 percent), palmar-plantar erythrodysesthesia (15 versus 71 percent), and alopecia (2 versus 21 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VEGF TK inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    appear to have activity in patients with brain metastases. An expanded access series of 321 patients with brain metastases reported on the safety and efficacy of sunitinib treatment in advanced RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/22\">",
"     22",
"    </a>",
"    ]. Sunitinib resulted in an objective response in 26 of 213 evaluable patients (12 percent). There were no differences in the toxicity profile of patients with brain metastases compared with patients without brain metastases. One patient with brain metastases had a mild, treatment-related cerebral hemorrhage.",
"   </p>",
"   <p>",
"    In contrast to these results, five patients died of an intracerebral hemorrhage within two weeks after initiating therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    in a retrospective analysis of 67 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/23\">",
"     23",
"    </a>",
"    ]. Four of these five had known brain metastases; among all seven patients with known brain metastases, four had a fatal intracerebral hemorrhage.",
"   </p>",
"   <p>",
"    Possible additional evidence of central nervous system activity comes from an analysis of 139 patients treated at two centers in the TARGET trial, in which previously treated patients with advanced RCC were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients treated with sorafenib had a statistically significant decrease in the risk of developing brain metastases compared to those given placebo (3 versus 12 percent). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Sorafenib'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H641642\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents in development include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The development of these agents will require randomized clinical trials to assess their efficacy compared to approved drugs. (See",
"    <a class=\"local\" href=\"#H16776896\">",
"     'Cross resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     BEVACIZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is a monoclonal antibody that binds circulating VEGF and prevents its interaction with the VEGF receptor. Two phase III trials, have demonstrated improved PFS with bevacizumab plus interferon alfa (IFNa) compared with IFNa alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532696837\">",
"    <span class=\"h2\">",
"     AVOREN trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the AVOREN trial, 649 previously untreated patients were randomly assigned to interferon alfa (IFNa, 9 million units three times per week for one year) plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two weeks) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. Bevacizumab (or placebo) was continued until there was evidence of progressive disease. Interferon plus bevacizumab resulted in the following compared to interferon plus placebo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in PFS (median, 10.2 versus 5.5 months, HR 0.63, 95% CI 0.45-0.72) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A significantly higher ORR (31 versus 13 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A trend toward improved OS (median survival 23.3 versus 21.3 months, HR 0.86, 95% CI 0.72-1.04) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/31\">",
"       31",
"      </a>",
"      ]. Approximately 60 percent of patients received second-line therapy, potentially obscuring a survival difference between the two treatment arms [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      More common serious adverse events (29 versus 16 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/27\">",
"       27",
"      </a>",
"      ]. Grade 3 or 4 adverse events that were more common in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      included thromboembolic events (3 versus 1 percent) and gastrointestinal perforation (1 versus 0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532696846\">",
"    <span class=\"h2\">",
"     CALGB 9026 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Cancer and Leukemia Group B (CALGB) trial 90206, 732 previously untreated patients with metastatic RCC were randomly assigned to either IFNa plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or IFNa plus placebo on schedules similar to that used in the AVOREN trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The final results of this trial found that there was a trend toward improved OS (median 18.3 versus 17.4 months, HR 0.86, p= 0.07) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/34\">",
"     34",
"    </a>",
"    ]. The analysis of survival was complicated by the fact that more than one-half of patients on both arms received second-line therapy, including VEGF-targeted therapy in 46 percent of those originally treated with IFNa alone.",
"   </p>",
"   <p>",
"    A previously published interim analysis found that PFS was significantly increased in patients treated with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    plus IFNa regimen (median 8.5 versus 5.2 months; HR 0.71, 0.61-0.83). There was also a statistically significant increase in the ORR (25.5 versus 13.1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532697053\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a frequent side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . Guidelines for pretreatment assessment, monitoring, and management of elevated blood pressure in patients receiving bevacizumab are available (",
"    <a class=\"graphic graphic_table graphicRef73373 graphicRef63338 \" href=\"UTD.htm?37/10/38061\">",
"     table 2A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link&amp;anchor=H21639449#H21639449\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Sequential inhibition of the VEGF pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although both the TK inhibitors and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    are thought to act by interrupting the VEGF signaling pathway, tumors do not appear to be totally cross-resistant to sequential therapy with different agents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In both the AVOREN and CALGB 9026 III trials, patients initially treated with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    were eligible for subsequent therapy with VEGF TK inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]. Post hoc analyses demonstrated the feasibility of sequential therapy. In patients who were able to receive sequential therapy following protocol participation, median survival ranged from 27 to 39 months in the two protocols. (See",
"    <a class=\"local\" href=\"#H532696837\">",
"     'AVOREN trial'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H532696846\">",
"     'CALGB 9026 trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Objective responses may also be seen when different VEGF TK inhibitors are used sequentially. As an example, in a phase II study, objective responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    were observed in 5 of 52 patients (10 percent) who had progressed on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , with a median time to progression of 16 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/36\">",
"     36",
"    </a>",
"    ]. In another phase II study of 62 patients previously treated with sorafenib, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    resulted in an ORR of 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/35\">",
"     35",
"    </a>",
"    ]. The median time to progression and OS were 7 and 14 months, respectively. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'VEGF TK inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Despite the promising results with various VEGF pathway inhibitors in patients with advanced RCC, many questions remain regarding the optimal use of these agents, including which agent to use in a particular patient, when to start treatment, and what is the optimal sequence of available agents and treatment approaches. All of these questions require further study, and thus clinical trials are still important in patients with treatment-naive advanced RCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     mTOR INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mammalian target of rapamycin (mTOR) pathway is downstream of the phosphoinositide 3-kinase and Akt pathway that is regulated by the PTEN tumor suppressor gene (",
"    <a class=\"graphic graphic_figure graphicRef65979 \" href=\"UTD.htm?14/4/14408\">",
"     figure 1",
"    </a>",
"    ). Although mutations in PTEN have not been found in RCC, diminished protein expression with increased levels of phospho-Akt has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/38\">",
"     38",
"    </a>",
"    ]. Activation of mTOR can also upregulate HIF-1 gene expression, which, in patients with VHL mutations, can magnify HIF accumulation and the expression of HIF-inducible genes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibition of the mTOR pathway has the potential to inhibit tumor progression at multiple levels. In randomized trials, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    have important clinical activity in patients with RCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Temsirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     Temsirolimus",
"    </a>",
"    is a parenterally administered rapamycin analog that functions as a competitive inhibitor of mTOR kinase. Temsirolimus has important clinical activity in both untreated and previously treated patients with advanced RCC.",
"   </p>",
"   <p>",
"    Based upon phase II results showing activity in previously treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/39\">",
"     39",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    was evaluated in a phase III trial in which 626 previously untreated poor-prognosis patients with metastatic or recurrent RCC were randomly assigned to temsirolimus (25 mg",
"    <span class=\"nowrap\">",
"     IV/week),",
"    </span>",
"    temsirolimus (15 mg",
"    <span class=\"nowrap\">",
"     IV/week)",
"    </span>",
"    plus IFNa (escalated up to 6 million units three times per week as tolerated), or IFNa monotherapy (escalated up to 18 million units three times per week as tolerated) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key results from this trial included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       Temsirolimus",
"      </a>",
"      as a single agent significantly prolonged the median OS compared to IFNa as a single agent (10.9 versus 7.3 months; HR for mortality 0.73, 95% CI 0.58-0.92).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       Temsirolimus",
"      </a>",
"      significantly prolonged PFS compared to single agent IFNa according to both investigator (median, 4 versus 2 months, respectively) and independent radiologic assessment (median, 6 versus 3 months). The independent assessment did not include clinical deterioration as a criterion, which may have accounted for the differences between the two analyses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both OS and PFS rates for the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    plus IFNa were not significantly better than with IFNa alone. The inferior results may be due to the lower dose intensity of temsirolimus in the combination arm.",
"   </p>",
"   <p>",
"    Side effects observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most frequent side effects were asthenia, rash, anemia, nausea, and anorexia (51, 47, 45, 37, and 32 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/40\">",
"       40",
"      </a>",
"      ]. Severe adverse events were uncommon; the most frequent grade 3 or 4 adverse events were anemia, asthenia, and hyperglycemia (20, 11, and 11 percent, respectively).",
"     </li>",
"     <li>",
"      Hypersensitivity reactions have also been reported and may be severe or life threatening [",
"      <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/41\">",
"       41",
"      </a>",
"      ]. Premedication with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      (25 to 50 mg IV prior to each dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"      ) is recommended. The management of patients with a hypersensitivity reaction to temsirolimus is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link\">",
"       \"Infusion reactions to systemic chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       Temsirolimus",
"      </a>",
"      has been associated with pneumonitis in 0.5 to 5 percent of patients with cancer who were enrolled in clinical studies; severe toxicity, including rare fatalities, was seen in some cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link&amp;anchor=H21#H21\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Temsirolimus'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The administration schedule and toxicities associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    are summarized in the attached table (",
"    <a class=\"graphic graphic_table graphicRef68554 \" href=\"UTD.htm?17/4/17485\">",
"     table 3",
"    </a>",
"    ). Dose modification for patients with hepatic dysfunction is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    is an orally administered mTOR inhibitor. In phase I and II studies, everolimus activity was observed in patients with clear cell RCC who had failed previous treatment with a VEGF TK inhibitor.",
"   </p>",
"   <p>",
"    In a phase III trial, 410 patients with metastatic clear cell RCC whose disease had progressed on a VEGF targeted were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    (10 mg per day) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. All patients had progressive disease either while on VEGF TK inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ) or within six months after completion of such therapy.",
"   </p>",
"   <p>",
"    Key results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PFS with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      was significantly prolonged compared to placebo (median, 4.9 versus 1.9 months, HR 0.30, 95% CI 0.22-0.40). The benefit extended to all stratification sets (risk group, prior treatment, age, sex, geographic region).",
"     </li>",
"     <li>",
"      There was no statistically significant difference in OS (median 14.8 versus 14.4 months, HR 0.87). However, patients who had been assigned to placebo were eligible for crossover to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      when progressive disease developed and 80 percent of placebo patients received everolimus.",
"     </li>",
"     <li>",
"      Objective responses were rare (1 and 0 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      and placebo, respectively), although stable disease was more common (63 and 32 percent, respectively).",
"     </li>",
"     <li>",
"      The most frequent severe laboratory abnormalities in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      were lymphopenia and hyperglycemia (15 versus 5 percent and 12 versus 1 percent, respectively, compared to placebo). Grade 3 or 4 adverse events more common with everolimus included stomatitis and pneumonitis (3 versus 0 percent and 3 versus 0 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these results,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    should be considered a standard treatment for patients with metastatic clear cell RCC who have progressed on VEGF TK inhibitors. Although the benefit associated with everolimus is significant in comparison to placebo, its value relative to either continuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    or crossing over to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    remains to be determined.",
"   </p>",
"   <p>",
"    Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    has been associated with pulmonary toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link&amp;anchor=H21#H21\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Temsirolimus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    was approved by the Food and Drug Administration for use after progression on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , or both. Everolimus is approved in Europe as an immunosuppressant for use in the prevention of rejection of solid organ transplants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     OTHER TARGETED APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Inhibition of EGFR pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite a high rate of epidermal growth factor receptor (EGFR) expression on RCCs, there does not appear to be a clinical role for inhibition of the EGFR pathway in patients with advanced RCC.",
"   </p>",
"   <p>",
"    Small molecules targeting the EGFR TK (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/44\">",
"     44",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/45\">",
"     45",
"    </a>",
"    ]) and monoclonal antibodies directed against the extracellular domain of the EGFR (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/46\">",
"     46",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/47\">",
"     47",
"    </a>",
"    ]) have not demonstrated significant clinical activity in clinical studies. The combination of an inhibitor of the EGFR pathway (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ) with blockade of the VEGF pathway using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    has not resulted in improved survival compared to bevacizumab alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Carbonic anhydrase IX inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbonic anhydrase IX (CAIX) is a member of the carbonic anhydrase family of proteins that is thought to play a role in the regulation of cellular proliferation in response to hypoxia. CAIX is expressed in the majority of RCCs, and high levels of expression are associated with a relatively favorable prognosis. The role of CAIX as a predictor of responsiveness to IL-2 is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H12#H12\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Histology and CAIX expression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CAIX may represent a useful therapeutic target in RCC, and studies with agents targeting CAIX are in progress. As an example, a chimeric monoclonal antibody against CAIX (WX-G250) appears to have some activity against RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/50-52\">",
"     50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro studies showed that WX-G250 can elicit antibody-dependent cellular cytotoxicity (ADCC), which could be upregulated by IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. This provided the rationale for the study of combined therapy with low-dose IL-2 and WX-G250 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In an early report of 35 patients with progressive metastatic clear cell RCC who received weekly infusions of WX-G250 combined with daily low-dose IL-2, three had a partial response and five had stable disease for six months or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/51\">",
"     51",
"    </a>",
"    ]. Median survival was 22 months. The contribution of WX-G250 to the apparently beneficial response could not be determined.",
"   </p>",
"   <p>",
"    Given that CAIX expression has been found to diminish with more advanced disease, WX-G250 may be more appropriate to study in the adjuvant setting. An international trial of comparing WX-G250 to placebo in patients who have undergone resection of high-risk RCC is currently underway (NCT00087022) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     NON-CLEAR CELL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecularly targeted agents have not been studied as extensively in patients with non-clear cell carcinoma as in those with clear cell tumors. However, multiple reports suggest that the molecularly targeted therapy may have clinically useful activity in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/57-65\">",
"     57-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a single-arm phase II trial, 57 patients with previously treated non-clear cell carcinoma received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    (50 mg daily for 28 days every six weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/65\">",
"     65",
"    </a>",
"    ]. The overall response rate was five percent (partial responses in two patients with chromophobe and one with an unclassified RCC). The median PFS and OS were 3 and 17 months, respectively. However, median PFS varied with histologic type; for patients with chromophobe tumors (n=5) it was 13 months, but for patients with papillary tumors (n=27) it was only two months. This suggests that non-clear cell tumors are biologically heterogenous and may not uniformly respond to treatment.",
"   </p>",
"   <p>",
"    Activating mutations of the MET gene have been identified in patients with hereditary and sporadic papillary RCC. Following promising results in a phase I trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/66\">",
"     66",
"    </a>",
"    ], a phase II trial of the oral multikinase inhibitor foretinib (which targets MET and VEGF receptors among others) was performed in 74 patients with papillary RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients were treated in one of two dosing cohorts using either 240 mg daily on days 1 through 5 every 14 days (intermittent dosing) or 80 mg daily (daily dosing). The major results were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foratenib resulted in an overall response rate was 13.5 percent; there was no difference in the response rate between the two dosing cohorts.",
"     </li>",
"     <li>",
"      The median PFS was nine months and the PFS rate at six months was 65 percent. One-year OS was 70 percent (64 percent in those receiving intermittent dosing and 76 percent in those treated with daily dosing).",
"     </li>",
"     <li>",
"      Of ten patients with a germline mutation, five patients had a response to treatment. In contrast, only 5 out of 57 patients without a germline mutation had a response.",
"     </li>",
"     <li>",
"      Serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities consisted of hypertension (51 percent), hypophosphatemia (19 percent), elevated lipase levels (16 percent), and diarrhea (10 percent). In addition, eight patients had a pulmonary embolus while on treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study suggests that foretinib or other MET inhibitors may be particularly useful in patients with papillary RCC harboring germline MET mutations. However, further clinical trials are required. We encourage all patients with non-clear cell carcinomas to enroll in appropriately designed studies.",
"   </p>",
"   <p>",
"    Beyond molecularly targeted therapy, additional options include cytotoxic chemotherapy, although data are limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21528?source=see_link&amp;anchor=H1056311562#H1056311562\">",
"     \"Overview of the treatment of renal cell carcinoma\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of areas for which data are inadequate to guide therapy with molecularly targeted therapy:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16776891\">",
"    <span class=\"h2\">",
"     Combination regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The understanding of the molecular pathogenesis of RCC might make it possible to further improve the efficacy of treatment by blocking multiple steps in the same pathway (\"vertical blockade\") or by simultaneously inhibiting more than one pathway (\"horizontal blockade\"). As an example, a study combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    suggested that the combination had more activity than everolimus alone in patients previously treated with a VEGF TK inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is currently no evidence that combinations are superior to sequential use of agents with different mechanisms. As an example, in a randomized phase II trial, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    showed no advantages compared with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or interferon alfa plus bevacizumab and may have resulted in increased toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/69\">",
"     69",
"    </a>",
"    ]. It may also be possible to combine a molecularly targeted approach with immunotherapy, although at least one trial has indicated that such a combination may be detrimental if it involves decreasing the dose of a targeted agent. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Molecular pathogenesis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H27\">",
"     'Temsirolimus'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16776896\">",
"    <span class=\"h2\">",
"     Cross resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of resistance to one molecularly targeted agent does not mean that inhibition elsewhere within that pathway may not remain a useful approach. For instance, patients with progressive disease following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    treatment or first generation VEGFR inhibitor may still respond to a different (or after a drug holiday) or even the same TK inhibitor. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Sequential inhibition of the VEGF pathway'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As an example, a phase II trial of the Met and VEGFR2 inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    , in patients with relapsed or refractory RCC was presented at the 2012 ASCO annual meeting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/25\">",
"     25",
"    </a>",
"    ]. In this trial, 25 patients received cabozantinib (140 mg daily). The majority of patients had been previously treated with anti-VEGF therapy (88 percent), anti-mTOR therapy (60 percent), or both (52 percent). In addition, 20 percent had received prior cytokines. The preliminary results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=see_link\">",
"       Cabozantinib",
"      </a>",
"      resulted in a median PFS of 15 months and a partial response in seven patients (28 percent).",
"     </li>",
"     <li>",
"      Serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity associated with treatment included hypophosphatemia (36 percent), hyponatremia (20 percent), fatigue (16 percent), and diarrhea (12 percent). Serious hypertension (grade 3) was seen in two patients (8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16776901\">",
"    <span class=\"h2\">",
"     Cytoreductive nephrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytoreductive nephrectomy has been shown to increase survival in patients who are subsequently treated with immunotherapy. Whether it will have similar value in patients who are then treated with molecularly targeted agents has not been evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H26#H26\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Cytoreductive (debulking) nephrectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16776907\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant immunotherapy has not been effective in improving long-term survival following nephrectomy. However, molecularly targeted agents are being evaluated in this setting because of the increased response rates and improved survival observed in patients with metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H34#H34\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Adjuvant immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16776912\">",
"    <span class=\"h2\">",
"     Biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of various biomarkers in predicting responsiveness to molecularly targeted agents remains unknown. Measurements of VEGF and the soluble VEGF receptor do change in response to treatment but whether such alterations can be used as a surrogate for tumor responsiveness remains unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/70\">",
"     70",
"    </a>",
"    ]. Analysis of data collected from the TARGET trial showed that high VEGF levels were independently associated with worse PFS and OS, reflecting an aggressive tumor biology [",
"    <a class=\"abstract\" href=\"UTD.htm?27/32/28170/abstract/13\">",
"     13",
"    </a>",
"    ]. Data from the TARGET trial also suggested that patients with a high VEGF level derived more benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    relative to placebo than those who had a low VEGF level, although the median PFS for sorafenib treatment in both groups was the same.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=see_link\">",
"       \"Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Previously untreated patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a good performance status and intact organ function, we suggest high-dose interleukin-2 (IL-2) rather than targeted therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H350646080\">",
"       'Untreated patients'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H2#H2\">",
"       \"Immunotherapy of renal cell carcinoma\", section on 'Interleukin-2'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with advanced clear cell RCC who are not candidates for (or refuse) high-dose IL-2 or who do not have access to IL-2 treatment, we recommend molecularly targeted therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Treatment can be stratified based on the risk of progression:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For good- and intermediate-risk patients, we suggest a VEGF pathway inhibitor rather than other molecularly targeted agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The available options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pazopanib'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Sunitinib'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Bevacizumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For poor-prognosis patients, we suggest the mTOR inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Temsirolimus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Previously treated patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who progressed after cytokine therapy (ie, IL-2 or interferon-alfa), we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest axitinib over other agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H104724963\">",
"       'Axitinib'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have progressed after a VEGF pathway inhibitor (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ), both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      are reasonable options. In the absence of prospective trials, a decision to use either agent is based on individual patient considerations, such as tumor response to the prior VEGF pathway inhibitor. (See",
"      <a class=\"local\" href=\"#H104724963\">",
"       'Axitinib'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Everolimus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without access to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      , alternative options include:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      . A choice between these agents is based on patient considerations (ie, comorbidities) and drug availability.",
"     </li>",
"     <li>",
"      There are currently no clinical data available for patients whose disease has progressed following therapy with an mTor inhibitor. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Everolimus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/1\">",
"      Furge KA, Lucas KA, Takahashi M, et al. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 2004; 64:4117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/2\">",
"      Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/3\">",
"      Atkins MB. Management of advanced renal cancer. Kidney Int 2005; 67:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/4\">",
"      Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115.",
"     </a>",
"    </li>",
"    <li>",
"     Motzer RJ, Figlin RA, Hutson TJ, et al. Sunitinib versus interferon-alfa (IFN-&Eacute;&oslash;) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors (abstract) J Clin Oncol 2007; 25:241s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/6\">",
"      Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584.",
"     </a>",
"    </li>",
"    <li>",
"     Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. J Clin Oncol 2011; 29: suppl 7, abstract #LBA308.",
"    </li>",
"    <li>",
"     Hutson TE, Gallardo J, Lesovoy V, et al. Axitinib versus sorafenib as first���line therapy in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31, 2013 (suppl 6; abstr LBA348).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/9\">",
"      Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931.",
"     </a>",
"    </li>",
"    <li>",
"     Rini BI, Gr&uuml;nwald V, Fishman MN, et al. Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol 30, 2012 (suppl; abstr 4503).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/11\">",
"      Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002; 62:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/12\">",
"      Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/13\">",
"      Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27:3312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/14\">",
"      Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008; 100:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/15\">",
"      Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:1280.",
"     </a>",
"    </li>",
"    <li>",
"     Amato RJ, Harris P, Dalton M, et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). (Abstract). J Clin Oncol 2007; 25:241s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/17\">",
"      Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061.",
"     </a>",
"    </li>",
"    <li>",
"     Sternberg C, Hawkins RE, Szczylik C, et al. Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma: Final overall survival results (abstract # LBA22). Ann Oncol 2010; 21:viii10.",
"    </li>",
"    <li>",
"     Escudier BJ, Porta C, Bono P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)&mdash;PISCES study, NCT 01064310. J Clin Oncol 30, 2012 (suppl; abstr CRA4502).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/20\">",
"      Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006; 66:9134.",
"     </a>",
"    </li>",
"    <li>",
"     Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin Oncol 30, 2012 (suppl; abstr 4501).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/22\">",
"      Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011; 117:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/23\">",
"      Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008; 53:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/24\">",
"      Massard C, Zonierek J, Gross-Goupil M, et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010; 21:1027.",
"     </a>",
"    </li>",
"    <li>",
"     Choueiri TK, Pal SK, McDermott DF, et al. Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol 30, 2012 (suppl; abstr 4504).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/26\">",
"      Eisen T, Joensuu H, Nathan PD, et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 2012; 13:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/27\">",
"      Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370:2103.",
"     </a>",
"    </li>",
"    <li>",
"     Escudier BJ, Bellmunt J, Negrier S, et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon- 945;2a (IFN) in metastatic renal cell carcinoma (mRCC) (abstract #5020). J Clin Oncol 2009; 27:239s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/29\">",
"      Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19:1470.",
"     </a>",
"    </li>",
"    <li>",
"     Escudier BJ, Ravaud A, Negrier S, et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis (Abstract). J Clin Oncol 2008; 26:256s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/31\">",
"      Escudier B, Bellmunt J, N&eacute;grier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/32\">",
"      Bracarda S, Bellmunt J, Melichar B, et al. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-&alpha;2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int 2011; 107:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/33\">",
"      Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26:5422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/34\">",
"      Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/35\">",
"      Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27:4462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/36\">",
"      Di Lorenzo G, Carten&igrave; G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009; 27:4469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/37\">",
"      Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009; 182:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/38\">",
"      Kondo K, Yao M, Kobayashi K, et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 2001; 91:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/39\">",
"      Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/40\">",
"      Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/41\">",
"      Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/42\">",
"      Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/43\">",
"      Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010; 116:4256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/44\">",
"      Drucker B, Bacik J, Ginsberg M, et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/45\">",
"      Ravaud A, Hawkins R, Gardner JP, et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008; 26:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/46\">",
"      Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/47\">",
"      Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/48\">",
"      Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25:4536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/49\">",
"      Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23:7889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/50\">",
"      Bleumer I, Knuth A, Oosterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004; 90:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/51\">",
"      Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006; 175:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/52\">",
"      Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX&reg;) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011; 29:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/53\">",
"      Surfus JE, Hank JA, Oosterwijk E, et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 1996; 19:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/54\">",
"      Liu Z, Smyth FE, Renner C, et al. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2002; 51:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/55\">",
"      Meropol NJ, Barresi GM, Fehniger TA, et al. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 1998; 46:318.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical trials database. file://www.clinicaltrials.gov/ (Accessed on November 23, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/57\">",
"      Molina AM, Feldman DR, Ginsberg MS, et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 2012; 30:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/58\">",
"      Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/59\">",
"      Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/60\">",
"      Pwint TP, Macaulay V, Roberts IS, et al. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. Urol Oncol 2011; 29:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/61\">",
"      Hou MM, Hsieh JJ, Chang NJ, et al. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. Clin Drug Investig 2010; 30:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/62\">",
"      Numakura K, Tsuchiya N, Yuasa T, et al. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol 2011; 16:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/63\">",
"      Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010; 116:5219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/64\">",
"      Vaz Fragoso CA, Gill TM. Defining chronic obstructive pulmonary disease in an aging population. J Am Geriatr Soc 2010; 58:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/65\">",
"      Tannir NM, Plimack E, Ng C, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012; 62:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/66\">",
"      Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010; 16:3507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/67\">",
"      Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/68\">",
"      Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010; 28:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/32/28170/abstract/69\">",
"      N&eacute;grier S, Gravis G, P&eacute;rol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011; 12:673.",
"     </a>",
"    </li>",
"    <li>",
"     Zuehlsdorf M, Christensen O, Strumber D, et al. VEGF, sVEGF, bFGF, and IL-8 as biomarkers of the pharmacological activity of BAY 57-9352, an oral VEGFR-2 receptor tyrosine kinase inhibitor, in patients with solid tumors (abstract). J Clin Oncol 2006; 24:129s.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2962 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28170=[""].join("\n");
var outline_f27_32_28170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H350645694\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350646080\">",
"      Untreated patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350645850\">",
"      Previously treated patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VEGF TK INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sunitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104724963\">",
"      Axitinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H465740478\">",
"      - First-line setting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H465740471\">",
"      - Second-line setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sorafenib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H803309751\">",
"      - Previously treated patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H803309767\">",
"      - Untreated patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pazopanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341047316\">",
"      Tivozanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Brain metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H641642\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      BEVACIZUMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H532696837\">",
"      AVOREN trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H532696846\">",
"      CALGB 9026 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H532697053\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Sequential inhibition of the VEGF pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      mTOR INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Temsirolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Everolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      OTHER TARGETED APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Inhibition of EGFR pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Carbonic anhydrase IX inhibition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      NON-CLEAR CELL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16776891\">",
"      Combination regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16776896\">",
"      Cross resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16776901\">",
"      Cytoreductive nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16776907\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16776912\">",
"      Biomarkers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Previously untreated patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Previously treated patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2962\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2962|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/51/25406\" title=\"algorithm 1\">",
"      Pathways endothelial cell",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2962|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/4/14408\" title=\"figure 1\">",
"      Bio pathways thera targets in RCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2962|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/7/22652\" title=\"table 2A\">",
"      HTN with VEGF inhib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/36/33356\" title=\"table 2B\">",
"      Risk factors BP VSP rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/4/17485\" title=\"table 3\">",
"      IV temsirolimus regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=related_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=related_link\">",
"      Molecular biology and pathogenesis of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21528?source=related_link\">",
"      Overview of the treatment of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=related_link\">",
"      Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=related_link\">",
"      Prognostic factors in patients with renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_32_28171="Histamine inducing drugs";
var content_f27_32_28171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F74197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F74197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications that can cause histamine release",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ciprofloxacin, vancomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barbiturates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Narcotic analgesics*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Neuromuscular antagonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Quaternary amine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Succinylcholine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Benzylisoquinolinium compounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Atracurium, cisatracurium, doxacurium, mivacurium, tubocurarine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Plasma expanders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dextran, polygeline (Haemaccel)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiocontrast agents",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The medications listed above can cause non-immunologic histamine release, which can predispose patients to vancomycin reactions and/or prevent successful vancomycin desensitization.",
"    <div class=\"footnotes\">",
"     * Fentanyl rarely induces histamine release.",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced and modified with permission from: Wazny LD, et al. Desensitization protocols for vancomycin hypersensitivity. The Annals of Pharmacotherapy 2001; 35:1458. Copyright &copy; 2001 Harvey Whitney.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28171=[""].join("\n");
var outline_f27_32_28171=null;
var title_f27_32_28172="ACC AHA surgery mitral stenosis";
var content_f27_32_28172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Surgery for mitral stenosis (MS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement that surgery (mitral valve repair, if possible), is indicated",
"in patients with moderate to severe MS* in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Among patients who are symptomatic (NYHA class III-IV) if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Percutaneous mitral balloon valvotomy (PMBV) is not available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. PMBV is contraindicated because of moderate to severe mitral regurgitation or of left atrial thrombus that persists despite anticoagulation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Mitral valve morphology is not favorable for PMBV in patients with an acceptable operative risk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull; Symptomatic patients who also have moderate to severe mitral regurgitation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or",
"opinion is in favor of the usefulness of surgery in patients with MS in",
"the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull; Among patients with severe MS, NYHA class I-II symptoms, and severe pulmonary arterial hypertension (pulmonary artery systolic pressure &gt;60 mmHg), mitral valve surgery (repair if possible) is reasonable in those who are not candidates for PMBV.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or",
"opinion is less well established for the usefulness of surgery in",
"patients with MS in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull; Mitral valve repair but not replacement may be considered in patients with asymptomatic moderate to severe MS* who have had recurrent embolic events despite adequate anticoagulation and have favorable valve morphology for repair.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that surgery for MS is not useful in in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Patients with mild MS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull; Among patients undergoing mitral valve repair, closed commissurotomy should not be performed; the preferred approach is open commissurotomy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * There may be variability in the measurement of mitral valve area; as a result, the mean transmitral gradient, pulmonary artery wedge pressure, and pulmonary artery pressure at rest or during exercise should also be taken into consideration.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28172=[""].join("\n");
var outline_f27_32_28172=null;
var title_f27_32_28173="Extraintestinal manifest IBD";
var content_f27_32_28173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Extraintestinal manifestations of inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Common extraintestinal manifestations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Musculoskeletal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arthritis - colitic type, ankylosing spondylitis, isolated joint involvement such as sacroiliitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypertrophic osteoarthropathy - clubbing, periostitis, metastatic Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Miscellaneous - osteoporosis, aseptic necrosis, polymyositis, osteomalacia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Skin and mouth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reactive lesions - erythema nodosum, pyoderma gangrenosum, aphthous ulcers, vesiculopustular eruption, necrotizing vasculitis, Sweet's syndrome, metastatic Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Specific lesions - fissures and fistulas, oral Crohn's disease, drug rashes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nutritional deficiency - acrodermatitis enteropathica (zinc), purpura (vitamins C &amp; K), glossitis (vitamin B), hair loss and brittle nail (protein)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Associated diseases - vitiligo, psoriasis, amyloidosis, epidermolysis bullosa acquisita",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Hepatobiliary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Specific complications - primary sclerosing cholangitis (PSC) and bile duct carcinoma, small duct PSC, cholelithiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Associated inflammation - autoimmune chronic active hepatitis, pericholangitis, portal fibrosis and cirrhosis, granuloma in Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metabolic - fatty liver, gallstones associated with ileal Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ocular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uveitis iritis, episcleritis, scleromalacia, corneal ulcers, retinal vascular disease, gastrobulbar neuritis, Crohn's keratopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Growth retardation in children and adolescents, delayed sexual maturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Less common extraintestinal manifestations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Blood and vascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anemia due to iron, folate, or B12 deficiency or autoimmune hemolytic anemia, anemia of chronic disease, thrombocytopenic purpura; leukocytosis and thrombocytosis; thrombophlebitis and thromboembolism, arteritis and arterial occlusion, polyarteris nodosa, Takayasu arteritis, cutaneous vasculitis, anticardiolipin antibody, hyposplenism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Renal and genitourinary tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urinary calculi (oxalate stones in ileal disease), local extension of Crohn's disease involving ureter or bladder, amyloidosis, drug-related nephrotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renal tubular damage with increased urinary excretion of various enzymes, eg, beta N-acetyl-D-glucosaminidase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Neurological",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Up to 3 percent of patients may have non-iatrogenic neurologic involvement, including peripheral neuropathy, myelopathy, vestibular dysfunction, pseudotumor cerebri, myasthenia gravis, and cerebrovascular disorders. Incidence equal in ulcerative colitis and Crohn's disease. These disorders usually appear five to six years after the onset of inflammatory bowel disease and are frequently associated with other extraintestinal manifestations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Airway and parenchymal lung disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary fibrosis, vasculitis, bronchitis, acute laryngotracheitis, interstitial lung disease, sarcoidosis. Abnormal pulmonary function tests without clinical symptoms are common (up to 50 percent of cases).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pericarditis, myocarditis, endocarditis, and heart block: more common in ulcerative colitis than in Crohn's disease; cardiomyopathy, cardiac failure due to anti-TNF therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pericarditis may also occur from sulfasalazine/5 aminosalicylates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Pancreas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute pancreatitis: more common in Crohn's disease than in ulcerative colitis. Risk factors include 6 mercaptopurine and 5 aminosalicylate therapy, duodenal Crohn's disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Autoimmune",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug-induced lupus and autoimmune diseases secondary to anti-TNF&alpha; therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Positive DNA, anti-double stranded DNA, cutaneous and systemic manifestations of lupus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TNF: tumor necrosis factor.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: New insights into autoimmune pathogenesis. Dig Dis Sci 1999; 44:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28173=[""].join("\n");
var outline_f27_32_28173=null;
var title_f27_32_28174="Radiation enteritis capsule";
var content_f27_32_28174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiation enteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abnormal jejunal villi and lacteals secondary to radiation enteritis as seen during capsule endoscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ingram Roberts MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28174=[""].join("\n");
var outline_f27_32_28174=null;
var title_f27_32_28175="Computing SAECG";
var content_f27_32_28175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computation of the signal averaged ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Successive QRS complexes meeting a predetermined coefficient of similarity are aligned (within the window indicated by dashed lines) on an ongoing basis. Their rolling arithmetic mean is computed until a predetermined noise threshold is achieved (shown as the typical criterion of the standard deviation of the TP segment &lt;1 V). The QRS complex is then filtered and analyzed for late potentials, defined when the filtered QRS duration is &gt;114 ms, root-mean-square (RMS) voltage in the terminal 40 ms is &lt;0 mV, and low amplitude signal (LAS) duration (the terminal signal duration from 40 mV to isopotential) is &gt;8 ms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_32_28175=[""].join("\n");
var outline_f27_32_28175=null;
